

US00RE40930E

(19) **United States**  
 (12) **Reissued Patent**  
**Reddy et al.**

(10) **Patent Number:** **US RE40,930 E**  
 (45) **Date of Reissued Patent:** **Oct. 6, 2009**

(54) **PORCINE ADENOVIRUS TYPE 3 GENOME**

(75) Inventors: **Police Seshidhar Reddy**, Chester Springs, PA (US); **Suresh Tikoo**, Saskatoon (CA); **Lorne A. Babiuk**, Saskatoon (CA)

(73) Assignee: **Vectogen Pty Ltd**, Northy Ryde (AU)

(21) Appl. No.: **11/518,612**

(22) Filed: **Sep. 8, 2006**

**Related U.S. Patent Documents**

Reissue of:

(64) Patent No.: **6,492,343**  
 Issued: **Dec. 10, 2002**  
 Appl. No.: **09/292,034**  
 Filed: **Apr. 14, 1999**

U.S. Applications:

(60) Provisional application No. 60/081,882, filed on Apr. 15, 1998.

(51) **Int. Cl.**

**A01N 43/04** (2006.01)  
**C12N 15/00** (2006.01)  
**C12N 5/00** (2006.01)  
**C12N 15/63** (2006.01)  
**C12N 15/85** (2006.01)  
**C12N 15/86** (2006.01)  
**C12N 15/74** (2006.01)  
**C12P 21/02** (2006.01)  
**C12P 21/00** (2006.01)

(52) **U.S. Cl.** ..... **514/44**; 435/320.1; 435/455; 435/325; 435/471; 435/488; 435/69.1

(58) **Field of Classification Search** ..... None  
 See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

6,492,343 B1 12/2002 Reddy et al. .... 514/44

**FOREIGN PATENT DOCUMENTS**

EP 0259149 3/1988  
 WO WO 99/08706 2/1999

**OTHER PUBLICATIONS**

Verma et al.; "Gene Therapy—Promises, Problems, and Prospects," *Nature*, vol. 389, pp. 239–242, Sep. 18, 1997.

Eck et al., "Gene-Based Therapy," Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th Edition, Chapter 5, pp. 77–101, 1996.

McCoy et al. Nucleotide and Amino Acid Sequence Analysis of the 100K Protein of a Serotype 3 Porcine Adenovirus. DNA Sequence—The Journal of Sequencing and Mapping, vol. 8, pp. 59–61, 1997.

McCoy et al. Porcine Adenovirus 3 hexon gene. GeBank, Accession No. U34592, Jun. 12, 1996.

Kleiboeker, S. B. et al. (1993). "Genomic cloning and restriction site mapping of a porcine adenovirus isolate: Demonstration of genomic stability in porcine adenovirus" *Arch. Virol.* 133(3–4):357–368.

Park, J. H. et al. (Jun. 1998). "Sequence analysis of the early region 1B (E1B) of porcine adenovirus type 3" *RDA J. Veterinary Sci.* 40(1):19–25 (Abstract only).

Reddy, P. S. et al. (Nov. 1998). "Sequence and transcription map analysis of early region–1 of porcine adenovirus type–3" *Virus Res.* 58(1–2):97–106.

Reddy, P. S. et al. (Nov. 25, 1998). "Nucleotide sequence and transcription map of porcine adenovirus type–3" *Virol.* 251(2):414–426.

Reddy, P. S. et al. (Mar. 1999). "Development of porcine adenovirus–3 as an expression vector" *J. Gen. Virol.* 80(3):563–570.

Animal Cell Culture Ed. R. Freshney, Oxford: IRL Press, 1986. Title page and table of contents only.

Antibodies: A Laboratory Manual, Eds. Harlow & Lane. New York: Cold Spring Harbor Press, 1988. Title page and table of contents only.

Ball et al. (1988). "Identification of Mouse Adenovirus Type 1 Early Region 1: DNA Sequence and a Conserved Transactivating Function," *Journal of Virology*, vol. 62, No. 11, 3947–3957.

Berk, Arnold and Sharp, Phillip. (1977). "Sizing and Mapping of Early Adenovirus mRNAs by Gel Electroporesis of S1 Endonuclease–Digested Hybrids," *Cell* vol. 12, 721–732.

Brennan, Sean and Savage, Robert. (1990). "Embryonic transcriptional activation of a *Xenopus* cytopus actine gene does not require a serum response element," *Roux's Arch Dev. Biol* vol. 199, 89–96.

Chartier, C. et al. (1996). "Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination in *Escherichia coli*," *Journal of Virology* vol. 70, No. 7, 4805–4810.

Chiocca, S., et al. (1996). "The Complete DNA Sequence and Genomic Organization of the Avian Adenovirus CELO" *Journal of Virology* vol. 70, No. 5, 2939–2949.

Current Protocols in Molecular Biology, Eds. Ausubel et al. New York: John Wiley & Sons, 1995. Title page and table of contents only.

Derbyshire, et al. (1975). "Serological and Pathogenicity Studies with Some Unclassified Porcine Adenoviruses," *J. Comp. Path.* vol. 85, 437–443.

(Continued)

*Primary Examiner*—James Martinell

(74) *Attorney, Agent, or Firm*—McAndrews Held & Malloy Ltd.

(57) **ABSTRACT**

The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3) is provided. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals. In addition, PAV-3 vectors can be used for gene therapy and expression of heterologous polypeptides. PAV-3 genome sequences can also be used for diagnostic purposes, to detect the presence of PAV-3 DNA in a subject or biological sample.

**39 Claims, 14 Drawing Sheets**

## OTHER PUBLICATIONS

- Derbyshire, J.B. "Adenovirus" Diseases of Swine, Ed. Leman, et al 7th ed. Ames, IA: Iowa State University Press, pp. 225–227, 1992.
- DNA Cloning: A Practical Approach, Ed. D. Glover. Oxford: IRL Press, vols. I, II & III, 1985, 1987. Title page and table of contents only.
- Fallaux, et al. (1996). "Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1–Deleted Adenoviral Vectors," *Human Gene Therapy* vol. 7, 215–222.
- Fallaux, et al. (1998). "New Helper Cells and Matched Early Region 1–Deleted Adenovirus Vectors Prevent Generation of Replication–Competent Adenoviruses," *Human Gene Therapy* vol. 9, 1909–1917.
- Gerard, Robert and Meidell, Robert. (1993). "Adenovirus–Mediated Gene Transfer," *TCM* vol. 3, No. 5, 171–177.
- Gorman, et al. (1982). "Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells," *Molecular and Cellular Biology* vol. 2, No. 9, 1044–1051.
- Graham, et al. (1977). "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," *J. General Virology* vol. 36, 59–72.
- Graham, et al. (1991). "Gene transfer and expression protocols," *Methods in Molecular Biology* vol. 7, 109–128.
- Grunhaus, A. and Horwitz, M.S. (1992). "Adenoviruses as cloning vectors," *Seminars in Virology* vol. 3, 237–252.
- Hanahan, Douglas (1983). "Studies on Transformation of *Escherichia coli* with Plasmids," *J. Mol. Biol.* vol. 166, 557–580.
- Hehir, et al. (1996). "Molecular Characterization of Replication–Competent Variants of Adenovirus Vectors and Genome Modifications To Prevent Their Occurrence," *Journal of Virology* vol. 70, No. 12, 8459–8467.
- Hirahara et al. (1989). "Isolation of Porcine Adenovirus from the Respiratory Tract of Pigs in Japan," *Jpn. J. Vet. Sci.* vol. 52, No. 2, 407–409.
- Hirt (1967). "Selective Extraction of Polyoma DNA from Infected Mouse Cell Cultures," *J. Mol. Biol.* vol. 26, 365–369.
- Imler, et al. (1995) "Novel complementation cells lines derived from human lung carcinoma A549 cells support the growth of E1–deleted adenovirus vectors." *Gene Therap.* vol. 3, 75–84.
- Imler, et al. (1995) "Trans–Complementation of E1–Deleted Adenovirus: A New Vector to Reduce the Possibility of Codissemination of Wild–Type and Recombinant Adenoviruses." *Human Gene Therapy* vol. 6, 711–721.
- Kleiboeker, S. "Sequence analysis of putative E3, pVIII, and fiber genomic regions of a porcine adenovirus," *Virus Research* vol. 36, 97–106 (1995).
- Kleiboeker, S. (1995). "Identification and sequence analysis of the E1 genomic region of a porcine adenovirus," *Virus Research* vol. 36, 259–268.
- Kleiboeker, S. (1995). "Sequence analysis of the fiber genomic region of a porcine adenovirus predicts a novel fiber protein," *Virus Research* vol. 39, 299–309.
- Klonjowski, et al. (1997). "A Recombinant E1–Deleted Canine Adenoviral Vector Capable of Transduction and Expression of a Transgene in Human–Derived Cells and In Vivo." *Human Gene Therapy* vol. 8, 2103–2115.
- Kunkel, et al. (1987). "Rapid and Efficient Site–Specific Mutagenesis without Phenotypic Selection," *Methods in Enzymology* vol. 154, 367–382.
- Ma, Yuliang and Mathews, Michael B. (1996). "Structure, Function, and Evolution of Adenovirus–Associated RNA: a Phylogenetic Approach," *Journal of Virology* vol. 70, No. 8, 5083–5099.
- Maniatis, et al., *Molecular Cloning: A Laboratory Manual*, New York: Cold Spring Harbor Press, 1982. Title page and table of contents only.
- McCoy, et al. (1996). "Genomic location and nucleotide sequence of a porcine adenovirus penton base gene," *Archives of Virology* vol. 141, 1367–1375.
- McCoy, et al. (1996). "Nucleotide and amino acid sequence analysis of the porcine adenovirus 23K protein," *DNA Sequence—The Journal of Sequencing and Mapping* vol. 6, 251–254.
- Methods in Nonradioactive Detection*, Ed. Howard. Norwalk: Appleton & Lange, 1993. Title page and table of contents only.
- Morrison, et al. (1997). "Complete DNA sequence of canine adenovirus type 1," *Journal of General Virology* vol. 78, 873–878.
- Nonisotopic DNA Probe Techniques*, Ed. Kricka, San Diego: Academic Press, 1992. Title page and table of contents only.
- Nonradioactive Labeling and Detection of Biomolecules*, Ed. Kessler., Berlin: Springer–Verlag, 1992. Title page and table of contents only.
- Nucleic Acid Hybridisation: A Practical Approach*, Eds. B.D. Harnes and S.J. Higgins. Oxford: IRL Press Ltd., 1985. Title page and table of contents only.
- Oligonucleotide Synthesis*, Ed. M.J., Gait, Oxford: IRL Press, 1984. Title page or table of contents only.
- Perbal, Bernard. *A Practical Guide to Molecular Cloning*, New York: John Wiley & Sons, 1984. Title page and table of contents only.
- Reddy, et al. (1995), "Comparison of the Inverted Repetition Sequences from Five Porcine Adenovirus Serotypes," *Virology* vol. 212, 237–239.
- Reddy, et al. (1995), "Molecular cloning and physical mapping of porcine adenovirus types 1 and 2," *Archives of Virology* vol. 140, 195–200.
- Reddy, et al. (1995). "Sequence analysis of putative pVIII, E3 and fibre regions of porcine adenovirus type 3," *Virus Research* vol. 36, 97–106.
- Reddy, et al. (1996). "Porcine adenoviruses type 1, 2 and 3 have short and simple early E–3 regions," *Virus Research* vol. 43, 99–109.
- Reddy, et al. (1997). "Characterization of the Early Region 4 of Porcine Adenovirus Type 3," *Virus Genes* vol. 15, No. 1, 87–90.
- Reddy, et al. (1998). "Nucleotide Sequence, Genome Organization, and Transcription Map of Bovine Adenovirus Type 3," *Journal of Virology* vol. 72, No. 2, 1394–1402.
- Reddy, et al. (1993). "Restriction Endonuclease Analysis and Molecular Cloning of Porcine Adenovirus Type 3," *Intervirology* vol. 36, 161–168.
- Sambrook, et al., Molecular Cloning: A Laboratory Manual*, 2.sup.nd ed. New York: Cold Spring Harbor Laboratory Press, Buples 1, 2, & 3 1989. Title page and table of contents only.
- Shaw, W.V. (1975). "Chloramphenicol Acetyltransferase from Chloramphenicol–Resistant Bacteria" *Meth. in Enzymology* vol. 43, 737–755.

Transcription and Translation, Eds. B. Hames and S. Higgins. Oxford: IRL Press, 1984, Title page and table of contents only.

Tuboly, et al. (1993). "Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs," *Research in Veterinary Science* vol. 54, 345–350.

Viral Diarrheas of Man and Animals, Eds. Saif et al., "Enteric Virus Vaccines: Theoretical Considerations, Current Status, and Future Approaches," Chapter 14, pp. 313–329, 1990.

Vrati, et al. (1996). "Unique Genome Arrangement of an Ovine Adenovirus: Identification of New Proteins and Proteinase Cleavage Sites," *Virology* vol. 220, 186–199.

Xiang, et al. (1996). "A Replication-Defective Human Adenovirus Recombinant Serves as a Highly Efficacious Vaccine Carrier," *Virology* vol. 219, 220–227.

Zheng, et al. (1994). "The E1 sequence of bovine adenovirus type 3 and complementation of human adenovirus type 5 E1A function in bovine cells," *Virus Research* vol. 31, 163–186.

Zoller, Mark and Smith, Michael. (1982). "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," *Nucleic Acids Research* vol. 10, No. 20, 6487–6500.

McCoy et al. Nucleotide and amino acid sequence analysis of the 100k protein of a serotype 3 porcine adenovirus. GeBank, Accession No. U82628, Dec. 18, 1996.

Redeclaration, Jan. 24, 2006.

Judgment, Aug. 9, 2006, patent Interference No. 105358.

Board Order Relating to Motion Times.

Johnson List of Intended Preliminary Motions, Paper 18.

Bett et al.; "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3," *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 8802–8806, Sep. 1994.

Crouzel et al.; "Recombinational construction of *Escherichia coli* of infections adenoviral genomes," *Proc. Natl. Acad. Sci. USA*, vol. 94, pp. 1414–1419, Feb. 1997.

Ketner et al.; Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone, *Proc. Natl. Acad. Sci. USA*, vol. 91, pp. 6186–6190, Jun. 1994.

He et al.; "A simplified system for generating recombinant adenoviruses," *Proc. Natl. Acad. Sci. USA*, vol. 95, pp. 2509–2514, Mar. 1998.

CATCATCAATAATATACCGCACACTTTTATTGCCCTTTTGTGGCGTGGTGATTGGCGGAGAGGGT  
TGGGGGCGGCGGGCGGTGATTGGTGGAGAGGGGTGTGACGTAGCGTGGGAACGTGACGTCGCGTGG  
GAAAATGACGTGTGATGACGTCCCGTGGGAACGGGTCAAAGTCCAAGGGGAAGGGGTGGAGCCCTG  
GGGCGTCTCCGCGGGGCGGGGCCGAGCGGCGGAAATCCCGCACAGGTGGAGAGTACCGCGGGA  
TTTTGTGCCCTCTGGACCGGACCTTCGCCCTCCGGTGTGGCACTTCCGCACCACACGTCCGCGGCC  
CGGTATCCCCACCTGACGACGGTGACACCACTCACCTGAGCGGGGTGTCTTCGCGCTGAGAGGT  
CCGCGGCGGCCGCCCGAGATGACGTGTGTGGGTGTATTTTTTCCCTCAGTGTATATAGTCCGCGC  
AGCGCCCGAGAGTCACTACTCTTGAGTCCGAAGGGAGTAGAGTTTTCTCTCAGCGGAACAGACCTT  
CGACATGGCGAACAGACTTCACCTGGACTGGGACGGAAACCCCGAGGTGGTGCCGGTGTGGAATG  
GGACCCGGTGGATCTGCGCGACCCCTCTCCGGGGGATGAGGGCTTCTGTGAGCCGTGCTGGGAGAG  
TCTGGTTCGATGGACTGCCGGACGAGTGGCTGGACAGTGTGGACGAGGTGGAGGTGATTGTGACTGA  
GGGGGGTGTGAGTCAGAGGACAGTGGTGGGAGTGCCGCTGGTACTCAGGTGGCTCTCAGGGGGTCTT  
TGAGATGGACCCCCAGAAGAGGGGGACAGTAATGAGGAGGATATCAGCGCGGTGGCTGCGGAGGT  
GCTGTCTGAACTGGCTGATGTGGTGTGTTGAGGACCCACTTGCGCCACCCCTCTCCGTTTTGTGTTGA  
CTGCCCCGAGGTACCTGGTGTGAACTGCCGCTCTTGTGATTACCATCGCTTTCCTCCAAGGACCC  
CAATCTGAAGTGCAGTCTGTGCTACATGAGGATGCATGCCTTTGCTGTCTATGGTGAGTGTTTTTG  
GACATTTGTGGGATTATGTGGAAAAAAGGAAAAAGTGCTTGTAAAGAAATCTCATGTGCTATTTCC  
CATTTTTGTCTTTTTAGAACTGTTTTCTCCAGCACCTCACAGGTCCGGTTCGCCGGGACTTGGAG  
ACCTGCCAGGACGCAAGAGGAAGTACTGCTATGACTCATGCAGCGAACAACTTTGGACCTGTCTA  
TGAAGCGCCCCGCGATTAATCATTAACTCAATAACAGCATGTGATGACTGATTGTCTGTG  
TCTCTGCCTATATATACCCTTGTGGTTTGCAGGGAAAGGGATGTGGTACTGAGCTATTCCTCAGCA  
TCATCATCGCTCTGCTTTTTTCTACTGCAGGCTATTTCTTGCTAGCTCGCTGTCCCTTTTCTTTTT  
CTGTGGGCATGGACTATCAACTTCTGGCCAAGCTTACTAACGTGAACTACCTTAGGAAGGTGATAG  
TACAGGGGTCTCAGAACTGCCCTTGGTGGAAAAAGATTTTTTTCGGACAGGTTTATCAAGGTAGTAG  
CAGAGGCCAGGAGGCAGTACGGGCAAGAGTTGATTGAGATTTTTGTGGAGGGTGGAGGGGGCTTTG  
GTCCTGAGTTCTGCGGGAAGGGGGACTGTACGAAGAGGCCGTTCTGAAAGAGTTGGATTTAGCA  
CCTTGGGACGCACCGTAGCTAGTGTGGCTCTGGTCTGCTTCATTTTTGAGAAGCTTCAGAAGCACA  
GCGGGTGGACTGACGAGGGTATTTTAAAGTCTTCTGGTCCCGCCACTATGTTCCCTGCTGGAGGCGC  
GAATGATGGCGGAGCAGGTGCGGCAGGGGCTGTGCATCATCAGGATGCCGAGCGCGGAGCGGGAGA  
TGCTGTTGCCAGTGGGTATCCGGCAGTGGCAGCGGGGCCGGATGCCGGACCAGGTGGTGCCCA  
AGCGCCCGCGGAGCAGGAAGAGGAGGAGGAGGACGAGGATGGGATGGAAGCGAGCGGGCGCAGGC  
TCGAAGGGCCGGATCTGGTTTAGATCGCCGCCCGGCCGGGGAGCGGGTGGAGAGGGGAGCGGGGA  
GGAGGCGGGGGGGTCTTCCATGGTTAGCTATCAGCAGGTGCTTTCTGAGTATCTGGAGAGTCTCT  
GGAGATGCATGAGCGCTACAGCTTTGAGCAGATTAGGCCCTATATGCTTCAGCCGGGGGATGATCT  
GGGGGAGATGATAGCCAGCACGCCAAGGTGGAGTTGCAGCCGGGCACGGTGTACGAGCTGAGGCG  
CCCGATCACCATCCGCAGCATGTGTTACATCATCGGGAACGGGGCCAAGATCAAGATTCGGGGGAA  
TTACACGGAGTACATCAACATAGAGCCGCGTAACCACATGTGTTCCATTGCGGGCATGTGGTCCGT  
GACTATCACGGATGTGGTTTTTGTGATCGGGAGCTACCGGCCCGGGTGGTCTGATTTTAGCCAACAC  
GCACTTCATCCTGCACGGCTGCAACTTCTGGGCTTTCTGGGCTCGGTAATAACGGCGAACGCCGG  
GGGGGTGGTGCGGGGATGCTACTTTTTCGCCTGCTACAAGGCGCTGGACCACCGGGGGCGGCTGTG  
GCTGACGGTGAACGAGAACACGTTTGAAGAGTGTGTGTACGCGGTGGTCTCTGCGGGCGTTGCAG  
GATCAAGTACAACCTCCTCCCTGTCCACCTTCTGCTTCTTGACATGAGCTATACGGGCAAGATAGT  
GGGGAACAGCATCATGAGCCCTTACACGTTACGCGACGACCCCTACGTGGACCTGGTGTGCTGCCA  
GAGCGGGATGGTGTGATGCCCCGAGCACGGTGCACATCGCTCCCTCGTCTCGCCTGCCCTACCCTGA  
GTTCCGCAAGAATGTGCTCCTCCGCAGCACCATGTTTGTGGGCGGCCGCTGGGCAGCTTCAGCCC  
CAGCCGCTGCTCCTACAGCTACAGCTCCCTGGTGGTGGACGAGCAGTCTACCGGGGTCTGAGTGT  
GACCTGCTGCTTCGATCAGACCTGTGAGATGTACAAGCTGCTGCAGTGTACGGAGGCGGACGAGAT  
GGAGACGGATACCTCTCAGCAGTACGCCTGCCTGTGCGGGGACAATCACCCCTGGCCGCAGGTGCG  
GCAGATGAAAGTGACAGACGCGCTGCGGGCCCCCGGTCCCTGGTGGAGCTGCAACTGGGGGGAGTT  
CAGCGATGACGATGACTGAGGATGAGTACCCCTCCCTCCTCTTGCAGGTACGTGGCCCCGCC  
AGTGGGATGGGCTTTGGATGGGGGAGGGGTGTTCCCTATAAAGGGGGATGGGGGTGGAGGCATGC  
AGCCCCACGGGGAAGCTTGTGTGGAGGATGTCTCCGAGGGTGGAGATCCGGACCTGCTTCATTTCA

FIG. 1-1

GCTCGTCTTCCCAGCTGGGCCGGCGTGCGTCAGGGAGTGGCCGGGACGAATGTGAACGGCGGAGTG  
GTGGGCGCCCCTGCCAGAGCGGGGTGCTGGCCTACTCCCGCTTCGTTTCAGCAGCAACAGCAGCAG  
CCGGGGACGGCGGGCGACGGGGTCTGTGTTCCGGGCGGTGTTTCCATCGGTGGATCTGAGCGCGGAG  
GTGGGCATGATGCGGCAGGCGCTGGCGGAGCTGCGGCAGCAGCTGCAGGAGCTGCGGGAGGTGGTG  
GAGATACAGCTGCGGGCCACGGCCTCGGAGGCGGCCGAGGAGGAAGAGGAGGAGGAGATTGTGGTG  
GACGAGGAGGTGGCGCCCCGGCGCTGGAGCGAACACCATGGAAGAGGAGGAGGATGAGATGGTCCTG  
ACGATGACTGTGGTGGGGGACCCTGAGCCTGCTGGAGTGGAAAGCCAGCCGCCACCACCACCACC  
CCGGAGAGCGACCCTGCGGTGCCTGCTACTACCCTACCCCGAAGCGGCTCAGCTACGGCGCGAGC  
AAGAGGAGCGGTCCATGCGCGGAGGACAACCTGACGCGGACTGTGGGGGGAAGAAGGGGGAGGAGGA  
AGAAGACCATGGAGACGGGTGTTTGTCTTTTCCAGCCCACTTTATTGAGAATAATAATAAAGC  
TTATGGATGTTTGGAAACGATAATAGCGTGTCCAGCGTCTCTGTCTTGCAGGGTCTTGTGTATCTT  
CTCGAGGCACCGGTAGACCTGGTGTGGACGTTGAAATACATGGGCATGACTCCCTCGGCGGGGTG  
CAGGTAAGCCACTGGAGGGCTGGGTGCGGGGGCAGGTGCAGTAGATGATCCAGTCATAGGCGTT  
CTGGTTGCGGTGGTGGTTGAAAATGTCCTTGAGGAGCAGGCTGATGGCGGTGGGCAGACCCTTGGT  
GTAGGCATTGATGAACCGGTTGACCTGGGCGGGCTGCATGAGGGGGGACATGATGTGGTACTTGGC  
CTGGATCTTGAGGTTGGAGATGTTGCCGCTCTGGTCCGGCGGGGGTTCATGTTGTGGAGGACGAC  
GAGGACGGCGTAGCCGGTGCAGCGGGGGAAGCGGGCGTGCAGCTTGGAGGGGAAGGCGTGGAAGAA  
CTTGGCGACCCCTTGTGTCCGCCGAGGTCCTCCATGCACTCGTCGAGGACGATGGCGATGGGTCC  
GCGGGCGGCGGCGCGGGCGAAGACGTTGCGTGAGTCAGTGACATCATAGTTGTGCTCCTGCATGAG  
GTCTGGTAGCTCATGCGGACAAAGTCTGGCATGAGGGTGGCGGTCTGGGGGATTAGGGTGTGGTC  
CGGACCGCTGCGGTAGTTGCCCTCGCAGATCTGGGTCTCCAGGCGACTACCTCCTGCGGGGGGAT  
CATGTCCACCTGCGGGGTGATGAAGAAAACAGTCTCCGGCGGGGGGAGAGGAGTTGGGAGGAGAT  
GAGGTTGCGGAGCAGCTGGGACTTGCCGGAGCCGGTGGGACCGTAGATGACAGCGATGACTGGCTG  
GACCTGGTAGTTGAGGGAGCGGCAGGTGCCAGCCGGGGTGGAGGAAGGGCATGCAGGCGTTGAGGGT  
GTCGCGCAGGTTGCGGTTCTCTTGGACGAGGTCCTGCAGGAGGTGTCGGCCTCCAGGGAGAGGAG  
GTGGGAGAGGGAGGCGAAGGCCTTGAGGGGCTTGAGGCCCTCGGCGTAGGGCATGTCCTGCAGGGC  
CTGGTGGAGCACGCGCATGCGCTCCAGAGCTCGGTTACATGTCCCACGGTATCGTCTCCAGCAG  
GTCTGGTTGTTTCTCGGGTTGGGGTTGCTGCGTGAGTACGGAACGAGGCGGTGGGCGTCGAGCGGG  
TGGAGGGTCCGGTCTTCCAGGGCCGGAGGGCCCGCGTGAGGGTGGTCTCGGTGACGGTGAAGGGG  
GCGGTCTGGGGCTGCTCGGTGGCCAGGGTCTCTTGGAGCTGAGGCGGCTGGTGCTGAAGGTGGCG  
CTTCCGAGCTGCGCGTCTGTTAGGTTAGCACTGGCGGAGGAGGTCATAGGAGAGGTTGTGGGTGGCA  
TGGCCCTTGGCGCGGAGCTTGCCGGGGCCGCGGTGCCCGCAAGCATCGCAAACGGTGTCCGCGCAGG  
GCGTAGAGCTTGGGGGCGAGCAGGACCGTCTCGGAGCTGTGGGCGTCGCTGCGGCAGCGCTCGCAC  
TGGGTCTCGCACTCGACCAGCCAGGTGAGCTGGGGGTTCTGGGGATCGAAGACGAGGGGGCCCCCG  
TTCCGCTTGAGGCGGTGTTTACCTTTGGTCTCCATGAGCTCGCGTCCGGCGCGGGTGGAGGAGAGG  
CTGTCCGTGTCCCCGTAGACGGAGCGCAGGGGCCGGTCCGGCATGGGGGTGCCGCGGTCTGTCGGCG  
TAGAGGATGAGGGCCCACTCGGAGATGAAGGCACGCGCCCAGGCGAGGACGAAGCTGGCGACCTGC  
GAGGGGTAGCGGTGTTGGGCACTAATGGCGAGGCCTGCTCGAGCGTGTGGAGACAGAGGTCCTCG  
TCGTCCGCGTCCAGGAAGTGGATTGGTCCGAGTGGTAGTCCACGTGACCGGCTTGGGGTCCGGGG  
GGTATAAAAGGCGCGGGCCGGGGTGGCGTGGCCGTCAGTTGCTTCCGAGGCCTCGTCACCGGAGTCC  
GCGTCTCCGGCGTCTCGCGCTGCGGCTGCATCTGTGGTCCCGGAGTCTTCAGGTGGGTACGCTACG  
ACAAAGTCCGGGGTGACCTCAGCGCTGAGGTTGTCTGTTTCTATGAAGGCGGAGGAGCCGACGGAG  
AGGTCGCCGCGGGCGATGGCTTCGGTGGTGGCGGGCGTCCATCTGGCTGGCGAAGACCACCTTCTTA  
TTGTGAGGCGTGTGGCGAAACTGCCGTAGAGGGCGTGGAGAGAAGCTTGGCGATGCTGCGGAGC  
GTTTGGTTTCTGTCCCAGGTCGGCCTTTTCTTGGCAGCGATGTTGAGCTGCACGTAGTCTCGGGCG  
AGGCAGCGCCACTCGGGGAAGATGCTGTTGCGCTCGTCCGGCAGGAGGCGCACGGCCAGCCACGG  
TTGTGGAGGGTGACCAGTCCACGGAGGTGGCTACCTCGCCGCGGAGGGGCTCGTTGGTCCAGCAG  
AGGCGGCCGCCCTTGGCGGAGCAGTAGGGGGGCGAGGACGTCCAGCTGGTCTCGTCCGGGGGGTCCG  
GCGTCGATGGTGAAGAGGGCGGGCAGGAGGTGGGGTCCGAAGTAGCTGAGGGGCTCGGGGCCGTCG  
AGGCGGTCTGCCAGCGGGCGGGCCAGGGCGCGGTCCGAAGGGGTTGAGGGGTTGGCCGGCGGGG  
AAGGGGTGGGTGAGGGCGCTGGCATAACATGCCCGCAGATGTCATAGACGTAGAGGGGCTCCCGCAGG  
AGGCCGATGAAGTTGGGGTAGCAGCGGCCCGCGCAGGCTCTTCGCGGACGTAGTCATACAGCTC  
GTGGGAGGGCGCGAGGAGGTTCCGGCCGAGGTGCGGGCGCTGGGGCCGGCTGGCGCGGTAGAGGAGC  
TGCTTGAAGATGGCGTGGGAGTTGGAGCTGATGGTGGGCCTCTGGAAGACATTGAAGGCGGCGTGG  
GGAAGGCCGGCCTGCGTGTGGACGAAGGCGCGGTAGGACTCTTGCAGCTTGCAGGACGAGCGGGCG  
GTGACGACGACGTCCTGGGCGCAGTAGCGCAGGGTGGCCTGGACGATGTCGTAAGCGTCCCCCTGG

**FIG. 1-2**

CTCTCCTTCTTCCACAGGTCCTTGTGAGGAGGTA CTCTGATCGCTGTCCCAGTACTTGGCGTGT  
GGGAAGCCGTCCTGATCGCGTAAGTAGTCCCCCGT GCGGTAGAACTCGTTCACGGCATCGTAGGGG  
CAGTGTCCCTTGTCCACGGCCAGCTCGTAGGCCGCGGGCCCTT GCGGAGGCTGGTGTGCGTGAGG  
GCGAAGGTGTCCCGGACCATGAACTTGACGTACTGGTGTGGGGGTCCTCGGGGGCCATGACGCC  
TCCTCCCAGTCCGCGTAGTCGCGGGCGGGCGGAAGGCGGGGT TGGGCAGGTTGAAGCTGATGTCA  
TTGAAGAGGATGCGGCCGTTGCGCGGCATGAAGGTGCGGGTG ACCAGGAAGGAGGGGGCACCTCG  
CGCGGTGGGCGAGCACCTGCGCGGCCAGGACGATCTCATCGAAGCCCGAGATGTTGTGGCCACG  
ATGTAGACCTCCAGGAAGAGGGGCGGCCCGCGCAGGCGGCGGCGCCG CAGCTGGGCATAGGCCAGG  
GGTCTTCGGGGTCGTCCGGCAGGCCGGGGCCCCGCTCCTGCGCCAGCTCGGCGAGGTCTGGGTG  
TGGGCCAGCAGGTGCTGCCAGAGGGTGTGGTGGAGGCGGGCCTGCAGGGCGTGCCGCAGGGCCTTG  
AAGGCGCGGCCGATGGCGCGCTTCTGCGGGCAGAGCATGTAGAAGGTGTGGGCTCGGGTCTCCAGC  
GCTGCAGGCGGGCTCTGGACGGCCACCACCTGCAGCGCGGCGTCCAGCAGCTCCTCGTCCCCCGAG  
AGGTGGAAGACCAGCAGGAAGGGCACGAGCTGCTTCCGAAGCGGCCGTGCCAGGTGTAGGTCTCC  
AGGTCATAGGTGAGGAAGAGGCGGGCGGGTGCCCTCGGGGGAGCCGATGGGGCGGAAGGCGATGGTC  
TGCCACCAGTCGGCCGTCTGGCGCTGAACGTGGTGGAAAGTAGAAGTCCCGGCGGCGCACGGAGCAG  
GTGTGGGCGGTCTGGAAGATGCGGCCGAGTGTCTCGCACTTCTGGGCCTCCTGGATGCTCTTGATG  
AGGTGGCAGCGGCCCTGGGTGAAGAGCAGGCGGAGGGGGAAGGGGAGGCGGGGCGGCGGGCCCTCG  
GGCGGGGGGTCCCAGCGCACGTGGTGCAGGTGGTGTGCTGGCGGGTGACCACCTGGACGAAGGTG  
GGCCCGGCGGCGCGGGCCAGCTCCACCGCGGTCTGGGGGGTAGCCTGCAGGAGGTGGGGGGCGGG  
CGCAGGAGGTGCAGCTGGAAGAGGTTGGCCAGGGCGCTGTCCCAGTGGCGGTGGTAGGTGATGCTC  
CAGCTCTCCCCGTCTGGGTGGTGCCTGGAGGCGGAGGGTGGCGCGGCGCTCGAGCAGGAGCCCC  
CGCGTGCCGGCCTCCGCGGCCTCGGCGGCGGCGGGCCGGTCTCAGGCGGGCAGCTGGGCCAGGGCA  
CGGGCGCGTTGAGCTCGGGCAGCGGGAGGTGGTCGCGGCGCAGACCGGAGGCGTGGGCGATGACGC  
GGCGGTTGATGTTCTGGATCTGCGGGTCCCGGAGAAGACCACGGGCCCGGTGACTCGGAACCTGA  
AAGAGAGTTCACGGAATCAATGTCGGCATCGTGGGTGGCCACCTGGCGCAGGATCTCGGACACGT  
CCCCGTGTTTTTCGCGGTAGGCGATGTCCTGCATGAACTGCTCGAGCTCGTCTTCGTCCAGGTCCC  
CGTGGCCGGCGCGCTCCACGGTGGCGGCCAGGTCGACGGTGATGCGGTTTCATGATGGCCACCAGGG  
CGTTCTCTCCGTTCTCGTTCACACGCGACTGTAGACCAGCTGGCCGTCCGGCGTCCCGCGCGCGCA  
TGACTACCTGGGCCAGGTTGAGCGCCACCAGGCGGTTGAAGGGCGCCTGCAGGCGCAGGGCGTGGT  
GCAGGTAGTTGAGGGTGGTGGCGATGTGCTCGCAGAGGAAGAAGTTTATGACCAGCGGCGCAGGG  
TCAGCTCGTTGATGTCGCCCAGGTCCTCGAGGCGCTGCATGACCCGGTAGAACTCGGGGGCGAAGC  
GAAAAAAGTCTGCTGGCGGGCCGAGACCGTGAGCTCCTCTTCCAGGGCGGGCGATGGCCTCGGCCA  
CCGCCTGCCGCACCTCCTCCTAAGGAGGGCGGGGGCGTGCTGGGTCCGGCCACCGCCCGCCTCTT  
CTTCTCTTCTCCCTCCAGGGGTGGCATCTCCTCGTCTTCTTCTTCTGCTGCTGCTGCCTCCGCGG  
GGACGGGGGGCGCAGGCCGGGGACGGCGCCGGCGCAAGGGCAGCCGGTCCACGAAGCGCTCGATGA  
CCTCGCCCCGCATGCGGGCGCATGGTCTCGGTGACGGCGCGGCCCGCCCTCCCGGGGCGCAGCTCGA  
AGGCGCCCCCGCGCAGCGCGGTGCCGCTGCAGAGGGGCGAGGCTGAGCGCACTGATGATGCAGCGTG  
TCAACTCTCTCGTAGGTACCTCCTGCTGTTGCAGCGCTTCGGCAAAGTCCGCGCACCTGCTCTTCGG  
ACCCGGCGAAGCGTTCGACGAAGGCGTCTAGCCAGCAACAGTCGCAAGGTAAGTTGAGCGCGGTGT  
GCGTCCGGGAGCCGAGGTGCCGGCTGACGAGGAAGTGAAGTAGGCCGTCTTGAAGTGCAGGATGG  
CGCGCAGGAGGGTGAAGTCTTTCGGGCCGGCGCGCTGCAGGCGGATGCGGTCCGGCCATGCCCCAGG  
CCTCCTGCTGGCAGCGGCCGATGTCCTTGAGCTGCTCCTGCAGCAGATGTGCCACGGGCACGTCCC  
GGTCCGGCGTCCAGGTGGGTGCCACCGTAGCCCCGAGGGGGCGCAGCAGCGCCAGGTCCGGCCACCA  
CGCGCTCGGCCAGGATGGCCTGCTGCATGCGCTGCAGGGAGTCTGAGAAGTCATCCAGGTCCAGGA  
ACCGGTGGTAGGCGCCCGTGTGATGGTGTAGGAGCAGTTGCCAGCACGGACCAGTTGACCACCT  
GGTAGTGGGGCTGGATGACCTCGGTGTAGCGCAGTCGACTGTAGGCGCGCGTGTCAAAGATGTAAT  
CGTTGCAGAGGGCGCAGCAGGTGCTGGTAGCCACGAGCAGGTGGGGCGGAGGGTAGAGGTAGAGGG  
GCCAGTGTTCGTTGGCCGGTGGCGGGGGGAGAGGTTTCATGAGCATGAGGCGGTGGTAGCGGTAGA  
TGAAGCGGGACATCCAGGCGATGCCGACGGCGGAGACGGAGGCGCGGGTCCACTGGTGGGCGCGGT  
TCCAAATGTTGCGCACCGGGCGGAAGAGCTCCACGGTGTAAATGGATTGCCCGTGAGGCGGGCGC  
AGTCGAGGGCGCTCTGTCAAAAAGAACCAGGGTGTGGTTGGTTGGTGTGTGGTAGCGATCTATCTTT  
CTTTGTGATCTTGGTAGTGAAGCCTGCCAGGCTCCAGCAGGGGGCGTCCGCCGTCTTTCCTTCTT  
CCCTATCTGGAGGTGTGTCTCTGTTCTCTTTTTTATTTTCATGTAGCCATGCATCCCGTCTGCGGC  
AGATGAAGCCGCGCGGGCCGGCGCCCTGGGCGCGGAGGGGGCGACGCGCTCTCGGTCCCGTCCCGT  
CGCTGACGCGGGCCGCGGAGGAGGGGGAGGGCCTGGCGCGGCTGTGGGGCGGGCGGGCCCCCGAGC  
GGCACCCACGGGTGCAGCTCAAGCGAGAGGCCATGGAGGCCATGTGCCGAGGCAGAATGCGTTC

FIG. 1-3

GCGAGCGACCGGGGAGGAGGGGAGGAGATGAGGGACCTGCGGTTCCGCGCGGGGCGGGAGATGC  
AGCTGGACCGGGAGCGAGTGCTCCAGCCCGAGGACTTTGAGGGGCGCGTGGAGGAGGCGGGGGGAG  
TGAGCGCGGCGCGGGCCACATGAGCGCGGCCAGCCTGGCCAGGCTACGAGCAGACGGTACGCG  
AGGAGGTCAACTTCCAAAAGACCTTCAACAACAACGTGCGCACCCCTGGTGAGCCGGGACGAGGTGA  
CCATGGGACTGATGCACCTGTGGGACTTTGTGGAGGCCTTCCCTGCAGCACCCCGGTCCCGCGCGC  
TGACCGCGCAGCTGCTGCTGATCGCGCAGCACTGCCGGGACGAGGGCATGGTGAAGGAGGCGCTGC  
TGAGCCTGGGCGCGCCCGAGAGCCGCTGGCTGGTGGACCTGGTGAACCTGCTCCAGACCATTTGTGG  
TGCAGGAGCGGTCCATGAGCCTGAGCGAGAAGGTGGCGGCCATCAACTACTCGGTGGCGACCCTGG  
CCAAGCACTACGCGCGCAAGATCTCCACCTTCTACATGCGCGCGGTGGTGAAGCTGCTGGTGTGG  
CCGACAACCTGGGCATGTACCGCAACAAGCGGCTGGAGCGCGTGGTCAGCACCTCGCGGGCGGCGCG  
AGCTCAATGACAAGGAAGCTCATGTTTGGCCTCCGCCGGGCGCTGGCCGGGAGGGCGAGGAGGAC  
CTGGAGGAGGAGGAGGACCTGGAGGAGGCGGAGGAGGAGGAGCTGGAAAGAGGAGGAGTTCCGTCC  
CCGGGGACCGCGGCGCGTGGAGGTGGCAGTCCCCGCTGACTGCGAGCGATGAGGGTGTGTGTACTG  
ATGGCAACCATCCCCCTTTTAAACAACAACAGCAGCATGGCGGCGAGCTCTGAAGCTGGGGCGGGC  
GCGGCGGGGGTGGAGCGCGGCTCCCTGGCGCCCGAGCGGGCGACGCGGATGCAGGCGCTGCCCTCC  
CTGGACGAGCCTTGGGAGCAGGCTCTGCGGCGCATCATGGCGCTGACGGCCGACGGGTCTCGGCGC  
TTCGCGAGCCAGCCCCTGGCCAACCGCATCGGGGCCATCCTGGAGGCGGTGGTGCCTCCGCGCACG  
AACCCGACGCACGAGAAGGTGCTGACCGTGGTGAACGCGCTGCTGGAGACCTCGGCCATCCGCCCG  
GACGAGGCCGGCATGGTGTACGATGCGCTGCTGGAGCGGGTCTCCCGCTACAACAGCGGCAACGTG  
CAGACCAACCTGGACCGGCTGTCCCAGGACGTGCGGCAGGTGATCGCCAGCGCGAGCGCTCGAGC  
GCCAACAACCTGGGCAGCCTGGCCGCGCTGAATGCCTTCATCGCCTCGCTGCCCGCAACGGTGGAG  
CGGGGCCAGGAGAGCTACCTGGGGTTCCTCAGCGCGCTGCGGCTGCTGGTGGAGCGAGGTGCCGAG  
ACGGAGGTGTTCCGCTCGGGGCGCACACCTTCTGCGAGGCGGCGCGGAACGGTTCAGAGCGGTG  
AACCTCAACCAGGCCATGGAGAACCTGCGGCCCTGTGGGGGCTGCAGGCCCCCGCTGGGGAGCGC  
GGGCACGTGTCTCCCTGCTGACGCCAACACCCGGCTGCTGCTGCTCCTGGTGGCTCCCTTCGCG  
GAGGAGATGAACGTCAGCCGGAGCTCCTACATTGGGCACCTGCTGACACTCTACCGCGAGACGCTG  
GCCAACTTGCATGTGGACGAGCGCACGTACCAGGAGATCACCAGCGTCAGCCGGGCGTTGGGCGAC  
GAGGACGACGCGGCGGGCTGCAGGCCACCCTCAACTTCTTCTGACCAACCGGCAGCGGCGGGCTG  
CCGGCGGCGTATGCCCTGACCGCCGAGGAGGAGCGCATCCTGCGCTACGTGCAGCAGGCCGTGAGC  
CTGTACCTGATGCAGGACGGGGCGACGGCCACGGGCGCCCTGGACGAGGCCAGCCGCAACCTGGAG  
CCCAGCTTCTACGCGGCGCACCGGGACTTCATCAACCGCCTGATGGACTACTTCCATCGCGCGGCC  
GCGGTGGCGCCCAACTACTTTATGAATGCCGTCTGAACCCCGCTGGCTGCCCTCGGAGGGCTTC  
TTCACCGGCGTGTATGACTTCCCGGAGCAGGACGAGGGGGAGGAGCGGCCCTGGGACGCCTTTGAC  
AGCGACGAGGAGGGCCGCTCATGCTGCGGTCCGCAGCCTCCTCAGAGCCCTCCTCCTCCTTACC  
CCCCTGCCCTGACCGAGGAGCCGCCCTCGCGGCCCTCCACCCCGGCCCTCTCGCGCGTCCCGTCC  
CGGGCATCCTCCCTGCTCTCTGTCCTCTGGGAAAGCGGGAGGGAGGGGACTCGCTCGCCTAC  
TCGCCGGCCACGCCACCTATGGCTCTCGCTGGGGCTCGCGCCGCTCCAGCCTGGCCAGCGGCGCC  
GACAGCCTGGAGTGGGACGCGCTGCTGGCCCTCCCAAGGATGTGAACGAGCACCCAGGCGCCGCC  
GCCGGCCGCCCGCCCGCGCCTCCCGCTCCTCCCTGGAGGAGGACATCGACGCCATCAGCAGCCGG  
CTGTTACCTGGCGCACGCGCGCCAGGAGATGGGCCTGCCCGTGGCCAGCTTCTCCCGCCGCCAC  
CAGCCGCGCCCCGGGGCCCTCGAAGACGACGAGGAGGAGGAAGACTGGCGCCAGGACCGGTCTTT  
CGCTTCGAAGCGCCCGAGGAAAACCCCTTCCGCCACATCGCCCCAAGGGGCTGTAATGCAAAAA  
GCAAAATAAAAAACCCCTCCCGGTCCAACCTCACCACGGCCATGGTTGTCTTGTGTGCCCGTCAGA  
TGAGGAGGATGATGCCAGCAGCGCCGCGCAGGGAGCGTCGCCTCCGCCGTCTACGAGAGTGTGG  
TGGGGTCTTCGCTCACGGAGCCTCTTTATGTGCCGCGCGGTACCTGGGCCCCACCGAGGGGCGGA  
ACAGCATCCGTTATTACAGCTCCCGCCGCTCTACGATACCACAAAGATCTATCTGATCGATAACA  
AGTCGGCGGATATCGCCAGTCTGAACTACCAAAACAACCACAGTGACTTTCTCACCAGCGTGGTGC  
AGAACAGCGACTTCAGGCCATGGAGGCGAGCACGCGAGACCATCAACCTGGATGAGCGCTCGCGCT  
GGGGCGGGGAGTTAAGAGCATTCTGACCACCAACATCCCCAACGTGACCCAGTACATGTTACGCA  
ACAGCTTCCGGGTGCGCCTGATGAGCGCGCGGATAAAGAGACAAATGCCCCACCTACGAGTGGT  
TCACCCTGACCCTGCCCGAGGGCAACTTCTCGGACATCGCGGTTCATCGACCTGATGAACAACGCGA  
TCGTGGAGAACTACCTGGCGGTGGGGCGGCAGCAGGGGGTCAAGGAGGAGGACATCGGGGTGAAGA  
TCGACACGCGCAACTTCCGCCTGGGCTATGACCCGGAGACCAAGCTGGTTCATGCCCGGCGAGCTACA  
CCAACATGGCCTTTCACCCCGACGTGGTGTGGCACCAGGGCTGCGCCATCGACTTACCTTCTCC  
GCCTAAACAACCTGCTGGGCATCCGCAAGCGCTACCCCTACCAGGAGGGCTTCATGCTGACCTACG  
AGGACCTGGCGGGGGCAACATCCCCGCGCTGCTGGACCTCACCACCTATGATCAGGAGAATCCA

**FIG. 1-4**

GCACCATCAAGCCCCTGAAGCAGGACAGCAAGGGTCGCAGCTACCACGTGGGCGAGGACCCCGAGG  
CGGGGGACACCTTCACCTACTACCGCAGCTGGTACCTGGCCTACAACCTACGGGGACCCGGCCACGG  
GCACCGCCTCCCAGACGCTGCTGGTCTCCCCGGACGTAACCTGCGGAGTGGAGCAGGTCTACTGGA  
GCCTGCCGGACCTGATGCAGGACCCGGTGACCTTCCGGCCCAGCCAGACGCCGAGCAACTACCCGG  
TGGTAGCCACGGAGCTACTGCCGCTGCGCTCCCCGGCCTTCTACAACACCCAGGCCGTGTACTCCC  
AGCTCCTGCAGCAGGCCACCAACAACACCCCTGGTCTTTAACCGCTTCCCGGAGAACCAGATCCTCC  
TGCGCCCGCCAGAGTCCACCATCACCTCCATCAGCGAGAACGTGCCCTCGCTGACGGACCACGGCA  
CGCTGCCGCTGCGTAACAGCATCCCCGGGGTGCAGCGGGTAACCGTCACCGACGCGCGGGCGCCGCG  
TGTGTCCCTATGTGTACAAGAGTCTCGGGGTGGTGACCCCGAGGGTGTCTCAGCAGCCGAACCTTCT  
AACCGACAGCCCTACCCGTACAGGGGAGACAGAGAAAAGACAGCCAGCCCCGCCATGGCCATCCT  
CGTCTCGCCAGCAACAACCTTTGGCTGGGGACTGGGCCTGCGCTCCATGTACGGGGGCGCCCGCCG  
CCTGTCCCCGGATCACCCCGTGATCGTCCGACGCCACTACCGGGCCAACCTGGGCCAGTCTGAAGGG  
ACGCGTGGCCCCCAGCACCATAGCGACAACGGATGACCTGTGGCCGACGTGGTCAACCGCATCGC  
CGGCGCCACCCGCCCGCCGGCGCCGCCATCGTCGACGTGGAGGGCCGCGCGCGTCTCCTCCGTGGC  
CGTCACCGGGGACCCGGTGGCCGATGTGGTCAACGCGGTGGAGGCGGTAGCCCGGCGCCCGCCGCG  
GCGGCGCCGTCTTCGCGCATGCAGACCACGGGGACCCCGTGGCGGATGTGGTGGCGGCGGTGGA  
AGCGGTGGCGCGCCGGAGGCGGAGCACCCGGCGGCGGCGCAGGCGCTCCGCGCCGCCATCCTGGG  
GGTGCGCCGACGCCCGCCTCCGCAAACGCACCTCGTCTGAGATTTTTGTGTTTTGTTTTTCT  
GCCTCCCGTGGGTGAACAAGTCCATCCATCCATCCAACATCCGTGGCTGCTGTGTCTTTGTCTTTT  
CTTTGCGTTGCGCCCCAGTTGAGCCGGCACCCGACGCGCTCGGCCATGGCCATCTCGCGCCGCGTGA  
AAAAGGAGCTGCTGCAGGCGTTGGCGCCGAGGTGTACGGGGCGCCTAAGAAGGAGGAGAAGGACG  
TCAAAGAGGAGTCAAAGCTGACCTTAACCGCTGAAGAAGCGGCGCAAGGCCAAGCGGGGGTTGA  
GCGACAGCGACGAGGTGCTGGTGTGGGCACGCGCCCCAGGCGCCGCTGGACGGGGCGGCGCGTGC  
GCGCCACCTACCGCCCGGTGCCAGCCTCGCCTACGTCCCGGGTCTTCGGAGGTTCGAGCGCCACCA  
AGCGCTCTGCGGACGAGTTGTATGCGGACACGGACATCCTGCAGCAGGCGTCCAGCGCCTGAACG  
AATTTGCTTATGGCAAGAGAGCCCGGCGGCGAGCGGGCGCCCGCCCTCGCCGACCCCGCGTCCC  
GCGGCCGACCACCAAGCGCTCTTATGACGAGGTGCTGGCAGACAGTGACATCCTGCAGCAACTTG  
GATCCGGGGACCGCTCCAATGAGTTCTCCTATGGCAAGCGGTGCTGCTGGGGGAGTCAGGAGACA  
CCGTCCCGGCTGTGGCCGTCCCGCTGGAGGAAGGCAGGAACCACACACCAGCCTGCAGCCGCTCA  
CCGAGCCCATGCCCTGGTGTCCCCTCGCACGGCCGTCAAGCGCCGGGCGCCCGCCGACGAGCCCA  
CCGCCTCACTGGTCCCCACCGTGCAGGTCTGGCCCCCAAGCGTCTGCTGCAGGAGGTGGTGGTGG  
AGCCGCCCCGCTCCAGCACCCACGCCGCCCTAGCCCCGCGGCGGTCCAGCCGGCGCATCATTCTGG  
CTCCGCGCCGGGCGGGCCGGCCCCAGGCCGTGCTGGCGCCGACGCTCAGCGCGGCCGCGGGCGCTGG  
AGCGGGCGGCGGCCGCGGTGCCCTGCCACCGGACACGGAGGACGACCTGGTGGAGATGGCAGAGG  
CTGTCCCGCGCCCGAGGTGCTGCCAGCCTCCCGTCTCCATCATGCCGCCACCGCCACGGAGG  
TGGCCCTGCCCGTACAGACCCCACTGCCGCCCGTGGCGGTGGCCAAGAGCTCCCTGACCCCGGCC  
TCCGCGCGCTGATGGGCACCGAGCGGGTGCCGGTTCCAGTCTGGAGGCGCCCTGGTGGCCATGC  
CCGTGCTCCGGGCCACCACCGCCCGTGCCGAGCCCCGCGCCGCGTGCCTCCGAGGGCCGTGCGGG  
ACATCCCGGCCAGGCAGCCCCGACGGTATCCCTGCCCGTGTCTACGGAGCCCGGCCCGGCCACCG  
CGGTCCCTCCGTGCGCGCGGCAGCCCAAGTCTTGCAGGCGCCCCCGCCCGACCGGCCACCGTCT  
CCGTGGGGGTGGGCACCGAGCCGGTGGTGCAGTCCATCACGGTCAAGCGGTCAAAGCGCCTGACCA  
AGCACCATCGGGGTGCAGACCATCGACGTACCGTGCCACCGTCCGCACTGTGAGCGTGGGCACC  
AACACGCCCCGGCTGAGGAGCGCCTCGGTGGGCGTCCAGACCGTCCCGAGACCCGCTCCAGGGG  
GTGCAGGTGGCTTTCCAACCAGCGTGCTAGCCACCGCACACCCAGGCAGGTGCGGCTGACGGCGG  
TGGTGCCCCCACC CGCGCCCGGGTGGTTCGGTGGCCCGGCGCCCGCGGCGGTTCGGTGCC  
TCCCCAGCCCTCCAGCCCCGCGCGCGCGCTGCGCCTCGCGCCCCAGAGCGCCTCGGGCTCG  
CCGCCGTACCCCGGTGGCGGTGGCAGCGCCGCCCGCCCGCAGCGGGCTCCCCCGCCCTCGGCTGC  
CGAGGCGGCCCATCGTGCTGCCCGGGTGCCTATCATCCAGTCAGGCCATGGCTCCACCGCCC  
AACCGTTCATCTGGCGTTGATTTATTTTTGGAGACCTGACTGTGTTGTGTTCTTAAATTTTTTAT  
CCTCCTCCTCCTCTGCTGAAGCCAGACGATGCTGACCTACCGGTTGCGGCTGCCCGTGCGGATGCG  
GAGACCGAGACTCCGCGGTGGGTTCGCGTGGCGCCTCGGCGCAGCGGCGGCAGGCGGCGGTACCG  
CCGGGGGCGGATGAGGGGTGGCATCCTGCCGGCGCTGGTGCCCATCATCGCGGCATCCATCTGGGC  
CATCCCCGGCATCGCCTCGGTGGCGATGAGTGCTAGACAACGCAATTAACGGCGCTGCTGTGTATG  
TGTGTCTTCATGTGCCTTCCTTCCTTCGTTCCCAACGGAACAGCAGCACCGTCTCCATGGAGGAC  
CTAAGCTTTTCCGCGTTGGCTCCACGCTTTGGCACGCGGCCGGTTCATGGGCACTTGGAGCGAAATC  
GGCACGAGTCAGATGAACGGCGGCGCGCTCAGCTGGAGCAATATCTGGAGCGGGCTGAAGAGCTTT

FIG. 1-5



GGTAGTTCTCTGGCCTCCACGGCCAACAAGGCCTGGAACAGCGGGACGGTGACGAGCGTGCGCAAC  
AAGTTGAAGGATGCCGACGTGCAGGGGAAGATAGGTGAGGTCATTGCCCTCCGGGGTCCACGGTGCC  
CTGGACGTGGCCAACCAGGCCGTCTCCACGCCGTGGACCGCCGGTGCAACAGCAGCAGCTGCGGC  
AGCAGCAGCTCCTCCGCCAGCAGCAGCAACAGATGGGCCTCGTGGAACCTCCTATGAGATGGAGA  
CAGACGAGCTGCCTCCTCCCCCGAGGACCTCTTGCTCCTCCTCCTCCGCCGCTGCCTCGG  
CCACTCCCAGCGGCCAATCCCAGCGGGACGTCCCGCCAAGCGCCCGCCGCCAGGAGATCATCA  
TCCGCTCCGACGAGCCCCCTCCCTATGAAGAGCTGTATCCCGACAAGGCCGGGATCCCCGCCACCT  
TGGAGCTGCGTCCCGAGACCAACTGCCCGCCGTGGCCACAATAAGATGCGCCCCCGCCGCGC  
TCACCACCACCACCTCCTCCGCTGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCCGCC  
GGCGTCCGGCCGCGGCTCCGGCCGCGGCTCCGGCGAGTTCAAAGGCCCCCCAGGTGGGGGTCCGC  
GCGCGCGGGTGGCAAACAACCAACTCAACACCATTGTGGGACTGGGTGTCCGCACATGCAAGCGCCGT  
CGTTGTTACTGAGAGAGACAGCATGGAGAAACAACAATGTCTGGATTCAAATAAAGACACGCCTAT  
TCTTCCACGGTGCTCCGCGCTGTGTTATTTCAACGGGCTGTTTCTTTTGCATCTCTGTGCCATC  
GCGCCACGGGGAATTCGCGAGGATGGCGACGCCGTGATGATGCCGAGTGGTCTATATGCACAT  
CTCCGGGCAGGACGCGTCCGAGTACCTGTCTCCCGGGCTGGTGCAGTTCTCCAGGCGACGGAGAC  
CTACTTTAACCTGAACAACAAGTTTAGGAACCCACCGTCGCGCCACCCACGATGTGACGACGGA  
GCGCTCGCAGCGGCTGCAGCTGCGCTTCGTCCCCGTGGACAAGGAGGACACTCAGTACACATAAA  
GACCCGCTTCCAGCTGGCGGTGGGCGACAACCGCGTGTGGACATGGCGAGCACCTTCTTTGACAT  
CCGGGGAACGCTGGACCGGGGACCCTCCTTCAAACCGTACTCGGGCACCGCGTACAACATCATGGC  
TCCAAGAGCGCTCCAACAACCTGTCAATATCTAGACCCTAAAGGTGAAACTGAGGCTGGCAAAGT  
TAATACCATTGCTCAAGCAAGTTTGTGGGTCCTATTGATGAAACCACGGGAGACATTAATAATTAC  
AGAAGAAGAAGACGAAGAGACCACCATCGATCCTTTGTATGAGCCCCAACCCAGCTTGGTCCAAG  
CTCGTGGTCAGACAATATACCTTCTGCGACTAGCGGAGCTGGAAGAGTTCTCAAACAGACCACACC  
GCGTCAACCTTGTACGGTTCTTATGCCTCTCCGACAATATTACGGTGGGCAAACGAAGGATGA  
CAAGGTTACACCATGTACTTTACAACAATCCCAGCCACCGAAGCCGAAGCACTCGAAGAAAATGG  
ATTAAAGCCAAATGTCACCCTATACTCAGAGGATGTTGACCTAAAAGCACCAGATACTCATCTGGT  
CTATGCTGTGAATCAAACCCAGGAATTCGCTCAATATGGACTTGGACAACAGGCCGCTCCAACAG  
GGCAATTACATCGGCTTCAGGGACAACCTTATCGGGCTGTTGTACTACAACAGCAATGGCAACCA  
GGGCATGCTAGCCGGTCAGGCCTCTCAGCTCAACGCGGTGGTGCACCTGCAGGACAGGAATCACCG  
AACTAGCTACCAGCTTCTCCTCGATAGCCTCTATGACAGGTCGAGGTACTTTAGCCTGTGGAACCA  
GGCCATCGATTCTTATGACAAGGATGTGCGTGTGCTGGAAAACAATGGCGTGGAGGACGAGATGCC  
CAACTTTTGCTTTCCCATCGGCGCCATCGAGACCAACATGACATTTACACAGCTCAAAAAGAGTGA  
GAATGGTGGCTCAAGAGCCACAACCTGGACAAGGAGAATGGGGATGATGGCGGAAACGGAGCGGA  
GCACTACCTGGGCATCGGCAACCTCAACGCCATGGAGATCAATCTCACGGCCAACCTCTGGCGCAG  
CTTCTCTACAGCAACGTGGCGCTGTACCTGCCTGACAAGTACAAGTTTTCCCGCCCAACGTCCC  
CATCGACCCCAACACGCACTCCTATGACTACATCAACAAGCGCTGCCCTCAACAACCTCATGTA  
TACCTTTGTCAACATCGGGGCGCGCTGGTCCCCGGATGTCATGGACAACGTCAACCCTTCAACCA  
CCACCGCAACTACGGCCTGCGCTACCGCTCCAGCTCCTGGGCAACGGCCGCTACTGCAAGTTCCA  
CATCCAGGTGCCGCAAAGTTCTTTGCCCTCAAGAGCCTGCTGCTCCTGCCGGGGGCGACCTACAC  
CTACGAGTGGTCTTCCGCAAGGACGTCAACATGATCCTCCAGTCCACGCTGGGCAACGACCTCCG  
CGCGGACGGGGCCAAAATCAACATCGAGAGCGTCAACCTCTACGCCAGCTTCTTTCCCATGGCCCA  
CAACACCGCCTCCACCCTGGAGGCCATGCTGCGCAACGACACCAACAACCAACCTTTATTGACTT  
CCTCTCCTCCGCCAACATGCTCTACCCCATCCCGGCCAACGTCAACCAACCTGCCATCTCCATTCC  
CAGCCGCAACTGGGCCGCTTCCGCGGCTGGAGCTTCACGCGGCTGAAGCACAACGAGACCCCCGC  
CCTGGGCTCGCCCTTCGACCCCTACTTTACCTACTCGGGCTCCATCCCCTACCTGGACGGGACCTT  
CTACCTGGGCCACACCTTCCGCCGATCAGCATCCAGTTCGACTCCTCCGTGGCCTGGCCGGGCAA  
TGACCGCCTGCTCACTCCAACGAGTTCGAGGTCAAGCGCACCGTGGACGGGGAGGGCTACACGGT  
GGCCAGACCAACATGACCAAGACTGGTTCCTGGTGCAGATGCTCGCCACTACAACATCGGCTA  
CCAGGGATACCACCTGCCAGAGGGCTACCGCGACCGCACCTACTCCTTCCCTGCGCAACTTTGAGCC  
CATGTGCCGCCAGGTGCCGACTACGCCAACCACAAAGATGAGTACCTGGAGGTGCCACCACCAA  
CCAGTTC AACAGCAGCGGCTTTGTATCCGCGGCCTTACCAGCCGGCATGCGCGAGGGGCACCCATA  
CCCCGCCAACTGGCCCTACCCGCTCATCGGCGAAGACGCCGTGCAGACCGTGACCCAGCGCAAGTT  
CCTCTGCGACCGCACGCTCTGGCGCATCCCCTTCTCCTCAACTTCATGTCCATGGGCACCCTCAC  
CGACCTGGGCCAGAACCTCCTTACGCCAACTCGGCCACGCCCTCGACATGACCTTCGAGGTCTGA  
CGCCATGGATGAACCCACCCTCTTGTATGTTCTGTTTCGAGGTCTTTGACGTCTGCGGCGTGCACCA  
GCCGCACCGAGGCGTCATCGAGGCCGTACCTGCGCACGCCCTTCTCCGCCGGGAACGCCACCAC

FIG. 1-6

CTAAGGCGGAGCCGCGCAGGCATGGGCAGCACCGAGGACGAGCTCCGAGCCATGGCGCGCGACCTC  
CAGCTGCCCCGCTTCCTGGGCACCTTTGACAAGTCCTTCCCAGGCTTCTTGCAAGAGTCCCAGCGC  
TGCTGCGCCATCGTCAACACGGCCGCCGCCACACCGGAGGCCGCACTGGCTGGCCGTCGCTGG  
GAGCCCCGCTCGCGCACCTTCTACTTCTTTGACCCCTTCGGCTTCTCCGACCGGGAGCTCGCCCAG  
GTCTATGACTTTGAGTACCAGCGCCTGCTGCGCAAGAGCGCCATCCAGAGCACCCCGGACCGCTGC  
CTCACGCTCGTCAAGAGCACCCAGAGCGTGCAGGGACCGCACAGCGCCGCTGCGGACTCTTCTGC  
CTCCTCTTCCTCGCCGCTTTGCCCCGCTACCCCGACAGCCCCATGGCCTACAATCCCGTCAATGGAC  
CTGGTGGAGGGCGTGGACAACGAGCGGCTCTTCGACGCCGACGTCCAGCCCATCTTCCGCGCCAAC  
CAGGAGGCTGCTACGCGTTCCTCGCTCGCCACTCCGCTACTTCCGCGCCCACCGCCACGCCATC  
ATGGAACAGACACACCTGCACAAAGCGCTCGATATGCAATAAAGGCTTTTTATTGTAAGTCAAAAA  
GGCCTCTTTTATCCTCCGTCGCTGGGGGTGTATGTAGATGGGGGGACTAGGTGAACCCGGACCCG  
CCGTCGGCTCCCCTCCATCCCCTCTTCTCTCAAAACAGGCTCTCATCGTCGTCTCCGTTCCCACG  
GGGAAGATGGTGTCTGCACCTGGAAGTGGGGCCCCACTTGAAGTCCGGGCACCGTCAGTGGAGGC  
CGCGTCTGCATCAGGGCGGCCACATCTGTTGGTCAAGTGCAGGGCCAGCATCACATCGGGGGCG  
CTGATCTTGAAATCACAATTCTTCTGGGGGTGCGCGCGACCCGCGGTACACCGGGTGTAGCAC  
TGGAACACCAGCACCGCGGGGTGGGTACGCTGGCCAGAATCTTGGGGTCTTCCACCAGCTGGGGG  
TTAGCGCCCGCCGACCCGCTCAGCGCAAGGGGGTGTATCTTGCAGGTCTGCCGGCCAGCAGGGG  
ACCTGGCGGCAGCCCCAGCCGAGTGCACACCAGCGGCATCAGCAGGTGCGTCTCCGCGTTGCC  
ATCCGGGGGTAGCAGGCCTTCTGGAAAGCCTTGAGCTGCTCGAAGGCCTGCTGCGCCTTGAGCCC  
TCCGAGTAGAAGAGGCCCGCAGGACCGCGCCGAGAAGGTGTTGGGGGCCGACCCACGTCGTGGCTG  
CAACACATGGCCCCGTCGTTGCGCAGCTGCACCACGTTGCGGCCCCAGCGGTTGGTGGTGTCTTG  
GCGCGCTCGGGGGTCTCGCGCAGGGCGCGCTGCCCGTCTCGCTGTTGAGATCCATCTCCACCAGC  
TGCTCCTTGTGATCATGGGCAGCCCGTGCAGGCAGTGCAGCCCCTCCGAGCCGCTGCGGTGCTGC  
CAGATCACGCACCCCGCAGGGGTCCACTCGGGCGTCTTCCAGACCCGCGCCTTACCACAAAGTCC  
AGCAGGAAGCGGGCCATCACTGTGAGCAGGCTCTTTTGCCTGCTGAAGTCAAGTCAAGTCAAGTCA  
TTGCGCTCGTTCAGCCAGGCTTGGGCCCGCGCCGGAAGCACTCCAGGGTGTGCTGCCGTCCGGCAGC  
AGCGTCAGGCCCTTGACATCCACCTTCCAGGGGACCAGCATCTGCACAGCCAGATCCATGGCCCGC  
TGCCACTTCTGCTCCTGAGCATCCAGCTGCAGCAGCGGCCGGGCCACCGCCGGGCTCGGGGTACC  
GGCGCGGGGGGGCGGGCCCCCTCCTCTTCCCTCCCCATCTTCGCCCTTCTCCTCGCGGGCCGCGCC  
GTCGCCGCTGCCGTCTCTTCAAGCTCGTCTCCTCCTCCTCGCTGACCAGGGGCTTGGCACGCGCG  
CGTTCGCGCGCTCCTGCACGGGCGGAGAGGCCGCGCGCTTGGCGCCTCCCCCGCGCCGGCTGGGG  
GTCGCGACAGGAGCGTCGTCCACAATCAGCACCCCTCTTCCCCGCTGTATAGTCAGACACGTC  
GAATAGCGGCGACTCATTTTGCTTCCCCTAGATGGAAGACCAGCACAGCGCAGCCAGTGAAGTGGG  
GTCCTCCGCGGGCCCCGACCTTCCGCGCCACCACCGCCGACCTCCGCCCACGTCACCGCCACC  
TTCACTGCAGCAGCGGCAGCAGGAGCCACCGAAACCGATGACGCGGAGGACACCTGCTCCTCGTC  
CTCCTCGTCTCCGCTCCAGCGAGTGTCTCGTCTCGCCGCTGGAAGACACGAGCTCCGAGGACTC  
GGCGGACACGGTGTCTCCCCTCCGAGCCCCGCGGGAGGAGGAGGAGGAGGAGGACTCGCCCGA  
CCGCTACATGGACGCGGACGTGCTGCAGCGCCACCTGCTGCGCCAGAGTACCATCCTGCGCCAGGT  
CCTGCAGGAGGCCGCCCCCGCGCAGCCGCGGAGGCCGCGGAGGCCCTCGGTGGCGGAGCTCAG  
CCGCCGCTGGAAGCGGCCCTCTTCTCCCCCGCCACGCGCCGCGCGCCAGGAGAACGGAACCTG  
CGCCCCGGACCCCCGCTCAACTTCTACCCGGTCTTCAATGCTGCCCGAGGCCCTGGCCACCTACCT  
CCTCTTCTTCCACAACCAAAAGATCCCCGTGAGTGCAGCGCCCAACCGCCACGAGCCGACGCGCA  
CTGGCGGCTGCCAGTGGGACCCCTTACCTGACTATCCAACCACCGACGAGGTTTACAAGATCTT  
TGAGGGCCTGGGGGACGAGGAGCCGGCCTGCGCCAACCAGGACCTGAAAGAGCGCGACAGCGTGT  
AGTCGAGCTCAAGCTGGACAACCCCCGCTGGCGGTGGTCAAGCAGTGCATCGCCGTCAACCACTT  
CGCCTACCCGGCCCTGGCGTGCACCCCAAGGTCAATGAGCAGCTCATGCAGACCCTGCTGGTGGC  
CCGCGCGAGCCCACTCCCCGACGAGGGCGAGACGCCCTCGAGGACCTCCTGGTGGTCAAGCAGCA  
GCAGCTGGCCCCGCTGGATGCACACCTCGGACCCCAAGGTCTGGAGGAGCGGGCGCAAGACCGTCA  
CGCCGCTGCATGGTCAAGTGCAGCTCCACTGCATGCACACCTTCTCACCTCCCGCGAGATGGT  
GCGCCGCTCGGAGAGTGCCTCCACTACATGTTCCGCCAGGGCTACGTCAAGCTAGCTAGCAAGAT  
CGCCAATATGGAAGTCTCTAACCTGGTCTCCTACTTGGGCATGCTGCACGAAAACAGGCTCGGTCA  
GCACGTGCTCCACCACACCCTCAAGCATGAGGCGAGACGCGACTACGTCCGGGACACCATTTACCT  
ATACCTGGTCTATACCTGGCAGACCGCCATGGGGGTCTGGCAGCAGTGCCTCGAGGACCGAAACCT  
GCGCGCCCTGGAAACGTCTCTGGCTCGCGCTCGCCAGAGCCTGTGGACGGGCTTTGATGAGCGCAC  
TATCGCGCAGGACCTCGCCGCTTCTTTTCCCCACCAAGCTCGTAGAGACCCTGCAGCGCTCGCT  
CCCCGACTTTGCCAGCCAGAGCATGATGCATGCCTTCCGCTCCTTCGTCCTCGAGCGCTCCGGCAT

FIG. 1-7

CCTGCCCGCCGTCTGCAACGCGCTCCCCTCTGACTTTGTGCCACCGTCTACCGCGAGTGCCCGCC  
GCCCCCTCTGGGCTCACTGCTACCTCCTGCGCCTCGCCAACTTCTCATGTACCACTGCGACCTCGC  
CGAGGACACCTCCGGCGAGGGCCTCTTTGAGTGCTACTGCCGCTGCAACCTCTGCGCACCGCACCG  
CTGCCTCGCCACCAACACCGCCCTCCTCAACGAGGTGCAAGCCATCAACACCTTTGAGCTCCAGCG  
GCCCCCAAGCCCGACGGCACCTTGCACCGCCCTTCAAGCTGACCCCGGTCTCTGGACCTCCGC  
CTTCTCCGCCACTTTGTCTCCGAGGACTACCACTCGGACCGCATCTTCTTCTACGAGGACGTGTC  
CCGCCCCCAGGGTGGAGCCCTCCGCCTGCGTCATCACGCACTCGGCCATTCTCGCGCAATTGCA  
TGACATCAAAAAGGCCAGGGAAGAGTTTTTGTGCTGACCAAGGCCACGGCGTCTACCTAGACCCCA  
CACCGGAGAGGAGCTCAACACCGCCGCCCCGTCCACCGCCCACCATGCCGCCCTCCGGAGGAAGC  
CCATCCGCAGCAGCACCAGCACCAGCAGCCGAGCCACCGCCGCCACCACCGCTCCAGCTA  
CGCAGACCGTGTCCGAAGCGAGCTCCACGCCTACGGCGGTGCGACCGGTTCCTCCCGCGACCCTGT  
CTCTGGCGGATGCTCTGCCAGAGGAACCCACTCCCGCATGCTGCTCGAAGAAGAGGCTCTCAGCA  
GCGAGACCAGCGGCAGCTCCGAAGGCAGTTTGTCTAGTACCCTCGAGGAACTGGAGGAGGAGGAGG  
AACCGGTCACACCGACGAGGCCATCCAAGCCCTCCTACACCAACAGCAGCAGCAGCAAGAGCATCA  
GCCAGCGCAGGAACTCCGTCTGTCACCGAGCGAGGCTCGTAGATGGAATCAGACATCCATCCACCGGA  
GTAGCCAGCCAGGTAGGACACCTCCGCCCTCGGCCCGCCGACGCTCCTGGCGCCGCTACCGCCACG  
ACATCCTCTCGGCCCTGGAGTACTGCGCCGGAGACGGAGCCTGCGTGCGCCGGTACCTACTCTACC  
ACCACAACATCAACATCCCTTCCAAGATCATCCGTTACTACAAATCCTCTTCCCCTTCCAGCGATC  
TCCAGGAAGGCCGACGAGCGGCCGAGCAGAACCAGCCACGTCAGCCAGCTGAGAGCTAAGATC  
TCCCCACGCTGTACGCCATCTTCCAGCAGAGCCGCGGCCGAGGACGCCCTCAAATCAGGAAC  
CGCACCTGCGCTCCCTACCAAGAGCTGTCTGTATCACCGCGAGGAGGCCAAGCTGGAACGCACG  
CTCTCGGACGCAGAAGCTCTTTCGAGAAGTACTGCGCTCGGCAGCGGCAGACCCGCGCGGTATTTA  
AGGAGCGGACCCTGCGTGCGGACACACCATGAGCAAACAAATCCCCACCCCGTACATGTGGTCTTA  
TCAGCCACAATCTGGGCGTGCCGCCGGTGCCTCCGTGATTACTCCACCCGCATGAATTGGCTCAG  
TGCCGGGCCCTTCCATGATTGGCCAGGTCAATGACATCCGACACACCAGGAACCAGATTCTCATTCCG  
CCAGGCCCTTATCACCGAGACGCCACGCCCCGTCCAAATCCCCGTCCTGGCCCGCCAGCCTGTT  
GCCTCAGATGACGCAACCGCCACCCACCTGCACCTGCCGCGTAACGAAATTTTGGAAAGGCAGACT  
GACTGACGCCGGCATGCAATTAGCCGGGGGCGGAGCCCTCGCACCCAGAGACTTATATGCCCTGAC  
CCTCCGCGGCAGAGGCATCCAGCTCAACGAGGACCTACCCCTCTCGGCAGCACTCTCCGGCCGGA  
CGGCATCTTCCAGCTCGGAGGCGGAGGCCGCTCCTCCTTCAACCCACCGACGCCTACCTGACGCT  
GCAGAACTCCAGCTCCCTTCCCCGCAGCGGCCGATCGGCAGCGAGCAATTTGTCCGCGAGTTCTG  
GCCACGGTCTACATCAACCCCTTCTCCGGACCGCCCGGGACCTACCCCGACCAGTTCATCGCCAA  
CTACAACATCCTAACGGACTCTGTAGCAGGCTATGACTGACGGTCCCAGGGTCAGCAGCGGCTGC  
GGGAGCTCCTCGACCAGCACCGCCGCGAGTGCCCTAACGGCTGCTGCTTCGCCAGGGAAGGGATTC  
ACCCGGAGTACTTTTGCATCACCCGCGAGCACTTTGAGGCCGAGTGATCCCCGACTCTCTGCAAG  
AAGGCCACGGTCTGCGCTTACGCTCCCCACCGCTACAGCGACCGCCGCCACCGCGATGGAGACC  
GCACCATCCTCACTTCGTACTACTGCGGCCCTGCTTCTTTCAAAGTTCGCTGTCTCTGCGGCCATC  
CTGCTCCTCACCTCTTCTTCTCGACCTTCTGTGTGAGCTGTACAACCGCTCGTAGCGTCAGCCCC  
TACACCTCCCCTCGCGTCCAATTTCTGTCCGACATAGAACCAGACTCTGACTCTTACTCGGGCTCT  
GGCTCTGGGGACGATGAAGATTATGAATATGAGCTGGCTACCAACACACCGAACGAAGACATTCTA  
GGCAGCATAGTCATCAACAACCAGATCGGGCCCAAGACCCTGGCCCTGGGATACTTTTATGCCGCC  
ATGCAGTTTGTCTTCTTTGCCATCATCATCGTCCCTCATCCTTACTACCGCCGCTACGTGCTG  
GCCACCGCCCTCATCGTGCAGCGCCAGATGTGGTCCCTCCGAGGGCCGTCCTGCGGAAAACCTTCTCG  
GCCACCGTTGTGGTTACTCCCCAAAACAAGTCACCCCTGCAACTGCTCCTGCCGCTTCGAGGAG  
ATGGTGTCTACTACACCACCTCCGTCTTCATGCCCTGGTGGGCCTCATCCTCCTGCTCACCGCCA  
TGGTCCGCCTGGCCAACTGGATAGTGGATCAGATGCCCAGCAGGAACCGCGCCCCCGCGCTGCCAC  
CGCCCTCACCTATGTGGGACCCTGCGCCGAGGACCACATCTACGATGAGCCAACCGTAGGGCAAT  
ACGTACAGATGAAGTAGCTCCCCCTCTTCCCATTCCCCATTTTCTCTATTCAATAAAGTTGCT  
TACCTGAGTTCATCCACACTCGGTCTGCCAGTGCAGTCTATCCATGCGCCGTTTTCCATACTCACA  
TAGCGCAGCCGCGCACGCCTCGCCAGGTGACGAACTGTCGAAATGTAACATTTGCGGCTTCTGTC  
AGCAGCACCCCGTTATAGACCAGTTCACCATGGGACCGAAGAAGCAGAAGCGCGAGCTACCCGAG  
GACTTCGATCCAGTCTACCCCTATGACGTCCCGCAGCTGCAGATCAATCCACCCCTTCGTCAGCGGG  
GACGGATTCAACCAATCCGTGGACGGGGTGTGTCCTGCACATCGCACCGCCCTCGTTTTTGAC  
AACACCAGGGCCCTCACCTGGCCTTCGGGGGAGGTCTACAGCTCTCGGGCAAGCAGCTCGTCTGTT  
GCCACCGAGGGCTCGGGGCTAACCAACCCGGATGGCAAGCTGGTTCTCAAAGTCAAGTCCCCC  
ATCACCTGACCGCCGAGGGCATCTCCCTGTCCCTGGGTCCCGGTCTTTCTAACTCAGAGACCGGC

**FIG. 1-8**

CTCAGTCTGCAAGTCACAGCTCCCCTGCAGTTCAGGGCAACGCCCTCACTCTTCCCCTCGCCGCC  
GGTCTCCAAAACACCGATGGTGGAAATGGGTGTCAAACCTGGGGAGCGGTCTCACCACGGACAACAGT  
CAGGCGGTGACCGTTCAGGTGGGAAATGGACTTCAGCTGAACGGCGAAGGACAACCTCACCGTCCCC  
GCCACGGCCCCCTTTAGTCTCAGGGAGCGCAGGCATCTCTTTCAACTACTCCAGCAATGACTTCGTCT  
TTAGACAATGACAGTCTCAGTTTGAGGCCAAAGGCCATCTCTGTCACCCCTCCGCTGCAGTCCACA  
GAGGACACAATCTCCCTGAATTATTCTAACGACTTTTCTGTGGACAATGGCGCCCTCACCTTGGCT  
CCAACCTTCAAACCCTACACGCTGTGGACTGGCGCCTCACCCACAGCAAATGTCATTTCTAACAAAC  
ACCACCACTCCCAACGGCACCTTTTTCTATGCCTGACACGTGTGGGTGGGTAGTTTTGGGTTC  
TTTGCCCTGAAATCATCCATCGACCTTACTAGTATGACCAAAAAGGTCAATTTTTATTTTTGATGGG  
GCAGGTCGGCTTCAGTCAGACTCCACTTATAAAGGGAGATTTGGATTTAGATCCAACGACAGCGTA  
ATTGAACCCACAGCCGCAGGACTCAGTCCAGCCTGGTTAATGCCAAGCACCTTTATTTATCCACGC  
AACACCTCCGGTTCCTCCCTAACATCATTTGTATACATTAATCAGACATATGTGCATGTGGACATC  
AAGGTAACACACTCTCTACAAACGGATATAGCCTAGAATTTAACTTTCAAACATGAGCTTCTCC  
GCCCCCTTCTCCACCTCCTACGGGACCTTCTGCTACGTGCCCGAAGGACAACCTCACCGTCCCCGC  
CACGGCCCCCTTAGTCTCAGGGAGCGCAGGCATCTCTTTCAACTACTCCAGCAATGACTTCGTCTT  
AGACAATGACAGTCTCAGTTTGAGGCCAAAGGCCATCTCTGTCACCCCTCCGCTGCAGTCCACAGA  
GGACACAATCTCCCTGAATTATTCTAACGACTTTTCTGTGGACAATGGCGCCCTCACCTTGGCTCC  
AACTTTCAAACCCTACACGCTGTGGACTGGCGCCTCACCCACAGCAAATGTCATTTCTAACAAACAC  
CACCCTCCCAACGGCACCTTTTTCTATGCCTGACACGTGTGGGTGGGTAGTTTTGGGTTCCTT  
TGCCCTGAAATCATCCATCGACCTTACTAGTATGACCAAAAAGGTCAATTTTTATTTTTGATGGGGC  
AGGTCCGGCTTCAGTCAGACTCCACTTATAAAGGGAGATTTGGATTTAGATCCAACGACAGCGTAAT  
TGAACCCACAGCCGCAGGACTCAGTCCAGCCTGGTTAATGCCAAGCACCTTTATTTATCCACGCAA  
CACCTCCGGTTCCTCCCTAACATCATTTGTATACATTAATCAGACATATGTGCATGTGGACATCAA  
GGTAAACACACTCTCTACAAACGGATATAGCCTAGAATTTAACTTTCAAACATGAGCTTCTCCGC  
CCCCCTTCTCCACCTCCTACGGGACCTTCTGCTACGTGCCCGAGAGTGCCTAGAGAACCCTGGCCGT  
CAGCCGGCCTCCCCCTCCCAGGCCACCCGGTACACCACCCGCTCCATGTTTCTGTATGTGTTCTC  
CTCCCGCCGCTTGTGCAGCACCACTCCCGCTGCTCGAGCTGAGGATCCGTGATGGACACAAAGCC  
AGGAAGACACATCCTCAGCTCCGTGGGGGCGTCCAACAACCTGTTTATGTAAAGGAAAATAAAGACT  
CAGAGAAAATCCAAGTTCATATGATTTTTCTTTTATTGATTGGGGGAATTGATTCAGGTGGGGTGT  
GCATAATCACAAAATCACATCAGCAGGTACACACCTGAGACATCAGACAGGGGTAAGGACAGCGC  
CTCAGCTTCTGGAACAGACATCAGAAATATTTAATCTGCTGGTAGCTAACACTCCTTCCCAACACC  
ATACACTCCTGGAGGGCCCTCTGCCTCTCCTCCTCCCGCTCCGCGTCCCTCTGCCGGGACCACCAC  
TCCCCCTCCGTGAACCTGCTGCTTCTCCCCCGCCGCTGCGCCCCGATGGCCTCCGCCGCCAGCTTC  
AGCCAGTGCCGCAAGCGCTGGGCGCAGCGCCGAGCCACCGGCTCGCTCAGCTCGTGGCAGCGCCGG  
CACACCAGCACTATGTAATTGGCATAGTCCCCGTCACAGTAGATGACCTCCCCCAGTGGAAACATG  
CGAACAGCTTCAGATCACAGTCATACATGATCTTTATGTACATCAGGTGGGCGCCTCGAAACATC  
ACACTGCCACGTACATCACGCGACTCACGCTGGGCAGGTTACCCGCTCCTTGAACCACCAGAAG  
ATGCGATTGTAICTCGCAGCCCCGGATGATCTCGCGCATCAGGGAGCGCATCACCACTGCCCCGCG  
CGGCACTCCAGACTGGACCTTTTCAGACAGTGGCAATGAAAGTTCACACAGCGTCGCGCCCCGCACAG  
CGTCTCCGGGCTGAAACATATCTGCTCCAGCTCCAACCCCCACACAGGCTGTACTGCAGGAAAAT  
CCATTCTTGATGGGAAAGGATGTAGCGCCAGGGGACCACAATCTCCAAACAGGGAAACAAAACATAC  
CGCGGCCCGGCTGTTGCGCACGGCCCCACCAGGATGCAACGTGCTCACGGAGCAGATACGGGTGGG  
ACAGCGGCCACGTCTCATAGCAAGTCAAGTCCGGAAGTGGCACGGGGTTCGCCACCACTGCTACT  
GCTGCCGCTGCGCCACCAGCTCCATCGGCTCCTCCATCCTCCTCCTGTTCCATCGGCTGAGGTGCT  
GCCTCCTCCTCCTCCTGCCGCTGCTCCATCATGCTCGTCTGCGGTTCATCAGGAGTCAAAAAATTCA  
TTGGCCACCGCACGCAGAGAGAACATGGAGCGCAGGGGCCAGGTGCCCGGCCGTCGCTCGCTC  
AACTCCCCCAGCAGGTAICTCATAGAGATGCTCCTCCAAATCCACCGCAAACCAGGCATGCAGAAAC  
TCTTCCGTTTCGAGGACCGCCACGGTAAAGACATAGCCCTCCCGCACCTTCACCGCTGCCAGCTGC  
ACGCGCTCATGTGCTGGGAGTACACCCGGACCCGGGCTGGATGTAICTCAGCACCTGATCGCTC  
AGACACCTCACAGAGATGCCAGCCTGAGCCAGCTTCTCATAGAGAGGTGGCTGAATCTTGAGCTTG  
AAGCAGCGAGCGGCTAGGCACTCCCCGCCCTTGGAACAGGGCGGCCGGGTTCAGCCATGGACTTC  
CTCTACATCCGGGGTCTGGCCACCTCACAACTATCTGGCCAATCGCCTGACCACGGGTACCAG  
GTAAGGATGATGTCCGTTGTTGCGAATGAGAATGCTCAGAGGTGACTCGGTAGCGTTATCAATCAC  
GTCCCCAAAGGTCCAAAGTCCCAGTTAGAAGTCAGGTGCTTCAGACCGCAGACACGCCCATAGCA  
ACCAGTGGGAAAAGCCAGCAAGAGATCCGTGGGCACATGCACCGAAGCTCCCGCAGGAATCTCCAC  
CCACTCCGAGGCGTAGACCGTGTAAAGCTACACACCCCGCCTCCCGAGTGGGAGCAGAAGCATCTC

**FIG. 1-9**

GCTCAGCCGAAAGAACTTCAGGGTGGCCTGCATATCCTCTTTTACTCACTTGTTAGCAGCTCCACA  
CAGACCAGGGTTGTGTTGGCGGGAATAGGCAGCAGGGGTACGTCCCCAGTGAGGGACACCTGGATG  
GGGGCAGAGGATTGATGCCAGGAAGCAGCAGGTAAGTGGGAAACAGAGACCAGATCCCTCCTCTGA  
AAAATCTCGCTCAGTCGGACAAACACAGCAAACCCAGTGGGCACGTAGACTAGCACATTA AAAAGG  
ATCACGCTGGGCTGTTCTGACGTCAGCACCAGATGTCGGGACGTGCGCAGATGAATGCGGTTCTGA  
TGAATTACCGGAGGCCCTCTCACCCGCAGCCAACAGCAGACCGGGCTGCTGATGCGGTCCCGCAGAC  
ATATATGAGTTCAATGTGTGTCTTTTTTCTAAACGTCTAGTGAGTGTGCTCGTCCTGCTCCTGCCA  
ATCAAATCCGGGCACCAGGGCTGGTGGTTGGACCCGATGAAGAAGCGAGGAGAGGGCGGCCTCCTG  
AGTGTGAAGAGTGTCCCGATCCTGCCACGCGAGGTAGGCCGAAGTACAGATAGAGCACGGCGAGAAC  
AGTCAGCACCGCGGCCAGCAGCAGTCGGTTCGTGGGCCATGAGAGGGGGCTGATGGGAAGATGGCCG  
GTGACTCCTCTCGCCCCGCTTTCGGTTTCTCCTCGTCTCGCTCTCAGTGTCTCTCTCTGTGTCAGC  
GCCGAGACGAGTGTGAGCGAACACCGCGAGCGGGCCGGTGATATACCCACAGCGGATGTGGCCACG  
CCTGCGGTTCGGTTAATCAGTACCCCATCGTCCGATCGGAATCCCCCGCCTCCGCGTTAACGATTA  
ACCCGCCAGAAGTCCCGGGAATTCGCCAGCCGGCTCCGCCGCGACCTGCGACTTTGACCCCGC  
CCCTCGGACTTTGACCGTTCCACGCCACGTCATTTTCCCACGCGACGTCACGTTCCACGCTACG  
TCACACCCCTCTCCACCAATCACCGCCCGCCGCCCAACCCTCTCCGCCAATCACCCAGCCACAA  
AAGGGCAATAAAAGTGTGCGGTATATTATTGATGATG

**FIG. 1-10**







FIG.-2





**FIG.\_3A**



**FIG.\_3B**



**FIG.\_7**








FIG.\_6




FIG.\_8

## PORCINE ADENOVIRUS TYPE 3 GENOME

**Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.**

### CROSS-REFERENCE TO RELATED APPLICATIONS

this application claims priority to U.S. Provisional Patent Application Ser. No. 60/081,882 filed Apr. 15, 1998, the full disclosure of which is incorporated herein by reference in its entirety.

### TECHNICAL FIELD

The present invention is in the field of recombinant mammalian viral vectors. More particularly, it concerns recombinant porcine adenovirus vectors for diagnostic and therapeutic purposes, such as vaccines and expression systems.

### BACKGROUND

Adenoviruses are double-stranded DNA viruses that have been isolated from a wide variety of avian and mammalian species, including swine. While the majority of adenovirus infections in swine are subclinical, porcine adenovirus (PAV) infection has been associated with encephalitis, pneumonia, kidney lesions and diarrhea. Derbyshire (1992) In: "Diseases of Swine" (ed. Leman et al.), 7th edition, Iowa State University Press, Ames, Iowa. pp. 225–227. Thus, there is a need for vaccines that will provide protection against PAV infection.

In addition to their potential ability to provide protection against PAV infection, PAVs could also be used as viral vaccine vectors, if insertion capacity can be determined, and appropriate insertion sites can be defined and characterized. It has been shown that PAV is capable of stimulating both humoral response and a mucosal antibody responses in the intestine of infected piglets. Tuboly et al. (1993) Res. in Vet. Sci. 54:345–350. Thus, recombinant PAV vaccine vectors would be especially useful, as they would be likely to be capable of providing both systemic and mucosal immunity to antigens encoded by native and/or recombinant PAV genomes.

Cross-neutralization studies have indicated the existence of at least five serotypes of PAV. Derbyshire et al. (1975) J. Comp. Pathol. 85:437–443; and Hirahara et al. (1990) Jpn. J. Vet. Sci. 52:407–409. Previous studies of the PAV genome have included the determination of restriction maps for PAV Type 3 (PAV-3) and cloning of restriction fragments representing the complete genome of PAV-3. Reddy et al. (1993) Intervirology 36:161–168. In addition, restriction maps for PAV-1 and PAV-2 have been determined. Reddy et al. (1995b) Arch. Virol. 140:195–200.

Nucleotide sequences have been determined for segments of the genome of various PAV serotypes. Sequences of the E3, pVIII and fiber genes of PAV-3 were determined by Reddy et al. (1995a) Virus Res. 36:97–106. The E3, pVIII and fiber genes of PAV-1 and PAV-2 were sequenced by Reddy et al. (1996) Virus Res. 43:99–109; while the PAV-4 E3, pVIII and fiber gene sequences were determined by Kleiboeker (1994) Virus Res. 31:17–25. The PAV-4 fiber gene sequence was determined by Kleiboeker (1995b) Virus Res. 39:299–309. Inverted terminal repeat (ITR) sequences for all five PAV serotypes (PAV-1 through PAV-5) were determined by Reddy et al. (1995c) Virology 212:237–239.

The PAV-3 penton sequence was determined by McCoy et al. (1996a) Arch. Virol. 141:1367–1375. The nucleotide sequence of the E1 region of PAV-4 was determined by Kleiboeker (1995a) Virus Res. 36:259–268. The sequence of the protease (23K) gene of PAV-3 was determined by McCoy et al. (1996b) DNA Seq. 6:251–254. The unpublished sequence of the PAV-3 hexon gene (and the 14 N-terminal codons of the 23K protease gene) has been deposited in the GenBank database under accession No. U34592. The unpublished sequence of the PAV-3 100K gene has been deposited in the GenBank database under accession No. U82628. The sequence of the PAV-3 E4 region has been determined by Reddy et al. (1997) Virus Genes 15:87–90.

Adenoviruses have proven to be effective vectors for the delivery and expression of foreign genes in a number of specific applications, and have a number of advantages as potential gene transfer and vaccine vectors. See Gerard et al (1993) Trends Cardiovasc. Med 3:171–177; Imler et al. (1995) Hum. Gene Ther. 6:711–721. The ability of these vectors to mediate the efficient expression of candidate therapeutic or vaccine genes in a variety of cell types, including post mitotic cells, is considered an advantage over other gene transfer vectors. Adenoviral vectors are divided into helper-independent and helper-dependent groups based on the region of the adenoviral genome used for the insertion of transgenes. Helper-dependent vectors are usually made by deletion of E1 sequences and substitution of foreign DNA, and are produced in complementing human cell lines that constitutively express E1 proteins. Graham et al. (1977) J. Gen. Virol. 36:59–74; Fallaux et al. (1996) Hum. Gene Ther. 7:215–222; Fallaux et al. (1998) Hum. Gene Ther. 9:1909–1917. However, porcine adenoviruses do not replicate in human cell lines; hence these lines are unsuitable for the propagation of E1-deleted PAV vectors.

Though E1-deleted viruses do not replicate in cells that do not express E1 proteins, the viruses can express foreign proteins in these cells, provided the genes are placed under the control of a constitutive promoter. Xiang et al. (1996) Virology 219:220–227. Vaccination of animals with adenovirus recombinants containing inserts in the E1 region induced a systemic immune response and provided protection against subsequent challenge. Imler et al (1995) Hum. Gene Ther. 6:711–721; Imler et al. (1996) Gene Therap 3:75–84. This type of expression vector provides a significant safety profile to the vaccine as it eliminates the potential for dissemination of the vector within the vaccinee and therefore, the spread of the vector to nonvaccinated contacts or to the general environment. However, the currently used human adenovirus (HAV) based vectors are endemic in most populations, which provides an opportunity for recombination between the helper-dependent viral vectors and wild type viruses. To circumvent some of the problems associated with the use of human adenoviruses, non human adenoviruses have been explored as possible expression vectors. All vectors developed to date, except one (Klonjowski et al (1997) Hum. Gene Ther. 8:2103–2115), contain an intact E1 region. Use of such vectors for gene therapy in humans and vaccination in animals is unsafe because they have the ability to replicate in normal cells, and they retain the oncogenic potential of the E1 region.

Recombinant PAV genomes containing heterologous nucleotide sequences have not yet been described. Similarly, sites where insertion of heterologous sequences would not interfere with the ability of a PAV vector to stimulate an immune response against a determinant encoded by an inserted sequence have not been identified. Consequently, the development of effective recombinant PAV vectors for

use in immunization, expression systems and gene therapy, awaits resolution of these issues. Similarly, there is a need for improved adenoviral vectors lacking E1 replication and oncogenic functions, for expression of transgenes in mammalian cells.

#### SUMMARY OF THE INVENTION

The present invention provides the complete nucleotide sequence of the porcine adenovirus type 3 (PAV-3) genome. Nucleic acid sequences that are substantially homologous to those comprising a PAV genome are also encompassed by the invention. Substantially homologous sequences include those capable of duplex and/or triplex formation with a nucleic acid comprising all or part of a PAV genome (or with its complement). As is known to those of skill in the art, duplex formation is influenced by hybridization conditions, particularly hybridization stringency. Factors affecting hybridization stringency are well-known to those of skill in the art. See, for example, Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*; Hames et al. 1985) *Nucleic Acid Hybridisation: A Practical Approach*, IRL Press Ltd., Oxford. Accordingly, it is within the skill of the art to identify a sequence that is substantially homologous to a sequence from a PAV genome.

In addition, novel porcine adenovirus (PAV) expression vector systems comprising PAV genome sequences are disclosed herein. The PAV-3 sequence includes regions into which heterologous sequences can be inserted including, but not limited to, the E1, E3 and E4 regions, and the region between E4 and the right end of the genome. The invention also provides non-essential regions which can be deleted to increase the capacity of a PAV vector for inserted heterologous sequences. These include, but are not limited to, the E3 and E4 regions, and the region between E4 and the right end of the genome. Essential regions, such as E1, can also be deleted, if virus bearing such deletions are propagated in helper cell lines supplying the deleted essential function. Thus, PAV genome sequences can be replaced by one or more foreign genes to generate recombinant PAV vectors expressing heterologous antigenic polypeptides (or antigenic fragments thereof) for the purposes of producing live recombinant virus, subunit vaccines, nucleic acid immunization, or other types of therapy. Multiple heterologous sequences can be inserted into the same, or different, locations in the genome, limited only by the capacity of the virus to accept heterologous sequences. This capacity can be expanded by deletion of viral sequences.

In addition, the invention provides PAV transcriptional and translational regulatory sequences which can be used for expression of heterologous genes that have been inserted into the vectors of the invention. Furthermore, the novel sequences of the present invention can be used for diagnostic purposes, to determine the presence of PAV antigens and/or PAV nucleic acids in a subject or biological sample.

In additional embodiments, the invention provides compositions providing immunity to PAV infection, through expression of antigenic PAV polypeptides. The invention also provides vectors comprising PAV genome sequences, including sequences encoding various PAV genes as well as PAV regulatory sequences, which are useful for controlling the expression of heterologous genes inserted into PAV vectors.

The invention provides defective recombinant PAV vectors that are deleted in their E1 region, as well as helper cell lines providing E1 function, in which such defective vectors can be propagated. Because these defective vectors replicate inefficiently in cells other than the helper cells, they are less likely to stimulate an immune response in a mammalian host. This makes them particularly suitable for use as vac-

cine vectors. In addition, since the amount of nucleic acid that can be packaged into an adenovirus virion is limited, deletion of the E1 region expands the capacity of these defective vectors, enabling them to accept larger inserts of heterologous sequence. Additional deletions in other regions of the genome can be used to expand the capacity of these defective vectors still further.

The invention further provides methods for obtaining recombinant PAV vectors. In a preferred embodiment, heterologous nucleotide sequences are introduced, through recombinant DNA techniques, into a bacterial plasmid comprising a defined portion of the PAV genome. The recombinant plasmid, containing heterologous sequences flanked by PAV sequences, is introduced into a host cell in combination with a full-length PAV genome or a plasmid containing a full-length or nearly full-length PAV genome. Within the host cell, recombination between the plasmid and the PAV genome generates a recombinant PAV genome. Alternatively, recombinant PAV genomes can be constructed in vitro, using standard techniques in molecular biology and biotechnology.

The invention also provides methods for preparing live recombinant virus and subunit vaccines for inducing protective immune responses to an infectious organism in a mammalian subject. Protective immune responses include humoral (antibody) responses, cell-mediated responses, mucosal responses, or any combination of these. The methods involve insertion, into the porcine adenovirus genome, of heterologous nucleotide sequences encoding one or more protective antigenic determinants of a pathogen. The heterologous sequences are inserted in such a way as to come under the regulatory control of a PAV promoter, or the heterologous sequences are inserted in operative linkage to a eukaryotic transcriptional regulatory sequence. Translation of transcribed heterologous sequences can be controlled by PAV translational regulatory elements, or the heterologous sequence can include non-PAV sequences which regulate its translation.

In another aspect, the invention includes the use of recombinant porcine adenoviruses and recombinant PAV vectors for the expression of a nucleotide or amino acid sequence of interest in a cell system, such as, for example, production of antigen to be used in the preparation of antibodies, or production of antisense RNA.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein heterologous nucleotide sequences are inserted. The inserted heterologous sequences can comprise one or more regulatory elements for transcription and/or translation, or can be inserted so as to come under the control of PAV regulatory elements. Inserted regulatory elements can be those that are normally associated with the heterologous sequence, or a heterologous sequence can be juxtaposed to and placed in operative linkage with a regulatory element with which it is not normally associated, using standard recombinant DNA techniques. Heterologous sequences can be inserted into a full-length PAV genome, or into a PAV genome which has been deleted in one or more regions. A deletion in the PAV genome can be made to provide a site for insertion of a heterologous sequence, or simply to increase the capacity of the PAV vector to accommodate heterologous sequences inserted at another location.

The invention also provides recombinant PAV polypeptides including, but not limited to, those encoded by the following genes: E1A, E1B, E4, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K. Such recombinant PAV polypeptides are produced in any eukaryotic expression vector known in the art, into which is inserted a PAV nucleotide sequence according to the invention. Also provided are methods and compositions for recombinant

production of heterologous polypeptides and RNAs in a PAV vector. Expression of heterologous polypeptides and RNAs in a PAV vector can be regulated by endogenous PAV regulatory sequences, or by non-PAV sequences. Non-PAV regulatory sequences can be those which normally regulate the heterologous sequence, or they can be sequences that are not normally associated with the heterologous sequence in a regulatory capacity.

Thus, in one embodiment, the invention includes an expression system in which one or more regions of the PAV genome are deleted and replaced with heterologous sequences. In another embodiment, the invention includes a PAV expression system in which heterologous sequences are introduced into the PAV genome without the removal of any PAV sequences. Intergenic regions of the PAV genome comprising regulatory sequences are useful in the practice of the invention for controlling the expression of homologous and heterologous sequences.

The invention also includes recombinant vector systems comprising two or more nucleic acid molecules. In one embodiment, the vector system comprises two plasmids, the first containing a full-length or nearly full-length PAV genome and the second containing a segment of the PAV genome, such as the left end (including the E1 region) or the right end (including the E3 and/or E4 regions). Introduction of heterologous nucleotide sequences into the second plasmid, followed by co-transfection of both plasmids into a suitable host cell, will allow homologous recombination between the two plasmids to generate a viral genome containing inserted heterologous sequences. In another embodiment, the vector system comprises a full-length or nearly full-length PAV genome and a plasmid containing a segment of the PAV genome. Insertion of heterologous sequences into the plasmid, followed by co-transfection and homologous recombination, will generate recombinant PAV genomes as above.

Additional aspects of the invention provide a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes an antigenic determinant of a disease-causing organism; and a recombinant PAV comprising a heterologous sequence wherein the heterologous sequence encodes a foreign gene or fragment thereof. In further embodiments, the invention provides pharmaceutical compositions comprising recombinant PAV for producing an immune response in a mammalian host, the recombinant PAV comprising a heterologous nucleotide sequence encoding a protective determinant of a pathogenic organism. The heterologous sequence is expressed in quantities sufficient for induction of a protective immune response, either through operative linkage to one or more non-PAV regulatory sequences, or through control by endogenous PAV regulatory sequences. The protective immune response can be humoral, cell-mediated and/or mucosal.

The recombinant PAV vectors of the invention will also allow the expression of various therapeutic polypeptides in a wide range of mammalian hosts and are thus useful in the practices of nucleic acid immunization and gene therapy. Exemplary hosts include, but are not limited to, human, equine, bovine, porcine, ovine, caprine, avian, and murine. Those of skill in the art are aware of various therapeutic polypeptides which can be usefully expressed in mammalian hosts. Such therapeutic polypeptides include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

The invention also provides diagnostic methods and compositions for the detection of PAV nucleic acids and proteins

in a cell or biological sample. The PAV nucleotide sequences disclosed herein can be used as hybridization probes to detect PAV nucleic acids. In addition, the PAV nucleotide sequences disclosed herein encode PAV polypeptides, which can be used for the production of antibodies reactive with various PAV antigens. Such antibodies can be used to detect PAV antigens by immunoassay. Alternatively, PAV polypeptides themselves can be used in competitive immunoassays to detect the presence of PAV antigens in a cell or biological sample. PAV polypeptides can be produced by the PAV vectors of the invention, or can be produced in any mammalian expression vector known in the art.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the complete nucleotide sequence of the PAV-3 genome (SEQ ID NO: 1).

FIG. 2 shows the transcriptional map of the PAV-3 genome derived from alignment of the sequences of cDNA clones with the genomic sequence, and nuclease protection mapping of viral transcripts. The PAV-3 genome is represented by the thick horizontal line, with the numbers below the line representing PAV-3 map units (i.e., percentage of genome length from the left end). Rightward-reading transcription units are depicted above the line and leftward-reading transcription units are shown below the line.

FIG. 3 shows immunoprecipitation of E1A and E1B proteins from various cell lines.

In FIG. 3A, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP11 monoclonal antibody, which recognizes the human adenovirus E1A protein. Lane 1: 293 cells (human cells transformed by HAV-5, which express adenovirus E1A and E1B); Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

In FIG. 3B, proteins in cell lysates were separated by gel electrophoresis, and analyzed by immunoblotting using the DP17 monoclonal antibody, which recognizes the human adenovirus E1B protein. Lane 1: human 293 cells; Lane 2: Fetal porcine retinal cells; Lane 3: VIDO R1 cells; Lane 4: 293 cells.

FIG. 4 shows a map of the plasmid pPAV-101.

FIG. 5 shows a map of the plasmid pPAV-102.

FIG. 6 shows a map of the plasmid pPAV-300.

FIG. 7 shows proteins labeled after infection of VIDO R1 cells with a recombinant PAV containing the PRV gp50 gene inserted in the E3 region. Labeled proteins were separated by gel electrophoresis; an autoradiogram of the gel is shown. Lane 1: Molecular weight markers of 30K, 46K, 69K and 96K, in order of increasing molecular weight. Lane 2: Mock-infected cells, 12 hours post-infection. Lane 3: PAV-3-infected cells, 12 hours post-infection. Lane 4: cells infected with a recombinant PAV containing the PRV gp50 gene, 12 hours post-infection. Lane 5: cells infected with a recombinant PAV containing the PRV gp50 gene, 16 hours post-infection. Lane 6: cells infected with a recombinant PAV containing the PRV gp50 gene, 24 hours post-infection.

FIG. 8 provides a schematic diagram of the construction of an E1- and E3-deleted PAV vector with a green fluorescent protein gene insertion.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides the complete nucleotide sequence and transcriptional map of the porcine adenovirus type 3 (PAV-3) genome. The sequence comprises a linear, double-stranded DNA molecule of about 34,094 base pairs, as shown in FIG. 1 (SEQ ID NO: 1). Previously-determined partial sequences can be aligned with the complete genomic sequence as shown in Table 1.

TABLE 1

Alignment of published PAV-3 sequences			
GenBank Accession No.	PAV Gene(s) included within sequence	Reference	Genome coordinates
L43077	ITR	Reddy et al., 1995c	1-144
U24432	penton	McCoy et al., 1996a	13556-15283
U34592	hexon; N-terminal 14 codons of 23K (protease) gene	unpublished	19036-21896
U33016	protease (23K)	McCoy et al., 1996b	21897-23676
U82628	100K	unpublished	24056-26572
U10433	E3, pVIII, fiber	Reddy et al., 1995a	27089-31148
L43363	E4	Reddy et al., 1997	31064-34094

Knowledge of the PAV genome sequence is useful for both therapeutic and diagnostic procedures. Regions suitable for insertion and regulated expression of heterologous sequences have been identified. These regions include, but are not limited to the E1, E3 and E4 regions, and the region between the E4 region and the right end of the genome. A heterologous nucleotide sequence, with respect to the PAV vectors of the invention, is one which is not normally associated with PAV sequences as part of the PAV genome. Heterologous nucleotide sequences include synthetic sequences. Regions encoding immunogenic PAV polypeptides, for use in immunodiagnostic procedures, have also been identified and are disclosed herein. These include the regions encoding the following PAV proteins: E1A, E1B, E4, pIX DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, 33K, pVIII, hexon and fiber (see Table 2). Regions essential for viral replication, such as E1 and E2A, can be deleted to provide attenuated strains for use as vaccines. Nonessential regions, such as parts of the E3 and E4 regions, can be deleted to provide insertion sites, or to provide additional capacity for insertion at a site other than the deleted region. Deletions of viral sequences can be obtained by any method known in the art, including but not limited to restriction enzyme digestion and ligation, oligonucleotide-mediated deletion mutagenesis, and the like.

The practice of the present invention employs, unless otherwise indicated, conventional microbiology, immunology, virology, molecular biology, and recombinant DNA techniques which are within the skill of the art. These techniques are fully explained in the literature. See, e.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual* (1982); DNA Cloning: A Practical Approach, vols. I & II (D. Glover, ed.); *Oligonucleotide Synthesis* (N. Gait, ed. (1984)); *Nucleic Acid Hybridization* (B. Hames & S. Higgins, eds. (1985)); *Transcription and Translation* (B. Hames & S. Higgins, eds. (1984)); *Animal Cell Culture* (R. Freshney, ed. (1986)); Perbal, *A Practical Guide to Molecular Cloning* (1984); Ausubel, et al., *Current Protocols In Molecular Biology*,

John Wiley & Sons (1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994, 1995, 1996); and Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2<sup>nd</sup> Edition); vols. I, II & III (1989).

### Nucleotide Sequence, Genome Organization, and Transcription Map of Porcine Adenovirus Type 3 (PAV-3)

The complete nucleotide sequence of PAV-3 genome is 34,094 base pairs (bp) in length and has a base composition of 31.3% G, 32.5% C, 18.3% A, and 17.9% T. Thus, the sequence of the PAV-3 genome has a G+C content of 63.8%, which is unusually high when compared with the G+C content of many other animal adenoviruses. The genome termini share inverted terminal repeats (ITR) of 144 bp. Reddy et al., 1995c, supra. The organization of the genome as determined by analysis of open reading frames (ORFs), nuclease protection mapping, and sequencing of cDNA clones, is summarized in Table 2 and FIG. 2.

One important feature of PAV-3 genome is the presence of a short virion associated (VA) RNA gene between the splice acceptor sites of the precursor terminal protein (pTP) and 52 kDa protein genes (FIG. 2). Expression of VA genes increases the kinetics of viral replication; thereby providing the potential for higher yields of recombinant gene products using the PAV vectors of the invention. The locations of the signature sequences present upstream and downstream of VA RNA genes indicate the VA RNA gene of PAV-3 is about 126 nucleotides (nt) in length. This is somewhat shorter than most VA RNAs, whose lengths are 163±14 nts, however shorter VA RNAs have also been reported in HAV-10 and CELO virus. Ma et al. (1996) *J. Virol.* 70:5083-5099; and Chiocca et al. (1996) *J. Virol.* 70:2939-2949. The VA RNA genes were not found in the genomes of BAV-3, CAV-1, and OAV. Reddy et al. (1998) *J. Virol.* 72:1394-1402; Morrison et al. (1997) *J. Gen. Virol.* 78:873-878; and Vрати et al. (1996) *Virology* 220:186-199.

In PAV-3 the major late transcript initiates at 17.7 map units (m.u.: an adenovirus map unit is 1% of genome length, starting from the left end of the genome). There are six 3'-coterminal families of late mRNAs, denoted L1 to L6 (see FIG. 2). All mRNAs produced from the major late promoter (MLP) contain a tripartite leader sequence (TPL). The first portion of the TPL lies next to the MLP and is 61 nts long. The second portion lies within the gene coding for pol and is 68 nt in length. The third portion is 99 nts long and is located within the gene coding for pTP. Thus the TPL of PAV-3 is 228 nt long and is derived from three exons located at 17.7, 20.9, and 28.1 m.u.

The MLP and TPL sequences can be used for expression of a heterologous sequence in a recombinant PAV vector or in any other adenoviral expression system.

TABLE 2

Transcriptional and Translational Features of the PAV-3 Genome							
Region	Gene	Transcription start size	ATG	Splice donor site	Splice acceptor site	Poly(A) signal	Poly(A) addition site
E1A	229R	heterogeneous	533			1286	1307
	214R		533	1043	1140	1286	1307
E1B	202R	1382	1461			4085	4110, 4112
	474R	1382	1829			4085	4110, 4112
pIX	Pix	3377	3394			4085	4110, 4112
E2A	DBP	17011c	24041c	26949c, 24714c	24793c, 24051c	22560c	22536c
E2B	pTP	17011c	13638c	26949c, 24714c	24793c, 13772c	4075c	4053c
	pol	17011c	13638c	26949c, 24714c	24793†c, 13772†c	4075c	4053c

TABLE 2-continued

Transcriptional and Translational Features of the PAV-3 Genome							
Region	Gene	Transcription start size	ATG	Splice donor site	Splice acceptor site	Poly(A) signal	Poly(A) addition site
IVa2	IVa2	5867c	5711c	5699c	5441c	4075c	4053c
E3		27473				28765	28793
E4		33730c				31189c	31170c
L1	52K	6064	10629	9684	10606	13601	13627
	IIIa	6064	11719	9684	11715	13601	13627
L2	pIII	6064	13662	9684	13662	15698*	15735
	pVII	6064	15170	9684	15139	15698*	15735
L3	pV	6064	15819	9684	15793	18992	19013
	pX	6064	17783	9684	17776	18992	19013
	pVI	6064	18076	9684	18063	18992	19013
L4	Hexon	6064	19097	9684	19096	22544	22567
	Protease	6064	21934	9684	21931†	22544	22567
L5	100k	6064	24056	9684	24056	28765	28793
	33K	6064	26181	9684	26130	28765	28793
	pVIII	6064	27089	9684	26792	28765	28793
L6	Fiber	6064	28939	9684	28910	31143	31164

Notes:

\*TTGTTT is present as a polydenylation signal instead of AATAAA

†The splice acceptor sites for the pol and protease genes were determined based on consensus splice acceptor sequences

"c" refers to sequences on the complementary (leftward-reading) strand of the PAV genome.

### Construction of Recombinant PAV Vectors

In one embodiment of the invention, a recombinant PAV vector is constructed by in vivo recombination between a plasmid and a PAV genome. Generally, heterologous sequences are inserted into a plasmid vector containing a portion of the PAV genome, which may or may not possess one or more deletions of PAV sequences. The heterologous sequences are inserted into the PAV insert portion of the plasmid vector, such that the heterologous sequences are flanked by PAV sequences that are adjacent on the PAV genome. The PAV sequences serve as "guide sequences," to direct insertion of the heterologous sequences to a particular site in the PAV genome; the insertion site being defined by the genomic location of the guide sequences.

The vector is generally a bacterial plasmid, allowing multiple copies of the cloned sequence to be produced. In one embodiment, the plasmid is co-transfected, into an appropriate host cell, with a PAV genome comprising a full-length or nearly full-length PAV genomic sequence. The PAV genome can be isolated from PAV virions, or can comprise a PAV genome that has been inserted into a plasmid, using standard techniques of molecular biology and biotechnology. Construction of a plasmid containing a PAV genome is described in Example 2, infra. Nearly full-length PAV genomic sequences can be deleted in regions such as E1, E3, E4 and the region between E4 and the right end of the genome, but will retain sequences required for replication and packaging. PAV genomes can be deleted in essential regions if the essential function can be supplied by a helper cell line.

Insertion of the cloned heterologous sequences into a viral genome occurs by in vivo recombination between a plasmid vector (containing heterologous sequences flanked by PAV guide sequences) and a PAV genome following co-transfection into a suitable host cell. The PAV genome contains inverted terminal repeat (ITR) sequences required for initiation of viral DNA replication (Reddy et al. (1995c), supra), and sequences involved in packaging of replicated viral genomes. Adenovirus packaging signals generally lie between the left ITR and the E1A promoter. Incorporation of the cloned heterologous sequences into the PAV genome thus places the heterologous sequences into a DNA molecule

containing viral replication and packaging signals, allowing generation of multiple copies of a recombinant PAV genome that can be packaged into infectious viral particles.

Alternatively, incorporation of the cloned heterologous sequences into a PAV genome places these sequences into a DNA molecule that can be replicated and packaged in an appropriate helper cell line. Multiple copies of a single sequence can be inserted to improve yield of the heterologous gene product, or multiple heterologous sequences can be inserted so that the recombinant virus is capable of expressing more than one heterologous gene product. The heterologous sequences can contain additions, deletions and/or substitutions to enhance the expression and/or immunological effect of the expressed gene product(s).

Attachment of guide sequences to a heterologous sequence can also be accomplished by ligation in vitro. In this case, a nucleic acid comprising a heterologous sequence flanked by PAV guide sequences can be co-introduced into a host cell along with a PAV genome, and recombination can occur to generate a recombinant PAV vector. Introduction of nucleic acids into cells can be achieved by any method known in the art, including, but not limited to, microinjection, transfection, electroporation, CaPO<sub>4</sub> precipitation, DEAE-dextran, liposomes, particle bombardment, etc.

In one embodiment of the invention, a recombinant PAV expression cassette can be obtained by cleaving a wild-type PAV genome with an appropriate restriction enzyme to produce a PAV restriction fragment representing, for example, the left end or the right end of the genome comprising E1 or E3 gene region sequences, respectively. The PAV restriction fragment can be inserted into a cloning vehicle, such as a plasmid, and thereafter at least one heterologous sequence (which may or may not encode a foreign protein) can be inserted into the E1 or E3 region with or without an operatively-linked eukaryotic transcriptional regulatory sequence. The recombinant expression cassette is contacted with a PAV genome and, through homologous recombination or other conventional genetic engineering methods, the desired recombinant is obtained. In the case wherein the expression cassette comprises the E1 region or some other

essential region, recombination between the expression cassette and a PAV genome can occur within an appropriate helper cell line such as, for example, an E1-transformed cell line. Restriction fragments of the PAV genome other than those comprising the E1 or E3 regions are also useful in the practice of the invention and can be inserted into a cloning vehicle such that heterologous sequences can be inserted into the PAV sequences. These DNA constructs can then undergo recombination *in vitro* or *in vivo*, with a PAV genome either before or after transformation or transfection of an appropriate host cell.

The invention also includes an expression system comprising a porcine adenovirus expression vector wherein a heterologous nucleotide sequence, e.g. DNA, replaces part or all of the E3 region, part or all of the E1 region, part or all of the E2 region, part or all of the E4 region, part or all of the late region and/or part or all of the regions occupied by the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes. The expression system can be used wherein the foreign nucleotide sequences, e.g. DNA, are optionally in operative linkage with a eukaryotic transcriptional regulatory sequence. PAV expression vectors can also comprise inverted terminal repeat (ITR) sequences and packaging sequences.

The PAV E1A, E1B, pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K genes are essential for viral replication. Therefore, PAV vectors comprising deletions in any of these genes, or which lack functions encoded by any of these genes, are grown in an appropriate complementing cell line (i.e., a helper cell line). Most, if not all, of the open reading frames in the E3 and E4 regions of PAV-3 are non-essential for viral replication and, therefore, deletions in these regions can be constructed for insertion or to increase vector capacity, without necessitating the use of a helper cell line for growth of the viral vector.

In another embodiment, the invention provides a method for constructing a full-length clone of a PAV genome by homologous recombination *in vivo*. In this embodiment, two or more plasmid clones, containing overlapping segments of the PAV genome and together covering the entire genome, are introduced into an appropriate bacterial host cell. Approximately 30 base pairs of overlap is required for homologous recombination in *E. coli*. Chartier et al. (1996) *J. Virol.* 70:4805–4810. Through *in vivo* homologous recombination, the PAV genome segments are joined to form a full-length PAV genome. In a further embodiment, a recombinant plasmid containing left-end sequences and right-end sequences of the PAV genome, separated by a unique restriction site, is constructed. This plasmid is digested with the restriction enzyme recognizing the unique restriction site, to generate a unit-length linear plasmid, which is introduced into a cell together with a full-length PAV genome. Homologous recombination within the cell will result in production of a recombinant plasmid containing a full-length PAV genome. Recombinant plasmids will also generally contain sequences specifying replication in a host cell and one or more selective markers, such as, for example, antibiotic resistance.

Suitable host cells include any cell that will support recombination between a PAV genome and a plasmid containing PAV sequences, or between two or more plasmids, each containing PAV sequences. Recombination is generally performed in procaryotic cells, such as *E. coli*, while transfection of a plasmid containing a viral genome, to generate virus particles, is conducted in eukaryotic cells, preferably mammalian cells, most preferably porcine cell cultures. The growth of bacterial cell cultures, as well as culture and main-

tenance of eukaryotic cells and mammalian cell lines are procedures which are well-known to those of skill in the art.

In one embodiment of the invention, a defective recombinant PAV vector is used for expression of heterologous sequences. The defective vector will be deleted in all or part of the E1 region. Construction of a deletion in the E1 region of PAV is described in Example 3, *infra*. Heterologous sequences can be inserted so as to replace the deleted E1 region, and/or can be inserted at other sites in the PAV genome, preferably E3, E4 and/or the region between E4 and the right end of the genome. Defective vectors with E1 deletions are grown in helper cell lines, which provide E1 function.

Accordingly, on one embodiment of the invention, a number of recombinant helper cell lines are produced according to the present invention by constructing an expression cassette comprising an adenoviral E1 region and transforming host cells therewith to provide complementing cell lines or cultures providing E1 functions. The terms “complementing cell,” “complementing cell line,” “helper cell” and “helper cell line” are used interchangeably herein to denote a cell line that provides a viral function that is deficient in a deleted PAV, preferably E1 function. These recombinant complementing cell lines are capable of allowing a defective recombinant PAV, having a deleted E1 gene region, wherein the deleted sequences are optionally replaced by heterologous nucleotide sequences, to replicate and express one or more foreign genes or fragments thereof encoded by the heterologous nucleotide sequences. PAV vectors with E1 deletions, wherein heterologous sequences are inserted in regions other than E1, can also be propagated in these complementing cell lines, and will express the heterologous sequences if they are inserted downstream of a PAV promoter or are inserted in operative linkage with a eukaryotic regulatory sequence. Preferred helper cell lines include VIDO R1 cells, as described in Example 1, *infra*. Briefly, the VIDO R1 cell line is a porcine retinal cell line that has been transfected with DNA from the human adenovirus type 5 (HAV-5) E1 region, and which supports the growth of PAV E1A deletions and HAV-5 E1 deletions.

Transformation of porcine cells with either PAV or HAV has not been reported due to the fact that exposure of permissive or semi-permissive cells to adenovirus normally leads to lysis of infected cells. Graham et al., *supra*. The approach used in the present study to create a PAV E1-complementing cell line employing the E1 region of HAV-5 is novel as E1A proteins of HAV-5 have been shown for the first time to complement PAV-3 E1 mutants. There are several reasons that the E1 region of HAV-5 was used for transformation of porcine embryonic retinal cells. The E1 region of HAV-5 was shown to transform human retina cells very efficiently. Fallaux et al. (1998) *supra*. In contrast to the E1 region of PAV-3, the E1 region of HAV-5 has been thoroughly characterized and the monoclonal antibodies against the E1 proteins are readily available from commercial sources. In addition, the E1 A region of HAV-5 was shown to complement the E1 A functions of several non-human adenoviruses. Ball et al. (1988) *J. Virol.* 62:3947–3957; Zhengetal. (1994) *Virus Res.* 31:163–186.

More generally, defective recombinant PAV vectors, lacking one or more essential functions encoded by the PAV genome, can be propagated in appropriate complementing cell lines, wherein a particular complementing cell line provides a function or functions that is (are) lacking in a particular defective recombinant PAV vector. Complementing cell lines can provide viral functions through, for example, co-infection with a helper virus, or by integrating or other-

wise maintaining in stable form a fragment of a viral genome encoding a particular viral function.

In another embodiment of the invention, E1 function (or the function of any other viral region which may be mutated or deleted in any particular viral vector) can be supplied (to provide a complementing cell line) by co-infection of cells with a virus which expresses the function that the vector lacks.

#### PAV Expression Systems

In one embodiment, the present invention identifies and provides means of deleting regions of the PAV genome, to provide sites into which heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof can be inserted to generate porcine adenovirus recombinants. In preferred embodiments, deletions are made in part or all of the nucleotide sequences of the PAV E1, E3, or E4 regions and/or the region between E4 and the right end of genome. E1 deletion is described in Example 3; E3 deletion and insertion of heterologous sequence in the E3 region are described in Example 4 and 5; and insertion of a heterologous sequence between the E4 region and the right end of the PAV genome, as well as expression of the inserted sequence, is described in Example 6, *infra*.

In another embodiment, the invention identifies and provides additional regions of the PAV genome (and fragments thereof) suitable for insertion of heterologous or homologous nucleotide sequences encoding foreign genes or fragments thereof to generate PAV recombinants. These regions include nucleotides 145–13,555; 15,284–19,035; 22,677–24,055; 26,573–27,088; and 31,149–34,094 (SEQ ID NO:1) and comprise the E2 region, the late region, and genes encoding the pIX, DBP, pTP, pol, IVa2, 52K, IIIA, pIII, pVII, pV, pX, pVI, and 33K proteins. These regions of the PAV genome can be used, among other things, for insertion of foreign sequences, for provision of DNA control sequences including transcriptional and translational regulatory sequences, or for diagnostic purposes to detect the presence, in a biological sample, of viral nucleic acids and/or proteins encoded by these regions. Example 7, *infra*, describes procedures for constructing insertions in these regions.

One or more heterologous sequences can be inserted into one or more regions of the PAV genome to generate a recombinant PAV vector, limited only by the insertion capacity of the PAV genome and ability of the recombinant PAV vector to express the inserted heterologous sequences. In general, adenovirus genomes can accept inserts of approximately 5% of genome length and remain capable of being packaged into virus particles. The insertion capacity can be increased by deletion of non-essential regions and/or deletion of essential regions whose function is provided by a helper cell line.

In one embodiment of the invention, insertion can be achieved by constructing a plasmid containing the region of the PAV genome into which insertion is desired. The plasmid is then digested with a restriction enzyme having a recognition sequence in the PAV portion of the plasmid, and a heterologous sequence is inserted at the site of restriction digestion. The plasmid, containing a portion of the PAV genome with an inserted heterologous sequence, in co-transformed, along with a plasmid (such as pPAV-200) containing a full-length PAV genome, into a bacterial cell (such as, for example, *E. coli*), wherein homologous recombination between the plasmids generates a full-length PAV genome containing inserted heterologous sequences.

Deletion of PAV sequences, to provide a site for insertion of heterologous sequences or to provide additional capacity

for insertion at a different site, can be accomplished by methods well-known to those of skill in the art. For example, for PAV sequences cloned in a plasmid, digestion with one or more restriction enzymes (with at least one recognition sequence in the PAV insert) followed by ligation will, in some cases, result in deletion of sequences between the restriction enzyme recognition sites. Alternatively, digestion at a single restriction enzyme recognition site within the PAV insert, followed by exonuclease treatment, followed by ligation will result in deletion of PAV sequences adjacent to the restriction site. A plasmid containing one or more portions of the PAV genome with one or more deletions, constructed as described above, can be co-transfected into a bacterial cell along with a plasmid containing a full-length PAV genome to generate, by homologous recombination, a plasmid containing a PAV genome with a deletion at a specific site. PAV virions containing the deletion can then be obtained by transfection of mammalian cells (such as ST or VIDO R1 cells) with the plasmid containing a PAV genome with a deletion at a specific site.

Expression of an inserted sequence in a recombinant PAV vector will depend on the insertion site. Accordingly, preferred insertion sites are adjacent to and downstream (in the transcriptional sense) of PAV promoters. The transcriptional map of PAV, as disclosed herein, provides the locations of PAV promoters. Locations of restriction enzyme recognition sequences downstream of PAV promoters, for use as insertion sites, can be easily determined by one of skill in the art from the PAV nucleotide sequence provided herein. Alternatively, various *in vitro* techniques can be used for insertion of a restriction enzyme recognition sequence at a particular site, or for insertion of heterologous sequences at a site that does not contain a restriction enzyme recognition sequence. Such methods include, but are not limited to, oligonucleotide-mediated heteroduplex formation for insertion of one or more restriction enzyme recognition sequences (see, for example, Zoller et al. (1982) *Nucleic Acids Res.* 10:6487–6500; Brennan et al. (1990) *Roux's Arch. Dev. Biol.* 199:89–96; and Kunkel et al. (1987) *Meth. Enzymology* 154:367–382) and PCR-mediated methods for insertion of longer sequences. See, for example, Zheng et al. (1994) *Virus Research* 31:163–186.

It is also possible to obtain expression of a heterologous sequence inserted at a site that is not downstream from a PAV promoter, if the heterologous sequence additionally comprises transcriptional regulatory sequences that are active in eukaryotic cells. Such transcriptional regulatory sequences can include cellular promoters such as, for example, the bovine hsp70 promoter and viral promoters such as, for example, herpesvirus, adenovirus and papovavirus promoters and DNA copies of retroviral long terminal repeat (LTR) sequences.

In another embodiment, homologous recombination in a procaryotic cell can be used to generate a cloned PAV genome; and the cloned PAV-3 genome can be propagated as a plasmid. Infectious virus can be obtained by transfection of mammalian cells with the cloned PAV genome rescued from plasmid-containing cells. Example 2, *infra* describes construction of an infectious plasmid containing a PAV-3 genome.

The invention provides PAV regulatory sequences which can be used to regulate the expression of heterologous genes. A regulatory sequence can be, for example, a transcriptional regulatory sequence, a promoter, an enhancer, an upstream regulatory domain, a splicing signal, a polyadenylation signal, a transcriptional termination sequence, a translational regulatory sequence, a ribosome binding site and a translational termination sequence.



## Therapeutic Genes and Polypeptides

The PAV vectors of the invention can be used for the expression of therapeutic polypeptides in applications such as in vitro polypeptide production, vaccine production, nucleic acid immunization and gene therapy, for example. Therapeutic polypeptides comprise any polypeptide sequence with therapeutic and/or diagnostic value and include, but are not limited to, coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

In a preferred embodiment, PAV vectors will contain heterologous sequences encoding protective determinants of various pathogens of swine, for use in subunit vaccines and nucleic acid immunization. Representative swine pathogen antigens include, but are not limited to, pseudorabies virus (PRV) gp50; transmissible gastroenteritis virus (TGEV) S gene; porcine rotavirus VP7 and VP8 genes; genes of porcine respiratory and reproductive syndrome virus (PRRS), in particular ORF 5; genes of porcine epidemic diarrhea virus; genes of hog cholera virus, and genes of porcine parvovirus.

Various foreign genes or nucleotide sequences or coding sequences (prokaryotic, and eukaryotic) can be inserted into a PAV vector, in accordance with the present invention, particularly to provide protection against a wide range of diseases. Many such genes are already known in the art; the problem heretofore having been to provide a safe, convenient and effective vaccine vector for the genes or sequences.

A heterologous (i.e., foreign) nucleotide sequence can consist of one or more gene(s) of interest, and preferably of therapeutic interest. In the context of the present invention, a gene of interest can code either for an antisense RNA, a ribozyme or for an mRNA which will then be translated into a protein of interest. A gene of interest can be of genomic type, of complementary DNA (cDNA) type or of mixed type (minigene, in which at least one intron is deleted). It can code for a mature protein, a precursor of a mature protein, in particular a precursor intended to be secreted and accordingly comprising a signal peptide, a chimeric protein originating from the fusion of sequences of diverse origins, or a mutant of a natural protein displaying improved or modified biological properties. Such a mutant can be obtained by deletion, substitution and/or addition of one or more nucleotide(s) of the gene coding for the natural protein, or any other type of change in the sequence encoding the natural protein, such as, for example, transposition or inversion.

A gene of interest can be placed under the control of regulatory sequences suitable for its expression in a host cell. Suitable regulatory sequences are understood to mean the set of elements needed for transcription of a gene into RNA (ribozyme, antisense RNA or mRNA), for processing of RNA, and for the translation of an mRNA into protein. Among the elements needed for transcription, the promoter assumes special importance. It can be a constitutive promoter or a regulatable promoter, and can be isolated from any gene of eukaryotic, prokaryotic or viral origin, and even adenoviral origin. Alternatively, it can be the natural promoter of the gene of interest. Generally speaking, a promoter used in the present invention can be chosen to contain cell-specific regulatory sequences, or modified to contain such sequences. For example, a gene of interest for use in the present invention is placed under the control of an immunoglobulin gene promoter when it is desired to target its expression to lymphocytic host cells. There may also be

mentioned the HSV-1 TK (herpesvirus type 1 thymidine kinase) gene promoter, the adenoviral MLP (major late promoter), in particular of human adenovirus type 2, the RSV (Rous Sarcoma Virus) LTR (long terminal repeat), the CMV (Cytomegalovirus) early promoter, and the PGK (phosphoglycerate kinase) gene promoter, for example, permitting expression in a large number of cell types.

Alternatively, targeting of a recombinant PAV vector to a particular cell type can be achieved by constructing recombinant hexon and/or fiber genes. The protein products of these genes are involved in host cell recognition; therefore, the genes can be modified to contain peptide sequences that will allow the virus to recognize alternative host cells.

Among genes of interest which are useful in the context of the present invention, there may be mentioned:

genes coding for cytokines such as interferons and interleukins;

genes encoding lymphokines;

genes coding for membrane receptors such as the receptors recognized by pathogenic organisms (viruses, bacteria or parasites), preferably by the HIV virus (human immunodeficiency virus);

genes coding for coagulation factors such as factor VIII and factor IX;

genes coding for dystrophins;

genes coding for insulin;

genes coding for proteins participating directly or indirectly in cellular ion channels, such as the CFTR (cystic fibrosis transmembrane conductance regulator) protein;

genes coding for antisense RNAs, or proteins capable of inhibiting the activity of a protein produced by a pathogenic gene which is present in the genome of a pathogenic organism, or proteins (or genes encoding them) capable of inhibiting the activity of a cellular gene whose expression is deregulated, for example an oncogene;

genes coding for a protein inhibiting an enzyme activity, such as  $\alpha_1$ -antitrypsin or a viral protease inhibitor, for example;

genes coding for variants of pathogenic proteins which have been mutated so as to impair their biological function, such as, for example, trans-dominant variants of the tat protein of the HIV virus which are capable of competing with the natural protein for binding to the target sequence, thereby preventing the activation of HIV;

genes coding for antigenic epitopes in order to increase the host cell's immunity;

genes coding for major histocompatibility complex classes I and II proteins, as well as the genes coding for the proteins which are inducers of these genes;

genes coding for antibodies;

genes coding for immunotoxins;

genes encoding toxins;

genes encoding growth factors or growth hormones;

genes encoding cell receptors and their ligands;

genes encoding tumor suppressors;

genes coding for cellular enzymes or those produced by pathogenic organisms; and

suicide genes. The HSV-1 TK suicide gene may be mentioned as an example. This viral TK enzyme displays markedly greater affinity compared to the cellular TK enzyme for certain nucleoside analogues (such as acy-

clovir or gancyclovir). It converts them to monophosphorylated molecules, which can themselves be converted by cellular enzymes to nucleotide precursors, which are toxic. These nucleotide analogues can be incorporated into replicating DNA molecules, hence incorporation occurs chiefly in the DNA of dividing cells. This incorporation can result in specific destruction of dividing cells such as cancer cells.

This list is not restrictive, and any other gene of interest can be used in the context of the present invention. In some cases the gene for a particular antigen can contain a large number of introns or can be from an RNA virus, in these cases a complementary DNA copy (cDNA) can be used. It is also possible that only fragments of nucleotide sequences of genes can be used (where these are sufficient to generate a protective immune response or a specific biological effect) rather than the complete sequence as found in the wild-type organism. Where available, synthetic genes or fragments thereof can also be used. However, the present invention can be used with a wide variety of genes, fragments and the like, and is not limited to those set out above.

Recombinant PAV vectors can be used to express antigens for provision of, for example, subunit vaccines. Antigens used in the present invention can be either native or recombinant antigenic polypeptides or fragments. They can be partial sequences, full-length sequences, or even fusions (e.g., having appropriate leader sequences for the recombinant host, or with an additional antigen sequence for another pathogen). The preferred antigenic polypeptide to be expressed by the virus systems of the present invention contain full-length (or near full-length) sequences encoding antigens. Alternatively, shorter sequences that are antigenic (i.e., encode one or more epitopes) can be used. The shorter sequences can encode a "neutralizing epitope," which is defined as an epitope capable of eliciting antibodies that neutralize virus infectivity in an *in vitro* assay. Preferably the peptide should encode a "protective epitope" that is capable of raising in the host a "protective immune response," i.e., a humoral (i.e. antibody-mediated), cell-mediated, and/or mucosal immune response that protects an immunized host from infection.

The antigens used in the present invention, particularly when comprised of short oligopeptides, can be conjugated to a vaccine carrier. Vaccine carriers are well known in the art: for example, bovine serum albumin (BSA), human serum albumin (HSA) and keyhole limpet hemocyanin (KLH). A preferred carrier protein, rotavirus VP6, is disclosed in EPO Pub. No. 0259149, the disclosure of which is incorporated by reference herein.

Genes for desired antigens or coding sequences thereof which can be inserted include those of organisms which cause disease in mammals, particularly porcine pathogens such as pseudorabies virus (PRV), transmissible gastroenteritis virus (TGEV), porcine rotavirus, porcine respiratory and reproductive syndrome virus (PRRS), porcine epidemic diarrhea virus (PEDV), hog cholera virus (HCV), porcine parvovirus and the like. Genes encoding antigens of human pathogens are also useful in the practice of the invention.

#### Therapeutic Applications

With the recombinant viruses of the present invention, it is possible to provide protection against a wide variety of diseases affecting swine, cattle, humans and other mammals. Any of the recombinant antigenic determinants or recombinant live viruses of the invention can be formulated and used in substantially the same manner as described for the antigenic determinant vaccines or live vaccine vectors.

The present invention also includes pharmaceutical compositions comprising a therapeutically effective amount of a recombinant vector, recombinant virus or recombinant protein, prepared according to the methods of the invention, in combination with a pharmaceutically acceptable vehicle and/or an adjuvant. Such a pharmaceutical composition can be prepared and dosages determined according to techniques that are well-known in the art. The pharmaceutical compositions of the invention can be administered by any known administration route including, but not limited to, systemically (for example, intravenously, intratracheally, intraperitoneally, intranasally, parenterally, enterically, intramuscularly, subcutaneously, intratumorally or intracranially) or by aerosolization or intrapulmonary instillation. Administration can take place in a single dose or in doses repeated one or more times after certain time intervals. The appropriate administration route and dosage will vary in accordance with the situation (for example, the individual being treated, the disorder to be treated or the gene or polypeptide of interest), but can be determined by one of skill in the art.

The vaccines of the invention carrying foreign genes or fragments can be orally administered in a suitable oral carrier, such as in an enteric-coated dosage form. Oral formulations include such normally-employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. Oral vaccine compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, containing from about 10% to about 95% of the active ingredient, preferably about 25% to about 70%. An oral vaccine may be preferable to raise mucosal immunity (which plays an important role in protection against pathogens infecting the gastrointestinal tract) in combination with systemic immunity.

In addition, the vaccine can be formulated into a suppository. For suppositories, the vaccine composition will include traditional binders and carriers, such as polyalkaline glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%.

Protocols for administering to animals the vaccine composition(s) of the present invention are within the skill of the art in view of the present disclosure. Those skilled in the art will select a concentration of the vaccine composition in a dose effective to elicit antibody, cell-mediated and/or mucosal immune responses to the antigenic fragment. Within wide limits, the dosage is not believed to be critical. Typically, the vaccine composition is administered in a manner which will deliver between about 1 to about 1,000 micrograms of the subunit antigen in a convenient volume of vehicle, e.g., about 1–10 ml. Preferably, the dosage in a single immunization will deliver from about 1 to about 500 micrograms of subunit antigen, more preferably about 5–10 to about 100–200 micrograms (e.g., 5–200 micrograms).

The timing of administration may also be important. For example, a primary inoculation preferably may be followed by subsequent booster inoculations, for example, several weeks to several months after the initial immunization, if needed. To insure sustained high levels of protection against disease, it may be helpful to readminister booster immunizations at regular intervals, for example once every several years. Alternatively, an initial dose may be administered orally followed by later inoculations, or vice versa. Preferred vaccination protocols can be established through routine vaccination protocol experiments.

The dosage for all routes of administration of in vivo recombinant virus vaccine depends on various factors including, the size of patient, nature of infection against which protection is needed, carrier and the like and can readily be determined by those of skill in the art. By way of non-limiting example, a dosage of between approximately  $10^3$  pfu and  $10^8$  pfu can be used. As with in vitro subunit vaccines, additional dosages can be given as determined by the clinical factors involved.

A problem that has beset the use of adenovirus vectors for immunization and gene therapy in humans is the rapid development of an immunological response (or indeed in some cases existing immunity) to human adenoviruses (HAVs). Recombinant PAV vectors are likely to be less immunogenic in humans and, for this and other reasons, will be useful either as a substitute for HAV vectors or in combination with HAV vectors. For example, as initial immunization with a HAV vector can be followed by booster immunizations using PAV vectors; alternatively, initial immunization with a recombinant PAV vector can be followed by booster immunizations with HAV and/or PAV vectors.

The presence of low levels of helper-independent vectors in the batches of helper-dependent human adenoviruses that are grown in complementing human cell lines has been reported. Fallaux et al. (1998) supra. This occurs as a result of recombination events between the viral DNA and the integrated adenoviral sequences present in the complementing cell line. Hehir et al. (1996) *J. Virol.* 70:8459-8467. This type of contamination constitutes a safety risk, which could result in the replication and spread of the virus. Complete elimination of helper-dependent adenoviruses in the batches of helper-dependent vectors can be achieved using two approaches. The first is by developing new helper cell lines and matched vectors that do not share any common sequences. Fallaux et al. (1998) supra. The second approach is to take advantage of possible cross-complementation between two distantly related adenoviruses such as HAV-5 and PAV-3. VIDO R1 cells contain the E1 coding sequences of HAV-5. Although there is no significant homology between the E1 regions of HAV-5 and PAV-3 at the nucleotide sequence level, the proteins produced from the region can complement each others' function(s). Thus, the problem of helper-independent vector generation by homologous recombination is eliminated when VIDO R1 cells are used for the propagation of recombinant PAV-3.

The invention also encompasses a method of treatment, according to which a therapeutically effective amount of a PAV vector, recombinant PAV, or host cell of the invention is administered to a mammalian subject requiring treatment. The finding that PAV-3 was effective in entering canine, sheep and bovine cells in which it does not replicate or replicates poorly is an important observation. See Example 8, infra. This may have implications in designing PAV-3 vectors for vaccination in these and other animal species.

#### PAV Expression Systems

Recombinant PAV vectors can be used for regulated expression of foreign polypeptides encoded by heterologous nucleotide sequences. Standard conditions of cell culture, such as are known to those of skill in the art, will allow maximal expression of recombinant polypeptide. They can be used, in addition, for regulated expression of RNAs encoded by heterologous nucleotide sequences, as in, for example, antisense applications and expression of ribozymes.

When the heterologous sequences encode an antigenic polypeptide, PAV vectors comprising insertions of heterolo-

gous nucleotide sequences can be used to provide large quantities of antigen which are useful, in turn, for the preparation of antibodies. Methods for preparation of antibodies are well-known to those of skill in the art. Briefly, an animal (such as a rabbit) is given an initial subcutaneous injection of antigen plus Freund's complete adjuvant. One to two subsequent injections of antigen plus Freund's incomplete adjuvant are given at approximately 3 week intervals. Approximately 10 days after the final injection, serum is collected and tested for the presence of specific antibody by ELISA, Western Blot, immunoprecipitation, or any other immunological assay known to one of skill in the art.

Adenovirus E1 gene products transactivate many cellular genes; therefore, cell lines which constitutively express E1 proteins can express cellular polypeptides at a higher levels than other cell lines. The recombinant mammalian, particularly porcine, cell lines of the invention can be used to prepare and isolate polypeptides, including those such as (a) proteins associated with adenovirus E1A proteins: e.g. p300, retinoblastoma (Rb) protein, cyclins, kinases and the like; (b) proteins associated with adenovirus E1B protein: e.g. p53 and the like; growth factors, such as epidermal growth factor (EGF), transforming growth factor (TGF) and the like; (d) receptors such as epidermal growth factor receptor (EGF-R), fibroblast growth factor receptor (FGF-R), tumor necrosis factor receptor (TNF-R), insulin-like growth factor receptor (IGF-R), major histocompatibility complex class I receptor and the like; (e) proteins encoded by proto-oncogenes such as protein kinases (tyrosine-specific protein kinases and protein kinases specific for serine or threonine), p21 proteins (guanine nucleotide-binding proteins with GTPase activity) and the like; (f) other cellular proteins such as actins, collagens, fibronectins, integrins, phosphoproteins, proteoglycans, histones and the like, and (g) proteins involved in regulation of transcription such as TATA-box-binding protein (TBP), TBP-associated factors (TAFs), Sp1 binding protein and the like.

#### Gene Therapy

The invention also includes a method for providing gene therapy to a mammal, such as a porcine, human or other mammal in need thereof, to control a gene deficiency. In one embodiment, the method comprises administering to said mammal a live recombinant porcine adenovirus containing a heterologous nucleotide sequence encoding a non-defective form of said gene under conditions wherein the recombinant virus vector genome is incorporated into said mammalian genome or is maintained independently and extrachromosomally to provide expression of the required gene in the target organ or tissue. These kinds of techniques are currently being used by those of skill in the art to replace a defective gene or portion thereof. Examples of foreign genes, heterologous nucleotide sequences, or portions thereof that can be incorporated for use in gene therapy include, but are not limited to, cystic fibrosis transmembrane conductance regulator gene, human minidystrophin gene, alpha-1-antitrypsin gene and the like.

In particular, the practice of the present invention in regard to gene therapy in humans is intended for the prevention or treatment of diseases including, but not limited to, genetic diseases (for example, hemophilia, thalassemias, emphysema, Gaucher's disease, cystic fibrosis, Duchenne muscular dystrophy, Duchenne's or Becker's myopathy, etc.), cancers, viral diseases (for example, AIDS, herpesvirus infection, cytomegalovirus infection and papillomavirus infection) and the like. For the purposes of the present invention, the vectors, cells and viral particles prepared by

the methods of the invention may be introduced into a subject either *ex vivo*, (i.e., in a cell or cells removed from the patient) or directly *in vivo* into the body to be treated. Preferably, the host cell is a human cell and, more preferably, is a lung, fibroblast, muscle, liver or lymphocytic cell or a cell of the hematopoietic lineage.

#### Diagnostic Applications

The PAV genome, or any subregion of the PAV genome, is suitable for use as a nucleic acid probe, to test for the presence of PAV nucleic acid in a subject or a biological sample. The presence of viral nucleic acids can be detected by techniques known to one of skill in the art including, but not limited to, hybridization assays, polymerase chain reaction, and other types of amplification reactions. Suitable labels and hybridization techniques are well-known to those of skill in the art. See, for example, Kessler (ed.), *Nonradioactive Labeling and Detection of Biomolecules*, Springer-Verlag, Berlin, 1992; Kricka (ed.) *Nonisotopic DNA Probe Techniques*, Academic Press, San Diego, 1992; Howard (ed.) *Methods in Nonradioactive Detection*, Appleton & Lange, Norwalk, 1993; Ausubel et al., *supra*; and Sambrook et al., *supra*. Diagnostic kits comprising the nucleotide sequences of the invention can also contain reagents for cell disruption and nucleic acid purification, as well as buffers and solvents for the formation, selection and detection of hybrids.

Regions of the PAV genome can be inserted into any expression vector known in the art and expressed to provide, for example, vaccine formulations, protein for immunization, etc. The amino acid sequence of any PAV protein can be determined by one of skill in the art from the nucleotide sequences disclosed herein. PAV proteins can be used for diagnostic purposes, for example, to detect the presence of PAV antigens. Methods for detection of proteins are well-known to those of skill in the art and include, but are not limited to, various types of direct and competitive immunoassays, ELISA, Western blotting, enzymatic assay, immunohistochemistry, etc. See, for example, Harlow & Lane (eds.): *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, New York, 1988. Diagnostic kits comprising PAV polypeptides or amino acid sequences can also comprise reagents for protein isolation and for the formation, isolation, purification and/or detection of immune complexes.

### EXAMPLES

#### Methods

##### Virus and Viral DNA

The 6618 strain of PAV-3 was propagated in the swine testis (ST) cell line and in E1-transformed porcine retinal cells (VIDO R1, see below). Porcine embryonic retinal cells were obtained from the eyeballs of piglets delivered by caesarian section two weeks before the parturition date. Uninfected cells were grown in MEM supplemented with 10% fetal bovine serum (FBS). MEM with 2% FBS was used for maintenance of infected cells. Viral DNA was extracted either from infected cell monolayers by the method of Hirt (1967) *J. Mol. Biol.* 26:365–369, or from purified virions as described by Graham et al. (1991) in "Methods in Molecular Biology" Vol. 7, Gene transfer and expression protocols, ed. E. J. Murray, Humana Press, Clifton, N.J., pp. 109–128.

##### Plasmids and Genomic DNA Sequencing

Selected restriction enzyme fragments of PAV-3 DNA were cloned into pGEM-3Z and pGEM-7Zf(+) plasmids (Promega). Nucleotide sequences were determined on both

strands of the genome by the dideoxy chain-termination method using Sequenase® enzyme (U.S. Biochemicals) and the dye-terminator method with an Applied Biosystems (Foster City, Calif.) DNA sequencer.

##### cDNA Library

A cDNA library was generated from polyadenylated RNA extracted from PAV-3 infected ST cells at 12 h and 24 h post infection. Double stranded cDNAs were made with reagents from Stratagene and cloned into Lambda ZAP vector. Plaques which hybridized to specific restriction enzyme fragments of PAV-3 DNA were plaque purified twice. Plasmids containing cDNAs were excised from the Lambda ZAP vector according to the manufacturer's protocol. The resulting plasmid clones were characterized by restriction endonuclease analysis and by sequencing of both ends of the cDNA insert with T3- and T7-specific primers. Selected clones were sequenced with internal primers. cDNA sequences were aligned with genomic sequences to determine the transcription map.

##### Viral Transcript Mapping by Nuclease Protection

Transcript mapping was conducted according to the method of Berk et al. (1977) *Cell* 12:721–732.

#### Example 1

##### Development of an E1-complementing Helper Cell Line (VIDO R1)

Primary cultures of porcine embryonic retina cells were transfected with 10 µg of plasmid pTG 4671 (Transgene, Strasburg, France) by the calcium phosphate technique. The pTG 4671 plasmid contains the entire E1A and E1B sequences (nts 505–4034) of HAV-5, along with the puromycin acetyltransferase gene as a selectable marker. In this plasmid, the E1 region is under the control of the constitutive promoter from the mouse phosphoglycerate kinase gene, and the puromycin acetyltransferase gene is controlled by the constitutive SV40 early promoter. Transformed cells were selected by three passages in medium containing 7 µg/ml puromycin, identified based on change in their morphology from single foci (i.e., loss of contact inhibition), and subjected to single cell cloning. The established cell line was first tested for its ability to support the growth of E1 deletion mutants of HAV-5. Subsequently the cell line was further investigated for the presence of E1 sequences in the genome by PCR, expression of the E1A and E1B proteins by Western blot, and doubling time under cell culture conditions. E1 sequences were detected, and production of E1A and E1B proteins was demonstrated by immunoprecipitation (FIG. 3). Doubling time was shorter, when compared to that of the parent cell line. Example 3, *infra*, shows that this cell line is capable of complementing a PAV E1A deletion mutant.

To assess the stability of E1 expression, VIDO R1 cells were cultured through more than 50 passages (split 1:3 twice weekly) and tested for their ability to support the replication of E1-deleted HAV-5. Expression of the E1A and E1B proteins at regular intervals was also monitored by Western blot. The results indicated that the VIDO R1 line retained the ability to support the growth of E1-deleted virus and expressed similar levels of E1 proteins during more than 50 passages in culture. Therefore, VIDO R1 can be considered to be an established cell line.

#### Example 2

##### Construction of a Full-length Infectious Clone of PAV-3

A plasmid clone containing a full-length copy of the PAV-3 genome (pPAV-200) was generated by first construct-

ing a plasmid containing left- and right-end sequences of PAV-3, with the PAV-3 sequences bordered by PacI sites and separated by a PstI restriction site (pPAV-100), then allowing recombination between PstI-digested pPAV-100 and an intact PAV-3 genome. Left- and right-end sequences for insertion into pPAV-100 were produced by PCR amplification, as follows.

The plasmid p3SB (Reddy et al., 1993, *Intervirology* 36:161–168), containing the left end of PAV-3 genome (position 1–8870) was used for amplification of the first 433 bp of the PAV-3 genome by PCR. Amplification primers were oligonucleotides 1

(5'-GCGGATCCTTAATTAACATCATCAATAATATA CCGCACACTTTT-3') (SEQ ID NO.: 2) and 2

(5'-CACCTGCAGATACCCACACACGTCATCTCG-3') (SEQ ID NO.: 3). In the sequences shown here, adenoviral sequences are shown in bold and engineered restriction enzyme sites are italicized.

For amplification of sequences at the right end of the PAV-3 genome, the plasmid p3SA (Reddy et al., 1993, *supra*) was used. This plasmid was used as template in PCR for amplification of the terminal 573 bp of the genome using oligonucleotide 1 (above) and oligonucleotide 3

(5'-CACCTGCAGCCTCCTGAGTGTGAAGAGTGTCC-3') (SEQ ID NO.: 4). The primers were designed based on the nucleotide sequence information described elsewhere (Reddy et al., 1995c, *supra*; and Reddy et al., 1997, *supra*).

For construction of pPAV-100, the PCR product obtained with oligonucleotides 1 and 2 was digested with BamHI and PstI restriction enzymes and the PCR product obtained using primers 1 and 3 was digested with PstI and PacI enzymes. Modified bacterial plasmid pPolyIIsn14 was digested with BamHI and PacI enzymes. This plasmid was used based on its suitability for homologous recombination in *E. coli*. The two PCR products described above were cloned into pPolyIIsn14 by three way ligation to generate the plasmid pPAV-100 which carries both termini of PAV-3, separated by a PstI site and bordered by PacI restriction enzyme sites.

Plasmid pPAV-200, which contains a full length PAV-3 genome, was generated by co-transformation of *E. coli* BJ 5183 recBC sbcBC (Hanahan, 1983, *J. Mol. Biol.* 166:557–580) with PstI-linearized pPAV-100 and the genomic DNA of PAV-3. Extensive restriction enzyme analysis of pPAV-200 indicated that it had the structure expected of a full-length PAV-3 insert, and that no unexpected rearrangements had occurred during recombination in *E. coli*.

The infectivity of pPAV-200 was demonstrated by lipofectin transfection (Life Technologies, Gaithersburg, Md.) of ST cells following PacI enzyme digestion of the plasmid to release the viral genome from the plasmid. Viral plaques were evident 7 days following transfection, and titers were equivalent to, or higher than, those obtained after infection with wild-type PAV. The plaques were amplified and the viral DNA was extracted and analyzed by restriction enzyme digestion. The viral DNA obtained by cleavage of pPAV-200 with PacI contained an extra 3 bases at each end; but these extra bases did not substantially reduce the infectivity of the PAV genome excised from pPAV-200. In addition, the bacterial-derived genomes lacked the 55-kDa terminal protein that is covalently linked to the 5' ends of adenoviral DNAs and which enhances infectivity of viral DNA.

#### Example 3

##### Generation of E1 Deletion Mutants of PAV-3

A plasmid (pPAV-101) containing the left (nucleotides 1–2,130) and the right (nucleotides 32,660–34,094) terminal

NcoI fragments of the PAV-3 genome was constructed by digesting pPAV-200 with the enzyme NcoI (which has no recognition sites in the vector backbone, but many sites in the PAV insert), gel-purifying the appropriate fragment and self-ligating the ends. See FIG. 4. The E1A sequences of pPAV-101, between nucleotides 407 and 1270 (PAV genome numbering), were deleted by digestion of pPAV-101 with NotI (recognition site at nucleotide 407) and AseI (recognition site at 1270), generation of blunt ends, and insertion of a double-stranded oligonucleotide encoding a XbaI restriction site to create a plasmid, pPAV-102, containing PAV left- and right-end sequences, separated by a NcoI site, with a deletion of the E1 A region and a XbaI site at the site of the deletion. See FIG. 5. Plasmid pPAV-201, containing a full-length PAV-3 genome minus E1A sequences, was created by co-transformation of *E. coli* BJ 5183 with NcoI linearized pPAV-102 and genomic PAV-3 DNA. The resulting construct, when transfected into VIDO R1 cells following digestion with PacI restriction enzyme, produced a virus that had a deletion in the E1 region. In similar fashion, construction of a virus with deletions in E1 and E3 was accomplished by transformation of BJ 5183 cells with NcoI linearized pPAV-102 and genomic PAV-3 DNA containing an E3 deletion. These E1A deletion mutants did not grow on either ST (swine testis) cells or fetal porcine retina cells and could only be grown in the VIDO R1 cell line.

#### Example 4

##### Generation of E3 Inserts and Deletion Mutants

To systematically examine the extent of the E3 region that could be deleted, a E3 transfer vector was constructed. The vector (pPAV-301) contained a PAV-3 segment from nucleotides 26,716 to 31,064 with a green fluorescent protein (GFP) gene inserted into the SnaBI site (located at nucleotide 28,702) in the same orientation as E3. The GFP gene was obtained from the plasmid pGreen Lantern-1™ (Life Technologies), by NotI digestion followed by purification of a 732-nucleotide fragment. Similarly, another construct was made with GFP cloned into the SacI site located at nucleotide 27,789. KpnI-BamHI fragments encompassing the modified E3 regions were then isolated from these E3 transfer vectors and recombined in *E. coli* with pPAV-200 that had been linearized at nucleotide position 28,702 by SnaBI digestion. Virus were obtained with a construct that had the GFP gene cloned into the SnaBI site.

To delete the non-essential portion of E3 from the transfer vector, a PCR approach was used. In this approach, the region of the PAV genome between nucleotides 27,402 and 28,112 was amplified using the following primers:

5'-GACTGACGCCGGCATGCAAT-3' SEQ ID NO: 5  
5'-CGGATCCTGACGCTACGAGCGGTTGTA-3' SEQ ID NO: 6

In a second PCR reaction, the portion of the PAV genome between nucleotides 28,709 and 29,859 was amplified using the following two primers:

5'-CGGATCCATACGTACAGATGAAGTAGC-3' SEQ ID NO: 7  
5'-TCTGACTGAAGCCGACCTGC-3' SEQ ID NO: 8

In the oligonucleotides designated SEQ ID NO: 6 and SEQ ID NO: 7, a BamHI recognition sequence is indicated by underlining. The template for amplification was a KpnI-BamHI fragment encompassing nucleotides 26,716–31,063 of the PAV genome, inserted into the plasmid pGEM3Z (Promega), and Pfu polymerase (Stratagene) was used for amplification. The first PCR product (product of amplification with SEQ ID NO: 5 and SEQ ID NO: 6) was digested

## 25

with BamHI and gel-purified. The second PCR product (product of amplification with SEQ ID NO: 7 and SEQ ID NO: 8) was digested with BamHI and SpeI and gel-purified. They were inserted into SmaI/SpeI-digested pBlueScript II SK(+) (Stratagene) in a three-way ligation reaction to generate pPAV-300. See FIG. 6. pPAV-300 contains the portion of the PAV-3 genome extending from nucleotides 27,402 to 29,859, with 594 base pairs (bp) between nucleotides 28,113 and 28,707 deleted from the E3 region. A virus with such a deletion was constructed as follows. A SphI-SpeI fragment from pPAV-300, containing part of the pVIII gene, a deleted E3 region, and part of the fiber gene was isolated (see FIG. 6). This fragment was co-transfected, with SnaBI-digested pPAV-200 (which contains a full-length PAV-3 genome) into *E. coli*. Homologous recombination generated a plasmid, pFPAV-300, containing a full-length PAV genome with a deletion in the E3 region. pFPAV-300 was digested with PacI and transfected into VIDO R1 cells (Example 1) to generate recombinant virus with a deletion in the E3 region of the genome.

## Example 5

Construction of a PAV Recombinant with an Insertion of the PRV gp50 Gene in the PAV E3 Region and Expression of the Inserted Gene

To construct a recombinant PAV expressing pseudorabies virus (PRV) gp50, the PRV gp50 gene was inserted at the SnaBI site of pPAV-300 to create plasmid pPAV-300-gp50. A SphI-SpeI fragment from pPAV-300-gp50, containing part of the pVII gene, a deleted E3 region with the PRV gp50 gene inserted, and part of the fiber gene, was purified and co-transfected, along with SnaBI-digested pFPAV-300 (E3-deleted) into *E. coli*. In the bacterial cell, homologous recombination generated pFPAV-300-gp50, a plasmid containing a PAV genome with the PRV gp50 gene replacing a deleted E3 region. Recombinant virus particles were obtained as described in Example 4.

Expression of the inserted PRV gp50 was tested after infection of VIDO R1 cells with the recombinant virus, by <sup>35</sup>S labeling of infected cells (continuous label), followed by immunoprecipitation with an anti-gp50 monoclonal antibody and gel electrophoresis of the immunoprecipitate. FIG. 7 shows that large amounts of gp50 are present by 12 hours after infection, and expression of gp50 persists up to 24 hours after infection.

## Example 6

Expression of the Chloramphenicol Acetyltransferase Gene from a Region that Lies Between the Promoter of the E4 Region and the Right ITR

The right terminal fragment of the PAV genome (encompassing nucleotides 31,054–34,094) (SEQ ID NO:1) was obtained by XhoI digestion of pPAV-200 and cloned between the XhoI and NotI sites of pPolyIIsn14. A Chloramphenicol acetyltransferase (CAT) gene expression cassette, in which the CAT gene was flanked by the SV40 early promoter and the SV40 polyadenylation signal, was inserted, in both orientations, into a unique HpaI site located between the E4 region promoter and the right ITR, to generate plasmids pPAV-400A and pPAV-400B. The modified terminal fragments were transferred into a plasmid containing a full-length PAV-3 genome by homologous recombination in *E. coli* between the isolated terminal fragments and HpaI-

## 26

digested pPAV-200. Recombinant viruses expressing CAT were obtained following transfection of VIDO R1 cells with the plasmids. PAV-CA2 contained the CAT gene cassette in a leftward transcriptional orientation (i.e., the same orientation as E4 region transcription), while, in PAV-CAT6, the CAT gene cassette was in the rightward transcriptional orientation.

These recombinant viruses were tested for expression of CAT, after infection of VIDO R1 cells, using a CAT Enzyme Assay System from Promega, following the instructions provided by the supplier. See, Cullen (1987) *Meth. Enzymology* 43:737; and Gorman et al, (1982) *Mol. Cell. Biol.* 2:1044. The results are shown in Table 3.

TABLE 3

CAT activity expressed by recombinant PAV viruses	
Sample	<sup>3</sup> H cpm
Mock-infected	458
CAT positive control*	199,962
PAV-CAT2	153,444
PAV-CAT6	63,386

\*the positive control sample contained 0.1 Units of purified CAT.

These results show that recombinant PAV viruses, containing an inserted gene, are viable and are capable of expressing the inserted gene.

## Example 7

Construction of Replication Defective PAV-3 Expressing GFP

A 2.3 kb fragment containing the CMV immediate early promoter, the green fluorescent protein (GFP) gene and the bovine growth hormone poly(A) signal was isolated by digesting pQBI 25 (Quantum Biotechnology) with BgIII and DraIII followed by filling the ends with T4 DNA polymerase. This fragment was inserted into the SrfI site of pPAV-102 in both orientations to generate pPAV-102GFP (FIG. 8). This plasmid, digested with PacI and SmaI enzymes, and the fragment containing part of the E1 sequence and the GFP gene was gel purified. This fragment and the SrfI digested pFPAV-201 were used to transform *E. coli* BJ 5183 to generate the full-length clone containing GFP in the E1 region (pFPAV-201-GFP) by homologous recombination. The recombinant virus, PAV3delE1E3.GFP was generated following transfection of VIDO R1 cells with PacI restricted pFPAV-201-GFP that had the GFP transcription unit in the opposite orientation to the E1. A similar virus with the GFP in the same orientation as E1 could not be rescued from transfected cells. Presence of the GFP gene in the viral genome was confirmed by restriction enzyme analysis. The recombinant virus replicated in VIDO R1 cells two logs less efficiently than the wild type PAV-3.

## Example 8

Virus Entry and Replication of PAV-3 in Human and Animal Cells

To initially characterize the host species restriction of PAV in vitro, monolayers of 11 cell types from 6 different mammalian species were infected with wild type PAV-3 or PAV3delE1E3.GFP. ST, VIDO R1 (porcine), 293, A549 (human), MDBK VIDO R2 (bovine), C3HA (mouse), COS, VERO (monkey), sheep skin fibroblasts or cotton rat lung cells were incubated with 1 pfu/cell of wild type PAV-3 or

helper-dependent PAV-3 expressing GFP. The cells infected with wild type PAV were harvested at 2 h and 3 days post-infection, subjected to two cycles of freeze-thaw, and virus titers were determined on VIDO R1 cells. Cells that were infected with the recombinant virus expressing GFP were observed with the aid of a fluorescent microscope for green fluorescence.

A ten-fold increase in virus titers in Vero and COS cells, and a hundred-fold increase in cotton rat lung fibroblasts and VIDO R2 cells, was noticed. No increase in the virus titers was observed with 293, A549, MDBK, sheep skin fibroblasts, dog kidney and C3HA cells. All of these cell types showed bright green fluorescence when infected with PAV3delE1E3. GFP except human cells, which showed a weak fluorescence. In addition, low levels of GFP expression were achieved in human cells with recombinant PAV-3. These observations suggest that virus entry into human cells is limited and/or the human cells are non-permissive for the replication of the virus. These results also demonstrated that GFP was expressed by the PAV-3 vector in cells which are semi-permissive (VERO, COS, Cotton rat lung fibroblasts and VIDO R2), or non-permissive (Sheep skin fibroblasts, MDBK and human cells) for virus replication.

#### Example 9

Insertions in the Regions of the PAV-3 Genome  
Defined by Nucleotides 145–13,555; 15,284–19,035;  
22,677–24,055; 26,573–27,088; and 31,149–34,094  
(SEQ ID NO:1)

Insertions are made by art-recognized techniques including, but not limited to, restriction digestion, nuclease digestion, ligation, kinase and phosphatase treatment, DNA polymerase treatment, reverse transcriptase treatment, and chemical oligonucleotide synthesis. Heterologous nucleic acid sequences of interest are cloned into plasmid vectors containing portions of the PAV genome (which may or may not contain deletions of PAV sequences) such that the foreign sequences are flanked by sequences having substantial homology to a region of the PAV genome into which insertion is to be directed. Substantial homology refers to homology sufficient to support homologous recombination. These constructs are then introduced into host cells that are co-transfected with PAV-3 DNA or a cloned PAV genome. During infection, homologous recombination between these constructs and PAV genomes will occur to generate recombinant PAV genome-containing plasmids. Recombinant virus

are obtained by transfecting the recombinant PAV genome-containing plasmids into a suitable mammalian host cell line. If the insertion occurs in an essential region of the PAV genome, the recombinant PAV virus is propagated in a helper cell line which supplies the viral function that was lost due to the insertion.

#### Deposit of Biological Materials

The following materials were deposited and are maintained with the Veterinary Infectious Disease Organization (VIDO), Saskatoon, Saskatchewan, Canada.

The nucleotide sequences of the deposited materials are incorporated by reference herein, as well as the sequences of the polypeptides encoded thereby. In the event of any discrepancy between a sequence expressly disclosed herein and a deposited sequence, the deposited sequence is controlling.

Material	Internal Accession No.	Deposit Date
<u>Recombinant plasmids</u>		
pPAV-101	VIDO 98-1	Apr. 10, 1998
pPAV-102	VIDO 98-2	Apr. 10, 1998
pPAV-200	VIDO 98-3	Apr. 10, 1998
pPAV-300	VIDO 98-4	Apr. 10, 1998
pPAV-400A	VIDO 98-5	Apr. 10, 1998
pPAV-400B	VIDO 98-6	Apr. 10, 1998

#### Recombinant Cell Lines

Porcine embryonic retinal cells transformed with HAV-5 E1 sequences:

VIDO R1	VIDOO 98C-1	Apr. 10, 1998
---------	-------------	---------------

While the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that various changes and modifications may be practiced without departing from the spirit of the invention. Therefore the foregoing descriptions and examples should not be construed as limiting the scope of the invention.

#### SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 34094

<212> TYPE: DNA

<213> ORGANISM: Porcine Adenovirus Type 3

<220> FEATURE:

<400> SEQUENCE: 1

catcatcaat aatataccgc acacttttat tgcccctttt gtggcgtggt gattggcgga 60

gagggttggg ggcggcgggc ggtgattggt ggagaggggt gtgacgtagc gtgggaacgt 120

gacgtcgcgt gggaaaatga cgtgtgatga cgtcccgtgg gaacgggtca aagtccaagg 180

- continued

---

ggaaggggtg	gagccctggg	gcggtcctcc	gcggggcggg	gccgagcggc	ggaaattccc	240
gcacaggtgg	agagtaccgc	gggattttgt	gccctctgga	ccggaccttc	gccctccggt	300
gtggcacttc	cgcaccacac	gtccgcggcc	cggtattccc	cacctgacga	cggtgacacc	360
actcacctga	gcggggtgtc	cttcgcgctg	agaggtccgc	ggcggccgcc	cgagatgacg	420
tgtgtgggtg	tattttttcc	cctcagtgtg	tatagtcgcg	gcagcgcgcc	agagtcacta	480
ctcttgagtc	cgaagggagt	agagttttct	ctcagcggaa	cagacctcgc	acatggcgaa	540
cagacttcac	ctggactggg	acggaaaccc	cgaggtgggt	ccggtgctgg	aatgggaccc	600
ggtggatctg	cgcgaccctc	ctccggggga	tgagggtctc	tgtgagccgt	gctgggagag	660
tctggtcgat	ggactgccgg	acgagtggct	ggacagtgtg	gacgaggtgg	aggtgattgt	720
gactgagggg	ggtgagtcag	aggacagtgg	tgggagtgcc	gctggtgact	caggtggctc	780
tcagggggtc	tttgagatgg	acccccaga	agagggggac	agtaatgagg	aggatatcag	840
cgcggtggct	gcgaggtgct	tgtctgaact	ggctgatgtg	gtgtttgagg	accacttgc	900
gccaccctct	ccgtttgtgt	tggactgccc	cgaggtacct	ggtgtgaact	gccgctcttg	960
tgattacat	cgctttcact	ccaaggacct	caatctgaag	tgcagtctgt	gctacatgag	1020
gatgcatgcc	tttgctgtct	atggtgagtg	tttttggaca	tttgtgggat	tatgtggaaa	1080
aaaaggaaaa	agtgcttgta	agaaatctca	tgtgctatct	cccatttttt	gtcttttttag	1140
aagctgtttc	tccagcacct	cacaggtcgg	gttccccggg	acttgagac	ctgccaggac	1200
gcaagaggaa	gtactgctat	gactcatgca	gcgaacaacc	tttgacctg	tctatgaagc	1260
gcccccgga	ttaatcatta	acctcaataa	acagcatgtg	atgatgactg	attgtctgtg	1320
tctctgccta	tataaccct	tgtggtttgc	agggaggga	tgtggtgact	gagctattcc	1380
tcagcatcat	catcgctctg	cttttttcta	ctgcaggcta	tttcttgcta	gctcgctgtc	1440
ccttttcttt	ttctgtgggc	atggactatc	aacttctggc	caagcttact	aacgtgaact	1500
accttaggaa	ggtgatagta	caggggtctc	agaactgccc	ttggtggaaa	aagatttttt	1560
cggacaggtt	tatcaaggta	gtagcagagg	ccaggaggca	gtacgggcaa	gagttgattg	1620
agatttttgt	ggaggggtgag	aggggctttg	gtcctgagtt	cctgcgggaa	gggggactgt	1680
acgaagaggc	cgttctgaaa	gagttggatt	tcagcacctt	gggacgcacc	gtagctagtg	1740
tggctctggg	ctgcttcatt	tttgagaagc	ttcagaagca	cagcgggtgg	actgacgagg	1800
gtattttaag	tcttctgggtg	ccgccactat	gttccctgct	ggaggcgcgga	atgatggcgg	1860
agcaggtgcg	gcaggggctg	tgcacatca	ggatgccgag	cgcggagcgg	gagatgctgt	1920
tgccagtggt	gtcatccggc	agtggcagcg	gggcccggat	gcgggaccag	gtggtgccca	1980
agcggccgcg	ggagcaggaa	gaggaggagg	aggacgagga	tgggatggaa	gcgagcgggc	2040
gcaggctcga	agggccggat	ctggtttaga	tcgcccggcg	cccgggggag	cggtgggaga	2100
ggggagcggg	gaggaggcgg	gggggtcttc	catggttagc	tatcagcagg	tgctttctga	2160
gtatctggag	agtcctctgg	agatgcatga	gcgctacagc	tttgagcaga	ttaggccta	2220
tatgcttcag	ccgggggatg	atctggggga	gatgatagcc	cagcacgcca	aggtggagtt	2280
gcagccgggc	acggtgtacg	agctgaggcg	cccgatcacc	atccgcagca	tgtgttacat	2340
catcggaac	ggggccaaga	tcaagattcg	ggggaattac	acggagtaca	tcaacataga	2400
gccgcgtaac	cacatgtgtt	ccattgcggg	catgtggctg	gtgactatca	cggatgtggt	2460
ttttgatcgg	gagctaccgg	cccgggggtg	tctgatttta	gccaacacgc	acttcacct	2520
gcacggctgc	aacttctggt	gctttctggg	ctcggtaata	acggcgaacg	ccgggggggt	2580



- continued

---

ggtgcgggga	tgctactttt	tcgectgcta	caaggcgtg	gaccaccggg	ggcggctgtg	2640
gctgacggtg	aacgagaaca	cgtttgaaaa	gtgtgtgtac	gcggtggtct	ctgcggggcg	2700
ttgcaggatc	aagtacaact	cctccctgtc	caccttctgc	ttcttgacac	tgagctatac	2760
gggcaagata	gtggggaaca	gcatcatgag	cccttacacg	ttcagcgacg	accctacgt	2820
ggacctggtg	tgctgccaga	gcgggatggt	gatgccccctg	agcacggtgc	acatcgctcc	2880
ctcgtctcgc	ctgccctacc	ctgagttccg	caagaatgtg	ctcctccgca	gcaccatggt	2940
tgtgggcggc	cgctgggca	gcttcagccc	cagccgctgc	tcctacagct	acagctccct	3000
ggtggtggac	gagcagtcct	accggggtct	gagtgtgacc	tgctgcttcg	atcagacctg	3060
tgagatgtac	aagctgctgc	agtgtacgga	ggcggacgag	atggagacgg	atacctctca	3120
gcagtacgcc	tgctgtgcg	gggacaatca	ccccggccg	caggtgcggc	agatgaaagt	3180
gacagacgcg	ctgcggggcc	cccggctcct	ggtgagctgc	aactgggggg	agttcagcga	3240
tgacgatgac	tgaggatgag	tcacccccctc	ccctcctctt	gcaggtacgt	ggccccgccc	3300
agtgggatgg	gctttggatg	ggggaggggt	gttccctata	aaaggggat	gggggtggag	3360
gcatgcagcc	ccacgggga	gcttgtgtgg	aggatgtctt	ccgagggatga	gatccggacc	3420
tgcttcattt	cagctcgtct	tcccagctgg	gccggcgtgc	gtcagggagt	ggccgggacg	3480
aatgtgaacg	gcggagtgg	gggcgcccct	gccagagcg	gggtgctggc	ctactcccgc	3540
ttcgttcagc	agcaacagca	gcagccgggg	acggcggcga	cggggtctgt	gttccgggcg	3600
gtgtttccat	cggtgatct	gagcgcggag	gtggcatga	tgccgcaggc	gctggcggag	3660
ctgcggcagc	agctgcagga	gctgcgggag	gtggtggaga	tacagctgcg	ggccacggcc	3720
tcggaggcgg	ccgaggagga	agaggaggag	gagattgtgg	tggacgagga	ggtggcgccc	3780
ggcgtggag	cgaacaccat	ggaagaggag	gaggatgaga	tggtcctgac	gatgactgtg	3840
gtgggggacc	ctgagcctgc	tggagtggaa	gccagccgc	caccaccacc	caccccgag	3900
agcagccctg	cggtgcctgc	tactaccact	accccgaagc	ggctcagcta	cgccgcgagc	3960
aagaggagcg	gtccatgctc	ggaggacaac	tgacgcggac	tgtgggggga	agaaggggga	4020
ggaggaaaga	agaccatgga	gacgggtggt	tgtctttttc	cagcccaact	ttattgagaa	4080
taataataaa	gcttatggat	gtttggaacg	ataatagcgt	gtccagcgtt	ctctgtcttg	4140
cagggctctg	tgtatcttct	cgaggcaccg	gtagacctgg	tggtggacgt	tgaaatacat	4200
gggcatgact	ccctcggcgg	ggtgcaggta	aagccactgg	agggctgggt	gcggggggca	4260
ggtgcagtag	atgatccagt	cataggcgtt	ctggttgcgg	tggtggttga	aaatgctctt	4320
gaggagcagg	ctgatggcgg	tgggcagacc	cttgggtgtag	gcattgatga	accggttgac	4380
ctgggcgggc	tgcatgaggg	gggacatgat	gtggtacttg	gcctggatct	tgaggttgga	4440
gatggtgccc	ctctggtcgc	ggcggggggt	catgttgtgg	aggacgacga	ggacggcgta	4500
gccggtgcag	cgggggaagc	gggcgtgcag	cttggagggg	aaggcgtgga	agaacttggc	4560
gacccccctg	tgtecgccga	ggtcctccat	gactcgtcgc	aggacgatgg	cgatgggtcc	4620
gcgggcggcg	gcgcgggca	agacgttgcg	tgagtcagtg	acatcatagt	tgtgctcctg	4680
catgaggctc	tggtagctca	tgccgacaaa	gtctggcatg	aggggtggcg	tctgggggat	4740
tagggtgtgg	tccggaccgc	tgccgtagtt	gccctcgcag	atctgggtct	cccaggcgac	4800
tacctcctgc	gggggatca	tgtccacctg	cggggtgatg	aagaaaacag	tctccggcgg	4860
gggggagagg	agttgggagg	agatgaggtt	gcggagcagc	tgggacttgc	cggagccggt	4920

- continued

---

gggaccgtag	atgacagcga	tgactggctg	gacctggtag	ttgagggagc	ggcaggtgcc	4980
agccgggggtg	aggaagggca	tgacggcggt	gaggggtgctg	cgcaggttgc	ggttctcttg	5040
gacgaggtcc	tgacgaggt	gtcggcctcc	cagggagagg	aggtgggaga	gggagggcaa	5100
ggccttgagg	ggcttgaggc	cctcggcgta	gggcatgtcc	tgacgggcct	ggtggagcac	5160
gcgcatgcgc	tcccagagct	cggttacatg	tcccacggta	tcgtcctcca	gcaggtctgg	5220
ttgtttctcg	ggttgggggt	gctgcgtgag	tacggaacga	ggcgggtgggc	gtcagagcggg	5280
tggaggggtcc	ggtccttcca	gggcccggagg	gcccgcgtga	gggtggtctc	ggtgacgggtg	5340
aagggggcgg	tctggggctg	ctcgggtggc	agggctctct	tgaggctgag	gcggctgggtg	5400
ctgaaggtgg	cgcttccgag	ctgcgcgtcg	ttcaggtagc	actggcggag	gaggtcatag	5460
gagaggtggt	gggtggcatg	gcccctggcg	cggagcttgc	cggggcccg	gtgcccgcaa	5520
gcatcgcaaa	cgggtgcgcg	cagggcgtag	agcttggggg	cgagcaggac	cgtctcggag	5580
ctgtgggcgt	cgctgcggca	gcgctcgcac	tgggtctcgc	actcgaccag	ccaggtgagc	5640
tgggggttct	ggggatcgaa	gacgaggggg	ccccggtcc	gcttgaggcg	gtgtttacct	5700
ttggtctcca	tgagctcgcg	tccggcgcgg	gtgaggaaga	ggctgtcgg	gtcccgtag	5760
acggagcgca	ggggccggtc	ggcgatgggg	gtcccgcggt	cgtcggcgta	gaggtgagg	5820
gcccactcgg	agatgaaggc	acgcgcccag	gcgaggacga	agctggcgac	ctgcgagggg	5880
tagcggctgt	tgggactaa	tggcgaggcc	tgctcgagcg	tgtggagaca	gaggtcctcg	5940
tcgtccgcgt	ccaggaagtg	gattggctgc	cagtggtagt	ccacgtgacc	ggcttgccgg	6000
tcggggggta	taaaaggcgc	gggcccgggt	gcgtggccgt	cagttgcttc	gcaggcctcg	6060
tcaccggagt	ccgcgtctcc	ggcgtctcgc	gctgcggctg	catctgtggt	cccggagtct	6120
tcaggtgggt	acgctacgac	aaagtccggg	gtgacctcag	cgctgaggtt	gtctgtttct	6180
atgaaggcgg	aggagcggac	ggagaggtcg	ccgcgggcga	tggcttcggt	ggtgcggggc	6240
tccatctggc	tggcgaagac	caccttctta	ttgtcgaggc	gtgtggcgaa	actgccgtag	6300
agggcggttg	agagaagctt	ggcgatgctg	cggagcggtt	ggtttctgtc	ccggctggcc	6360
ttttccttgg	cagcgatggt	gagctgcacg	tagtctcggg	cgaggcagcg	ccactcgggg	6420
aagatgctgt	tgcgctcgtc	cggcaggagg	cgacaggccc	agccacgggt	gtggaggggtg	6480
accacgtcca	cggaggtggc	tacctcgcg	cggaggggct	cgttgggtcca	gcagagggcg	6540
ccgcccttgc	gggagcagta	ggggggcagg	acgtccagct	ggctcctcgtc	gggggggtcg	6600
gcgtcgatgg	tgaagaggc	gggcaggagg	tcggggctga	agtagctgag	gggctcgggg	6660
ccgtcgaggc	ggctcctcca	gcggcggggc	gccagggcgc	ggctgaagg	ggtgaggggt	6720
tggccggcgg	ggaaggggtg	ggtgagggcg	ctggcataca	tgccgcagat	gtcatagacg	6780
tagaggggct	cccgcaggag	gcccgatgaag	ttggggtagc	agcggccgcc	gcgcaggctc	6840
ttcgcggacg	tagtcataca	gctcgtggga	gggcgcgagg	aggttcggcc	gaggtgcggc	6900
gcctggggcc	ggctggcgcg	gtagaggagc	tgcttgaaga	tggcgtggga	ggtggagctg	6960
atggtggggc	tctggaagac	attgaaggcg	gcgtggggaa	ggccggcctg	cgtgtggacg	7020
aaggcgcgg	aggactcttg	cagcttgcgg	accagacggg	cggtagcagc	gacgtcctgg	7080
gcgcagtagc	gcaggggtggc	ctggacgatg	tcgtaagcgt	ccccctggct	ctccttcttc	7140
cacaggtcct	tgttgaggag	gtactcctga	tcgctgtccc	agtacttggc	gtgtgggaag	7200
ccgtcctgat	cgcgtaagta	gtccccctg	cggtagaact	cgttcacggc	atcgtagggg	7260
cagtgtccct	tgtccacggc	cagctcgtag	gccgcggcgg	ccttgcggag	gctgggtgtgc	7320

-continued

---

gtgagggcga	aggtgtcccg	gacccatgaac	ttgacgtact	ggtgctgggg	gtcctcgggg	7380
gcatgacgc	cctcctcca	gtccgcgtag	tcgcgccgcg	ggcggaaggc	ggggttgggc	7440
aggttgaagc	tgatgtcatt	gaagaggatg	cggccgttgc	gcggcatgaa	ggtgcgggtg	7500
accaggaagg	aggggggcac	ctcgcggcgg	tggcgagca	cctgcgcggc	caggacgatc	7560
tcatcgaagc	ccgagatggt	gtggcccacg	atgtagacct	ccaggaagag	ggcgggcccg	7620
cgcagggcgc	ggcgccgcag	ctgggcatag	gccagggggt	cctcggggtc	gtccggcagg	7680
ccggggcccc	gctcctgccc	cagctcggcg	aggtctgggt	tgtgggcccag	caggtgctgc	7740
cagaggggtg	cggtgaggcg	ggcctgcagg	gcgtgccgca	gggccttgaa	ggcgcgcccg	7800
atggcgcgct	tctgcgggca	gagcatgtag	aaggtgtggg	ctcgggtctc	cagcgctgca	7860
ggcgggctct	ggacggccac	cacctgcagc	gcggcgcca	gcagctctc	gtccccgag	7920
aggtggaaga	ccagcaggaa	gggcacgagc	tgctttccga	agcgccctg	ccaggtgtag	7980
gtctccaggt	cataggtgag	gaagaggcgg	cgggtgccct	cgggggagcc	gatggggcgg	8040
aaggcgatgg	tctgccacca	gtcggccgtc	tggcgctgaa	cgtggtggaa	gtagaagtcc	8100
cggcgccgca	cggagcaggt	gtgggcggtc	tggaagatgc	ggcgcagtg	ctcgacttc	8160
tggcctcct	ggatgctctt	gatgaggtgg	cagcgccct	gggtgaagag	caggcggagg	8220
gggaagggga	ggcgggcgg	cgggcccctc	ggcggggggt	cccagcgcac	gtggtgcagg	8280
tgggtgtgct	ggcggtgac	cacctggacg	aaggtgggcc	cgcgggcgcg	ggccagctcc	8340
accgcggtct	ggggggtagc	ctgcaggagg	tcggggggcg	ggcgcaggag	gtgcagctgg	8400
aagaggttg	ccagggcgct	gtcccagtg	cgggtgtagg	tgatgctcca	gctctcccc	8460
tctgggtgg	tgccctggag	gcggaggggtg	gcgcggcgct	cgagcaggag	cccccgctg	8520
ccggcctccg	cggcctcggc	ggcgggcgcc	ggtctcaggc	gggcagctgg	gccaggggca	8580
cggcgcgctt	gagctcgggc	agcgggaggt	ggtcgcggcg	cagacgcgag	gcgtgggcca	8640
tgacgcggcg	gttgatgttc	tggatctgcg	ggttcccgga	gaagaccacg	ggccccgtga	8700
ctcggaaacct	gaaagagagt	tccacggaat	caatgtcggc	atcgtgggtg	gccacctggc	8760
gcaggatctc	ggacacgtcc	ccgctgtttt	cgcggtaggc	gatgtcctgc	atgaactgct	8820
cgagctcgtc	ctcgtccagg	tccccgtggc	cggcgcgctc	cacggtggcg	gccaggtcga	8880
cggatgatgcg	gttcatgatg	gccaccaggg	cgttctctcc	gttctcgttc	cacacgcgac	8940
tgtagaccag	ctggccgctc	gcgtcccgcg	cgcgcatgac	tacctgggcc	aggttgagcg	9000
ccaccaggcg	gttgaagggc	gcctgcaggc	gcagggcggtg	gtgcaggtag	ttgaggggtg	9060
tggcgatgtg	ctcgcagagg	aagaagttaa	tgaccacagc	gcgcagggtc	agctcgttga	9120
tgtcggcccag	gtcctcaggg	cgtgcatga	cccggtagaa	ctcggggggcg	aagcgaaaa	9180
actcgtgctg	gcgggccgag	accgtgagct	cctcttccag	ggcgggcgatg	gcctcggcca	9240
ccgctgccg	cacctctcc	tctaaggagg	gcggggcgct	gctgggtccg	gccaccgccg	9300
cctctctctc	ctctctccc	tccaggggtg	gcctctctc	gtctctctct	tctgctgctg	9360
ctgcctccgc	ggggacgggg	ggcgcaggcc	ggggacggcg	ccggcgcaag	ggcagccggt	9420
ccacgaagcg	ctcgatgacc	tgcggccgca	tgcgccgcat	ggtctcgggtg	acggcgcggc	9480
cgccctcccg	ggggccgagc	tgaaggcgc	ccccgcgag	cgcggtgccg	ctgcagaggg	9540
gcaggctgag	cgcactgatg	atgcagcgtg	tcaactctct	cgtaggtacc	tctgctgctt	9600
gcagcgcttc	ggcaaacctc	cgcacctgct	cttcggacc	ggcgaagcgt	tcgacgaagg	9660

- continued

---

cgcttagcca	gcaacagtcg	caaggtaagt	tgagcgcggt	gtgctgcggg	agccggaggt	9720
gccggctgac	gaggaagtga	aagtaggccg	tcttgagctg	ccggatggcg	cgcaggaggg	9780
tgaggtcttt	gcgcccgcg	cgctgcaggc	ggatgcggtc	ggccatgccc	caggcctcct	9840
gctggcagcg	gccgatgtcc	ttgagctgct	cctgcagcag	atgtgccacg	ggcacgtccc	9900
ggtcggcgtc	caggtgggtg	cgaccgtagc	cccgcagggg	gcgagcagc	gccaggtcgg	9960
ccaccacgcg	ctcggccagg	atggcctgct	gcatgcgctg	cagggagtct	gagaagtcat	10020
ccaggtccag	gaaccggtgg	taggcgcccg	tgttgatggt	gtaggagcag	ttgcccagca	10080
cggaccagtt	gaccacctgg	tagtggggct	ggatgacctc	ggtgtagcgc	agtcgactgt	10140
aggcgcgctg	gtcaaagatg	taatcgttgc	agaggcgcag	caggtgctgg	tagcccacga	10200
gcaggtgggg	cggagggtag	aggtagaggg	gccagtgttc	cgtggccggt	tggcgggggg	10260
agaggttcat	gagcatgagg	cggtggtagc	ggtagatgaa	gcgggacatc	caggcgatgc	10320
cgacggcgga	gacggaggcg	cggtccact	ggtggcgcg	gttccaaatg	ttgcgcaccg	10380
ggcgaagag	ctccacggtg	taaattgatt	gccccgtgag	gcgggcgag	tcgagggcgc	10440
tctgtcaaaa	agaaccgggt	gtggttggtt	ggtgtgtggt	agcgatctat	ctttctttgt	10500
gatcttggtg	gtgaagcctg	ccaggctcca	gcagggggcg	tccgcctct	ttccttctt	10560
ccctatctgg	aggtgtgtct	ctgttctctt	ttttatttca	tgtagccatg	catcccgttc	10620
tgcggcagat	gaagccgccc	gccggcgccc	tgggcgcgga	ggggcgagc	cgctctcgg	10680
cgcctcggc	gtcgtgacg	cggccgcgcg	aggaggggga	ggcctggcg	cggctgtcgg	10740
gcgcgcggc	ccccgagcgg	caccacggg	tgacgtcaa	gagagaggcc	atggaggcct	10800
atgtgccgag	gcagaatgcg	ttccgcgagc	gaccggggga	ggagggggag	gagatgaggg	10860
acctgcgggt	ccgcgcgggg	cgggagatgc	agctggaccg	ggagcgagtg	ctccagcccc	10920
aggactttga	ggggcgctg	gaggagggcg	gggagtgag	cgcggcgcg	gcccacatga	10980
gcgcgccag	cctggcccag	gcctacgagc	agacggtacg	cgaggaggtc	aacttccaaa	11040
agaccttcaa	caacaacgtg	cgcaccctgg	tgagccggga	cgaggtgacc	atgggactga	11100
tgacactgtg	ggactttgtg	gaggccttcc	tgacgacccc	ccggtcccgc	gcgctgaccg	11160
cgcagctgct	gctgatcgcg	cagcactgcc	gggacgaggg	catggtgaag	gaggcgctgc	11220
tgaccctggg	cgcgcccag	agccgctggc	tggtagacct	ggtgaacctg	ctccagacca	11280
ttgtggtgca	ggagcgggtc	atgagcctga	gcgagaaggt	ggcgccatc	aactactcgg	11340
tggcgaccct	ggccaagcac	tacgcgcgca	agatctccac	cttctacatg	cgcgcggtgg	11400
tgaagctgct	ggtgctggcc	gacaacctgg	gcatgtaccg	caacaagcgg	ctggagcgcg	11460
tggtcagcac	ctcgcggcgg	cgcgagctca	atgacaagga	agctcatggt	tggcctccgc	11520
cggcgctgg	ccggggaggg	cgaggaggac	ctggaggagg	aggaggacct	ggaggaggcg	11580
gaggaggagg	agctggaaa	aggaggagtt	cggccccggg	ggaccgcggc	gcgtgaggtg	11640
gcagtccccg	ctgactgcga	gcgatgaggg	tgatgtgtac	tgatggcaac	catccccctt	11700
tttaacaaca	acagcagcat	ggcgggcagc	tctgaagctg	ggcgggcggc	ggcggggggtg	11760
agcgcggcct	ccctggcgcc	cgagcggggc	acgcggatgc	aggcgctgcc	ctccctggac	11820
gagccttggg	agcaggtctt	gcggcgcatc	atggcgctga	cggccgacgg	gtctcggcgc	11880
ttcgcgagcc	agcccctggc	caaccgcatc	ggggccatcc	tggaggcggg	ggtgcctccg	11940
cgcacgaacc	cgacgcacga	gaaggtgctg	accgtggtga	acgcgctgct	ggagacctcg	12000
gcatccggcc	cggacgaggc	cggcatggtg	tacgatgcgc	tgctggagcg	ggtctcccgc	12060

- continued

---

tacaacagcg	gcaacgtgca	gaccaacctg	gaccggctgt	cccaggacgt	gcggcaggtg	12120
atcgcccagc	gcgagcgctc	gagcgccaac	aacctgggca	gcctggccgc	gctgaatgcc	12180
ttcatcgctt	cgctgcccgc	aacggtggag	cggggccagg	agagctacct	ggggttcctc	12240
agcgcgctgc	ggctgctggt	gagcgaggtg	ccgcagacgg	aggtgttccg	ctcggggccg	12300
cacaccttcc	tgcaggcggc	gcggaacggt	tccaagacgg	tgaacctcaa	ccaggccatg	12360
gagaacctgc	ggccccctgtg	ggggctgcag	gcccccgctg	gggagcgcgg	gcacgtgtcc	12420
tccttctgta	cgcccaacac	ccggctgctg	ctgctcctgg	tggctccctt	cgcgaggag	12480
atgaacgtca	gccggagctc	ctacattggg	cacctgctga	cactctaccg	cgagacgctg	12540
gccaacttgc	atgtggacga	gcgcacgtac	caggagatca	ccagcgtcag	ccgggcggtg	12600
ggcgacgagg	acgacgcggc	gcggctgcag	gccaccctca	acttcttctc	gaccaaccgg	12660
cagcggcggc	tgccggcggc	gtatgccctg	accgccgagg	aggagcgcac	cctgcgctac	12720
gtgcagcagg	ccgtgagcct	gtacctgatg	caggacgggg	cgacggccac	gggcgccttg	12780
gacgaggcca	gccgcaacct	ggagcccagc	ttctacgcgg	cgaccggga	cttcatcaac	12840
cgcttctgta	actacttcca	tgcgcgggcc	gcggtggcgc	ccaactactt	tatgaatgcc	12900
gtcctgaacc	cccgtggtct	gccctcggag	ggcttcttca	ccggcgtgta	tgacttcccg	12960
gagcaggacg	agggggagga	gcggccctgg	gacgcctttg	acagcgacga	ggagggccgc	13020
ctcatgctgc	ggtccgcagc	ctctcagag	ccctcctcct	ccttcacccc	cctgcccctg	13080
accgaggagc	cgccctcgcg	gccctccacc	ccggccctct	cgcgctccc	gtcccgggca	13140
tcctccctgc	tctctctggc	ctctctggga	aagcgggagg	gaggggactc	gctcgcctac	13200
tgcgggcca	cgccaccta	tggctctcgc	tgggctcgc	gccgctccag	cctggccagc	13260
ggcgccgaca	gcctggagtg	ggacgcgctg	ctggccctc	ccaaggatgt	gaacgagcac	13320
ccaggcgcgc	ccgcccggcg	ccgcgcgcgc	gcctcccgt	cctccctgga	ggaggacatc	13380
gacgccatca	gcagccggt	gttcacctgg	cgacgcgcgc	cccaggagat	gggcctgccc	13440
gtggccagct	tctcccgcgc	ccaccagccg	cgcccgggg	ccctcgaaga	cgacgaggag	13500
gaggaagact	ggcgccagga	ccggttcttt	cgcttcgaag	cgcccagga	aaacccttc	13560
cgccacatcg	cccccaagg	gctgtaatgc	aaaaaagcaa	aataaaaaac	ccctcccgg	13620
ccaactcacc	acggccatgg	ttgtccttgt	gtgcccgtca	gatgaggagg	atgatgccag	13680
cagcgcgcgc	gcagggagcg	tgcctccgc	cgctctacga	gagtgtggtg	gggtcttcgc	13740
tcacggagcc	tctttatgtg	ccgcccgggt	acctgggccc	caccgagggg	cggaacagca	13800
tccgttattc	acagctcccg	ccgctctacg	ataccacaaa	gatctatctg	atcgataaca	13860
agtccggcga	tatcgccagt	ctgaactacc	aaaacaacca	cagtgacttt	ctcaccagcg	13920
tggtgagaaa	cagcgacttc	acgcccattg	aggcgagcac	gcagaccatc	aacctggatg	13980
agcgctcgcg	ctggggcggg	gagtttaaga	gcattctgac	caccaacatc	cccacgtga	14040
cccagtacat	gttcagcaac	agcttccggg	tgcgcctgat	gagcgcgcgc	gataaagaga	14100
caaatgcccc	cacctacgag	tggttcacc	tgacctgcc	cgagggcaac	ttctcggaca	14160
tgcgggtcat	cgacctgatg	aacaacgcga	tcgtggagaa	ctacctggcg	gtggggcggc	14220
agcagggggg	caaggaggag	gacatcgggg	tgaagatcga	cacgcgcaac	ttccgcctgg	14280
gctatgacct	ggagaccaag	ctggctcatg	ccggcagcta	caccaacatg	gcctttcacc	14340
ccgacgtggt	gctggcaccg	ggctgcgcca	tcgacttcac	cttctcccgc	ctaaacaacc	14400

- continued

---

tgctgggcat	ccgcaagcgc	taccctacc	aggaggctt	catgctgacc	tacgaggacc	14460
tggcgggggg	caacatcccc	gcgctgctgg	acctcaccac	ctatgatcag	gagaactcca	14520
gcaccatcaa	gcccctgaag	caggacagca	agggtcgcag	ctaccacgtg	ggcgaggacc	14580
ccgaggcggg	ggacaccttc	acctactacc	gcagctggta	cctggcctac	aactacgggg	14640
acccggccac	gggcaccgcc	tcccagacgc	tgctggtctc	cccggacgta	acctgcggag	14700
tggagcaggt	ctactggagc	ctgccggacc	tgatgcagga	cccggtgacc	ttccggccca	14760
gccagacgcc	gagcaactac	ccggtggtag	ccacggagct	actgccgctg	cgctcccggg	14820
ccttctacaa	caccagggc	gtgtactccc	agctcctgca	gcaggccacc	aacaacaccc	14880
tggtctttaa	ccgcttccc	gagaaccaga	tcctcctgcg	cccgccagag	tccaccatca	14940
cctccatcag	cgagaacgtg	ccctcgctga	cggaccacgg	cacgctgccg	ctgcgtaaca	15000
gcatccccgg	ggtgcagcgg	gtaaccgtca	ccgacgcgcg	gcgccgcgtg	tgtccctatg	15060
tgtacaagag	tctcggggtg	gtgaccccga	gggtgctcag	cagccgaacc	ttctaaccga	15120
cagccctacc	cgtcacaggg	gagacagaga	aaagacagcc	agccccgcca	tggccatcct	15180
cgtctcgccc	agcaacaact	ttggctgggg	actgggcctg	cgctccatgt	acggggggcg	15240
ccgcccctg	tccccgcatc	accccgtgat	cgtccgacgc	cactaccggg	ccaactgggc	15300
cagtctgaag	ggacgcgtgg	ccccagcac	catagcgaca	acggatgacc	ctgtggccga	15360
cgtggtcaac	gcgatcgccg	gcgccacccg	ccgccggcgc	cgccatcgtc	gacgtcggag	15420
ggccgcgcgc	gtctcctccg	tggccgtcac	cggggacccg	gtggccgatg	tggtcaacgc	15480
ggtggaggcg	gtagcccggc	gccgcgcgcg	gcggcgcctg	tcttcgcgca	tgcagaccac	15540
gggggacccc	gtggcggatg	tggtggcggc	ggtggaagcg	gtggcgcgcc	ggaggcggag	15600
cacccgccgg	cggcgcaggc	gctccgcgcc	ggccatcctg	ggggtgcgcc	gcagccgccg	15660
cctccgcaaa	cgcacctcgt	cctgagattt	ttgtgttttg	ttttttctgc	ctcccgtggg	15720
tgaacaagtc	catccatcca	tccaacatcc	gtggctgctg	tgtctttgtc	ttttctttgc	15780
gttgccccc	agttgagccg	gcaccgacgc	gctcggccat	ggccatctcg	cgccgcgtga	15840
aaaaggagct	gctgcaggcg	ttggcgcccc	aggtgtacgg	ggcgcctaag	aaggaggaga	15900
aggacgtcaa	agaggagtcc	aaagctgacc	ttaaaccgct	gaagaagcgg	cgcaaggcca	15960
agcggggggt	gagcgacagc	gacgaggtgc	tggtgctggg	cacgcgcccc	aggcgcctct	16020
ggacggggcg	gcgcgtgcgc	gcccacctac	cgcccgggtg	cagcctcgcc	tacgtcccgg	16080
gtcttcggag	gtcgagcgcc	accaagcgct	ctgcggacga	gttgtatgcg	gacacggaca	16140
tcttcagca	ggcgtcccag	cgctgaacg	aatttgctta	tggcaagaga	gcccggcggc	16200
agcggcgggc	ccgcccctcg	ccgacccccg	cgtcccgcgg	ccggaccacc	aagcgtctct	16260
atgacgaggt	cgtggcagac	agtgacatcc	tgcagcaact	tggatccggg	gaccgctcca	16320
atgagttctc	ctatggcaag	cggtcgctgc	tgggggagtc	aggagacacc	gtcccggctg	16380
tggcgtccc	gctggaggaa	ggcaggaacc	acacaccacg	cctgcagccg	ctcaccgagc	16440
ccatgcccct	ggtgtcccct	cgcacggccg	tcaagcgccg	ggcgcccgcc	gacgagccca	16500
ccgcctcact	ggtccccacc	gtgcaggtcc	tggcccccaa	gcgtcgtctg	caggaggtgg	16560
tggtggagcc	gcccgcctca	gcacccacgc	cgcccctagc	cccgcggcgg	tccagccggc	16620
gcatcattct	ggctccgcgc	cgggcggggc	ggccccaggc	cgctcgtggc	ccgcagctca	16680
gcgcggccgc	ggcgtggag	cgggcggggg	ccgcctgccc	cctgccaccg	gacacggagg	16740
acgacctggt	ggagatggca	gaggctgtcg	ccgcgcccga	ggtgctgccc	agcctccccg	16800

-continued

---

tctccatcat	gccgcccacc	gccacggagg	tggccctgcc	cgtacagacc	ccactgccgc	16860
ccgtggcggg	ggccaagagc	tccctgaccc	ccggcctccg	cgcgctgatg	ggcaccgagc	16920
gggtgccggg	tccagtccctg	gaggcgcccc	tgggtggccat	gcccgtgctc	cgggcccacca	16980
ccgcccgtgc	cgagcccccg	cgcccgctgc	cccgcagggc	cgtgcgggac	atcccggcca	17040
ggcagccccg	cacggtatcc	ctgcccgtgc	tcacggagcc	cggcccggcc	accgcggtcg	17100
cctccgtgcg	cgcggcagcc	caagtccctgc	aggcgcccc	cgcccgaccg	gccaccgtct	17160
ccgtgggggt	gggcaccgag	ccggtgggtgc	agtccatcac	ggtcaagcgg	tcaaagcgcc	17220
tgaccaagca	ccatcggggg	gcagaccatc	gacgtcaccg	tgcccaccgt	ccgcaactgtc	17280
agcgtgggca	ccaacacgcc	ccggctgagg	agcgcctcgg	tgggcgtcca	gaccgctccc	17340
gagaccgct	cccagggggg	gcaggtggct	ttccaaccag	cgtgctagcc	caccgcacac	17400
ccaggcaggt	gcggtgacg	gcggtgggtgc	ccccacccc	gcgcgccccg	gtggttccgg	17460
tggcccggcg	cccggggcgg	ttccgggtgc	tccccagcc	cctccagccc	cgcgcgcgcc	17520
gcgtgcgct	cgcgccccca	gagcgcctcg	gcgtcgcgc	cgtaccccgg	tggcgggtggc	17580
agcgcgccc	gcccgcagcg	gcggtccccc	gccctcggt	gcccaggcgg	cccacgtgc	17640
tgcccggggg	gcgctatcat	cccagtcagg	ccatggctcc	caccgcccga	cgcgtcatct	17700
ggcgttgatt	tatTTTTgga	gacctgactg	tgttgtgttc	cttaaatttt	ttatcctcct	17760
cctcctctgc	tgaagccaga	cgatgctgac	ctaccggttg	cggctgcccg	tgcggatgcg	17820
gagaccgaga	ctccgcggtg	ggttccgcgt	ggcgcctcgg	cgcagcggcg	gcaggcggcg	17880
gtaccgcccg	gggcccgatga	ggggtggcat	cctgcggcg	ctggtgcccga	tcatcgcggc	17940
atccatctgg	gccatccccg	gcacgcctc	ggtggcgatg	agtgctagac	aacgcaatta	18000
acggcgtgc	tgtgtatgtg	tgtcttccat	gtgccttcc	tccttcgttc	ccaacggaac	18060
agcagcaccg	tctccatgga	ggacctaagc	ttttccgcgt	tggctccacg	ctttggcacg	18120
cggccggtca	tgggcacttg	gagcgaaatc	ggcacgagtc	agatgaacgg	cggcgcgctc	18180
agctggagca	atatctggag	cgggctgaag	agctttggta	gttctctggc	ctccacggcc	18240
aacaaggcct	ggaacagcgg	gacggtgacg	agcgtgcgca	acaagttgaa	ggatgccgac	18300
gtgcagggga	agataggtga	ggtcattgcc	tccggggctc	acggtgccct	ggacgtggcc	18360
aaccaggccg	tctcccacgc	cgtggaccgc	cggtgcaaca	gcagcagctg	cggcagcagc	18420
agctcctccg	ccagcagcag	caacagatgg	gcctcgtgga	accctcctat	gagatggaga	18480
cagacgagct	gcctcctccc	cccaggacc	tcttgccctc	tcctcctcct	cgcgcgctg	18540
cctcggccac	tcccgcgcgc	caatcccgcg	ggacgtcccg	ccaagcggcc	gcccgcggcc	18600
aggagatcat	catccgctcc	gacgagcccc	ctccctatga	agagctgtat	cccgacaagg	18660
ccgggatccc	cgccaccttg	gagctgcgtc	ccgagaccaa	actgcccggc	gtggcccaca	18720
ataagatgcg	ccccccgccc	ccgctcacca	ccaccacctc	ctccgctgcc	gcccgcggcc	18780
ccgcccggc	ccccgcggct	cctgtgcgtc	ggcgtccggc	cgcggctccg	gcccgcggctc	18840
cggcgagttc	caaaggcccc	ccaggtgggg	gtccgcgcgc	gcgggtggca	aaacaaactc	18900
aacaccattg	tgggactggg	tgtccgcaca	tgcaagcgcc	gtcgttggtta	ctgagagaga	18960
cagcatggag	aaacaacaat	gtctggattc	aaataaagac	acgcctattc	ttccacgggtg	19020
ctccgcgctg	tgttatTTTc	aacgggctgt	ttccttttgc	atctctgtgc	catcgcgcca	19080
cggggaattc	cgcaggatgg	cgacgcgctc	gatgatgccg	cagtggctcct	atatgcacat	19140

- continued

---

ctccgggcag gacgcgtccg agtacctgtc tcccgggctg gtgcagttct cccaggcgac 19200  
ggagacctac tttaacctga acaacaagtt taggaacccc accgtcgcgc ccacccacga 19260  
tgtgacgacg gagcgtcgc agcggctgca gctgcgcttc gtccccgtgg acaaggagga 19320  
cactcagtac acatacaaga cccgcttcca gctggcggtg ggcgacaacc gcgtggtgga 19380  
catggcgagc accttctttg acatccgggg aacgctggac cggggaccct ccttcaaacc 19440  
gtactcgggc accgcgtaca acatcatggc tcccaagagc gctcccaaca actgtcaata 19500  
tctagacctt aaagtgaaa ctgaggctgg caaagttaat accattgctc aagcaagttt 19560  
tgtgggtcct attgatgaaa ccacgggaga cattaataat acagaagaag aagacgaaga 19620  
gaccaccatc gatcctttgt atgagcccca accccagctt ggtccaagct cgtggtcaga 19680  
caatatacct tctgcgacta gcgagctgg aagagtctc aaacagacca caccgcgtca 19740  
acctgttac ggttcttatg cctctccgac aatattcac ggtgggcaa cgaaggatga 19800  
caaggttaca ccattgtact ttacaaaca tcccgccacc gaagccgaag cactcgaaga 19860  
aatggatta aagccaaatg tcaccctata ctgagaggat gttgacctaa aagcaccaga 19920  
tactcatctg gtctatgctg tgaatcaaac ccaggaattc gctcaatatg gacttggaca 19980  
acaggccgct ccaaacaggg ccaattacat cggcttcagg gacaacttta tcgggctgtt 20040  
gtactacaac agcaatggca accagggcct gctagccggc caggcctctc agctcaacgc 20100  
ggtggtcgac ctgcaggaca ggaatcaccg aactagctac cagctcttcc tcgatagcct 20160  
ctatgacagg tcgaggtact ttagcctgtg gaaccaggcc atcgattctt atgacaagga 20220  
tgtgcgtgtg ctggaaaaca atggcgtgga ggacgagatg cccaactttt gctttcccat 20280  
cggcgcctac gagaccaaca tgacatttac acagctcaaa aagagtgaga atggtggctc 20340  
aagagccaca acctggacaa aggagaatgg ggatgatggc ggaaacggag cggagcacta 20400  
cctgggcctc ggcaacctca acgccatgga gatcaatctc acggccaacc tctggcgcag 20460  
cttctctac agcaacgtgg cgctgtacct gcctgacaag tacaagtttt ccccgcccaa 20520  
cgtccccatc gaccccaaca cgcactccta tgactacatc aacaagcgc tgcccctcaa 20580  
caacctcatt gataccttg tcaacatcgg ggccgctgg tcccggatg tcatggacaa 20640  
cgtcaacccc ttcaaccacc accgcaacta cggcctgcgc taccgctccc agctcctggg 20700  
caacggccgc tactgcaagt tccacatcca ggtgccgcaa aagttctttg ccctcaagag 20760  
cctgctgctc ctgcggggg cgacctacac ctacgagtg tcttccgca aggacgtcaa 20820  
catgatcctc cagtcacgc tgggcaacga cctccgcgcg gacggggcca aatcaacat 20880  
cgagagcgtc aaactctacg ccagcttctt tcccatggcc cacaacaccg cctccaccct 20940  
ggaggccatg ctgcgcaacg acaccaaaa ccaaactttt attgacttcc tctcctcgc 21000  
caacatgctc taccatcc cgccaacgt caccaacctg cccatctcca ttcccagccg 21060  
caactgggccc gccttccgcg gctggagctt cacgcgctg aagcacaacg agacccccgc 21120  
cctgggctcg cccttcgacc cctactttac ctactcgggc tccatccctt acctggacgg 21180  
gacctctac ctgggccaca ccttccgccc catcagcatc cagttcgact cctccgtggc 21240  
ctggccgggc aatgaccgcc tgctcactcc caacgagttc gaggtcaagc gcaccgtgga 21300  
cggggagggc tacacgggtg cccagaccaa catgacaaa gactggttcc tgggagat 21360  
gctcggccac tacaacatcg gctaccagg ataccacctg ccagagggtt accgcgaccg 21420  
cacctactcc ttctgcgca actttgagcc catgtgcgc caggtgccc actacgcaa 21480  
ccacaaagat gactacctg aggtgcccac caccaaccag ttcaacagca gggctttgt 21540



- continued

---

atccgcggcc ttcaccgccc gcatgcgcga ggggcaccca taccccgcca actggcccta 21600  
cccgtcatc ggcaagacg ccgtgcagac cgtgaccag cgcaagttcc tctgcgaccg 21660  
cacgctctgg cgcaccccct tctcctccaa cttcatgtcc atgggcaccc tcaccgacct 21720  
gggcagAAC ctctctacg ccaactcggc ccacgcctc gacatgacct tcgaggtcga 21780  
cgccatggat gaaccacccc tcttgatgt tctgttcgag gtctttgacg tctgcggcgt 21840  
gcaccagccg caccgaggcg tcacgaggc cgtctacctg cgcacgcctc tctccgcccg 21900  
gaacgccacc acctaaggcg gagccgcgca ggcatgggca gcaccgagga cgagctccga 21960  
gcatggcgc gcgacctcca gctgccccgc ttctgggca cctttgaaa gtcttccccg 22020  
ggcttcttgc aagagtccca gcgctgctgc gccatcgta acacggccgc ccgccacacc 22080  
ggaggcggcc actggctggc cgtgcctgg gagccgcct cgcgcacct ctacttcttt 22140  
gacccttcg gcttctccga ccgggagctc gccaggctc atgactttga gtaccagcgc 22200  
ctgctgcgca agagcgccat ccagagcacc ccggaccgct gcctcacgct cgtcaagagc 22260  
accagagcg tgcagggacc gcacagcgc gccctgcggac tcttctgcct cctcttctc 22320  
gccgcctttg ccgctacc cgcacagccc atggcctaca atcccgcat ggacctggtg 22380  
gagggcgtgg acaacgagcg gctcttcgac gccgacgtc agcccatctt ccgcgccaac 22440  
caggaggcct gctacgcgtt cctcgtcgc cactccgct acttccgcg ccaccgccac 22500  
gcatcatgg aacagacaca cctgcacaaa gcgctcgata tgcaataaag gctttttatt 22560  
gtaagtcaaa aaggcctctt ttatcctccg tcgctgggg gtgtatgtag atggggggac 22620  
taggtgaacc cggaccgccc gtgggctccc ctccatcccc tcttctctca aaacaggctc 22680  
tcacgctcgt cctccgttcc cacggggaag atggtgttct gcacctgga ctggggcccc 22740  
cacttgaact cgggcaccgt cagtggaggc cgcgtctgca tcaggcgggc ccacatctgt 22800  
ttggtcagct gcagggccag catcacatcg gggcgctga tcttgaatc acaattcttc 22860  
tgggggttgc cgcgcgacc gcggtacacc gggttgtagc actggaacac cagcaccgcg 22920  
gggtgggtca cgtggccag aatcttgggg tcttccacca gctgggggt cagcgcgccc 22980  
gaccgctca gcgcgaagg ggtgatctt caggctctgc ggcccagcag gggcacctgg 23040  
cggcagcccc agccgcagtc gcacaccagc ggcatcagca ggtgcgtctc cgcgttgcct 23100  
atccgggggt agcaggcctt ctggaaagcc ttgagctgct cgaaggcctg ctgcgccttg 23160  
gagccctccg agtagaagag gccgcaggac cgcgcccaga aggtgttggg ggccgacccc 23220  
acgtcgtggc tgcaacacat ggccccgctc ttgcgcagct gcaccagct gcggccccag 23280  
cggttggtgg tgatcttggc gcgctcgggg gtctcgcgca gggcgcgctg cccgttctcg 23340  
ctgttgagat ccactctccac cagctgctcc ttgttgatca tgggcagccc gtgcaggcag 23400  
tgcagcccc cgcagccgct gcggtgctgc cagatcacgc accgcaggg gttccactcg 23460  
ggcgtcttca gaccgcccgc cttcaccaca aagtccagca ggaagcgggc catcactgtc 23520  
agcaggctct tttgcgtgct gaaggtcagc tggcagctga tcttgcgctc gttcagccag 23580  
gcttgggccc cgcgcccgaa gcaactccagg gtgctgcctg ccggcagcag cgtcaggccc 23640  
ttgacatcca cctcagggg gaccagcatc tgcacagcca gatccatggc ccgctgccac 23700  
ttctgctcct gagcatccag ctgcagcagc ggccgggcca ccgcccggct cggggtcacc 23760  
gggcgcgggg ggccggcccc ctctcttcc tccccatctt cgccttctc cctcgcgggc 23820  
cgcgcgctc ccgctgccgt ctcttcagcc tcgtcctcct cctcctcgt gaccaggggc 23880

- continued

---

ttggcacgcg	cgcgcttccg	ccgctcctgc	acgggcbgag	aggccgcgcg	cttgccgctt	23940
cccccgccg	ggctgggggt	cgcgacagga	gcgtcgtcca	caatcagcac	ccctcttcc	24000
ccgctgtcat	agtcagacac	gtccgaatag	cggcgactca	ttttgcttcc	cctagatgga	24060
agaccagcac	agcgcagcca	gtgagctggg	gtcctccgcg	gccccgaccc	ttccgcccgc	24120
accaccgccc	ccacctccgc	ccacgtcacc	gccaccttca	ctgcagcagc	ggcagcagga	24180
gcccccgaa	accgatgacg	cggaggacac	ctgctcctcg	tcctcctcgt	cctccgcctc	24240
cagcgagtgc	ttcgtctcgc	cgctggaaga	cacgagctcc	gaggactcgg	cggacacggt	24300
gtccccctcc	gagccccgcc	gggacgagga	ggagcaggag	gaggactcgc	ccgaccgcta	24360
catggacgcg	gacgtgctgc	agcgcacact	gctgcgccag	agtaccatcc	tgcgccaggt	24420
cctgcaggag	gcccggcccg	gcgagccgcg	ggaggccgcc	gaggcgcctt	cgggtggcgga	24480
gctcagccgc	cgctggaag	cggccctctt	ctccccgccc	acgccgcccg	ggcgccagga	24540
gaacggaacc	tgcgcccccg	acccccgcct	caacttctac	ccggtcttca	tgctgcccga	24600
ggccctggcc	acctacctcc	tcttcttcca	caaccaaag	atccccgtca	gctgccgccc	24660
caaccgccc	cgagccgacg	cgcactggcg	gctgccaggt	gggacccctt	tacctgacta	24720
tccaaccacc	gacgaggttt	acaagatctt	tgagggcctg	ggggacgagg	agccggcctg	24780
cgccaaccag	gacctgaaag	agcgcgacag	cgtgttagtc	gagctcaagc	tggacaaccc	24840
ccgctggcg	gtggtcaagc	agtgcctcgc	cgtcaccac	ttcgctacc	cggccctggc	24900
gctgccaccc	aaggatcatg	gcacgctcat	gcagaccctg	ctggtgcgcc	gcgcgagccc	24960
actccccgac	gagggcgaga	cgccccctga	ggacctcctg	gtggtcagcg	acgagcagct	25020
ggcccgctgg	atgcacacct	cggaccccaa	ggtcctggag	gagcggcgca	agaccgtcac	25080
cgcgcctcgc	atggtcacgg	tgcagctcca	ctgcatgcac	accttctca	cctccccgca	25140
gatggtgcgc	cgctcggag	agtgcctcca	ctacatgttc	cgccagggct	acgtcaagct	25200
agctagcaag	atcgccaata	tggaactctc	taacctggtc	tcctacttgg	gcatgctgca	25260
cgaaaacagg	ctcggtcagc	acgtgctcca	ccacaccctc	aagcatgagg	cgagacgcga	25320
ctacgtccgg	gacaccattt	acctatacct	ggtctatacc	tggcagaccg	ccatgggggt	25380
ctggcagcag	tgcctcgagg	accgaaacct	gcgcgccctg	gaaacgtctc	tggctcgcgc	25440
tgcgagagc	ctgtggacgg	gctttgatga	gcgcactatc	gcgcaggacc	tgcgcccgtt	25500
ccttttcccc	accaagctcg	tagagaccct	gcagcgtcgc	ctccccgact	ttgccagcca	25560
gagcatgatg	catgccttcc	gctccttctg	cctcgagcgc	tccggcatcc	tgcccgcctg	25620
ctgcaacgcg	ctccccctg	actttgtgcc	caccgtctac	cgcgagtgcc	cgcgcccctt	25680
ctgggctcac	tgtacctcc	tgcgctcgc	caacttctc	atgtaccact	gcgacctcgc	25740
cgaggacacc	tccggcgagg	gcctctttga	gtgctactgc	cgctgcaacc	tctgcgcacc	25800
gcaccgctgc	ctcggccacca	acaccgccct	cctcaacgag	gtgcaagcca	tcaaacacctt	25860
tgagctccag	cggcccccca	agccccgacg	caccctgcca	ccgcccctca	agctgacccc	25920
cggctctctg	acctccgcct	tcctccgcca	ctttgtctcc	gaggactacc	actcggaccg	25980
catcctcttc	tacgaggacg	tgtcccgcgc	cccaggggtg	gagccctccg	cctgcgctcat	26040
cacgcactcg	gccattctcg	cgcaattgca	tgacatcaaa	aaggccaggg	aagagttttt	26100
gctgacaaa	ggccacggcg	tctacctaga	ccccacacc	ggagaggagc	tcaaacaccgc	26160
cgccccgtcc	accgcccacc	atgcgccccc	tccggaggaa	gcccatacgc	agcagcacca	26220
gcaccagcag	cagccgagcc	accgcccgcg	ccaccaccgc	tccagctacg	cagaccgtgt	26280

- continued

---

ccgaagcgag ctccacgcct acggcggtgc gaccggttcc tcccgegacc ctgtctctgg 26340  
 cggatgctct gccagaggaa cccactcccg cgatgctgct cgaagaagag gctctcagca 26400  
 gcgagaccag cggcagctcc gaaggcagtt tgctcagtac cctcgaggaa ctggaggagg 26460  
 aggaggaacc ggtcacaccg acgaggccat ccaagccctc ctacaccaac agcagcagca 26520  
 gcaagagcat cagccagcgc aggaactccg tcgtccccag cgaggctcgt agatggaatc 26580  
 agacatccat ccaccggagt agccagccag gtaggacacc tccgcctcgt gcccgccgac 26640  
 gtcctggcg ccgctaccgc caccacatcc tctcggcoct ggagtactgc gccggagacg 26700  
 gagcctgcgt gcgcccgtac ctactctacc accacaacat caacatccct tccaagatca 26760  
 tccgttacta caaatcctct tcccgttcca gcgatctcca ggaaggccgc agcagcggcg 26820  
 gcagcagaac cagcccacgt cagccagctg agagctaaga tcttccccac gctgtacgcc 26880  
 atcttccagc agagccgcgg cggccaggac gccctcaaaa tcaggaaccg caccctgcgc 26940  
 tccctcacca agagctgtct gtatcaccgc gaggaggcca agctggaacg cacgctctcg 27000  
 gacgcagaag ctctcttcga gaagtactgc gctcggcagc ggcagaccg ccggtattta 27060  
 aggagcggac cctgcgtgcg gacacacat gagcaaaaa atccccacc cgtacatgtg 27120  
 gtcttatcag ccacaatctg ggcgtgccgc cgggtgcctcc gtcgattact ccaccgcat 27180  
 gaattggctc agtgccgggc cttccatgat tggccaggtc aatgacatcc gacacaccag 27240  
 gaaccagatt ctcatcgcg aggcccttat caccgagacg ccacgccccg tccaaaatcc 27300  
 cccgtcctgg cccgccagcc tgttgccctca gatgacgcaa ccgcccacc acctgcacct 27360  
 gccgcgtaac gaaatthtgg aaggcagact gactgacgcc ggcagcaat tagccggggg 27420  
 cggagccctc gcaccagag acttatatgc cctgaccctc cgcggcagag gcatccagct 27480  
 caacgaggac ctaccctct cggcgagcac tctccggccg gacggcatct tccagctcgg 27540  
 aggcggaggc cgctcctct tcaacccccac cgacgcctac ctgacgctgc agaactccag 27600  
 ctcccttccc cgcagcggcg gcatcggcag cgagcaatth gtcgcgagt tcgtgcccac 27660  
 ggtctacatc aacccttct cgggaccgcc cgggacctac cccgaccagt tcatcgccaa 27720  
 ctacaacatc ctaacggact ctgtagcagg ctatgactga cggccccag ggtcagcagc 27780  
 ggctgcggga gtcctcagc cagcaccgcc gccagtgcc taaccgctgc tgettgcgca 27840  
 ggaagggat tcaccggag tacttttgca tcaccgcgga gcactttgag gccgagtgca 27900  
 tcccgcactc tctgcaagaa ggccacggtc tgcgctcag cctccccacg cgctacagcg 27960  
 accgcgcca ccgcgatgga gaccgcacca tctcacttc gtactactgc ggccctgctt 28020  
 ctttcaaagt tcgctgtctc tggggccatc ctgctcctca cctcttctt ctgcacctc 28080  
 tgtgtgagct gtacaaccgc tcgtagcgtc agcccctaca cctcccctcg cgtccaatth 28140  
 ctgtccgaca tagaaccaga ctctgactct tactcgggct ctggctctgg ggacgatgaa 28200  
 gattatgaat atgagctggc taccaacaca ccgaacgaag acattctagg cagcatagtc 28260  
 atcaacaacc agategggccc caagaccctg gccctgggat acttttatgc cgccatgcag 28320  
 tttgtcttct ttgccatcat catcatcgtc ctcatcctct actaccgccc ctacgtgctg 28380  
 gccaccgccc tcacgtgca gcgccagatg tggctcctcg aggcctcct gcggaaaacc 28440  
 ttctcgcca ccgthtgggt tactccccca aaacaagtca cccctgcaa ctgctcctgc 28500  
 cgcttcgagg agatggtgtt ctactacacc acctccgtct tcatgcctg gtgggctca 28560  
 tcctcctgct caccgcatg gtcgcctgg ccaactggat agtggatcag atgcccagca 28620

- continued

---

ggaaccgcg cccgcccgtg ccaccgcccc tcacctatgt gggaccctgc gccgaggacc 28680  
 acatctacga tgagccaacc gtagggcaat acgtacagat gaagtagctc cccctctttc 28740  
 ccattcccc atttttctct attcaataaa gttgcttacc tgagttcatc cactctcggt 28800  
 ctgccagtgc agtctatcca tgcgcccgtt tccatactca catagcgag ccgcgcacgc 28860  
 ctcgccaggt gacgaaactg tcgaaatgta acatttcgag cttctgtcag cagcaccocg 28920  
 ttatagacca gttccaccat gggaccgaag aagcagaagc gcgagctacc cgaggacttc 28980  
 gatccagtct acccctatga cgtcccgcag ctgcagatca atccaccctt cgtcagcggg 29040  
 gacggattca accaatccgt ggacgggggt ctgtccctgc acatcgcacc gcccctcggt 29100  
 tttgacaaca ccagggcct caccctggcc ttcgggggag gtctacagct ctgggcaag 29160  
 cagctcgtcg ttgccaccga gggctcgggg ctaaccacca acccgatgg caagctgggt 29220  
 ctcaaagtca agtccccat caccctgacc gccgaggga tctccctgc cctgggtccc 29280  
 ggtctttcta actcagagac cggcctcagt ctgcaagtca cagctccct gcagttccag 29340  
 ggcaacgccc tcaactctcc cctcgcgcc ggtctccaaa acaccgatgg tggatgggt 29400  
 gtcaaactgg ggagcgtct caccacggac aacagtcagg cggtgaccgt tcaggtggga 29460  
 aatggacttc agctgaacgg cgaaggaca ctcaccgtcc ccgccacggc ccttttagtc 29520  
 tcagggagcg caggcatctc tttcaactac tccagcaatg acttcgtctt agacaatgac 29580  
 agtctcagtt tgaggccaaa ggccatctct gtcaccctc cgctgcagtc cacagaggac 29640  
 acaatctccc tgaattatc taacgacttt tctgtggaca atggcgcct caccctggct 29700  
 ccaactttca aaccctacac gctgtggact ggcgcctcac ccacagcaa tgtcattcta 29760  
 acaaacacca ccaactccaa cggcaccttt ttcctatgcc tgacacgtgt ggggtgggta 29820  
 gttttgggtt cctttgcct gaaatcatcc atcgacctta ctagtatgac caaaaaggtc 29880  
 aattttattt ttgatggggc aggtcggctt cagtcagact ccacttataa agggagattt 29940  
 ggatttagat ccaacgacag cgtaattgaa cccacagccg caggactcag tccagcctgg 30000  
 ttaatgcaa gcaccttat ttatccacgc aacacctccg gttcttcctt aacatcattt 30060  
 gtatacatta atcagacata tgtgcatgtg gacatcaagg taaacacact ctctacaaac 30120  
 ggatatagcc tagaatttaa ctttcaaaac atgagcttct ccgccccctt ctccacctcc 30180  
 tacgggacct tctgctacgt gcccgaagg acaactcacc gtccccgcca cggccccttt 30240  
 agtctcaggg agcgcaggca tctctttcaa ctactccagc aatgacttcg tcttagacia 30300  
 tgacagtctc agtttgaggc caaaggccat ctctgtcacc cctccgctgc agtccacaga 30360  
 ggacacaatc tcctgaatt attctaacga cttttctgtg gacaatggcg ccctcacctt 30420  
 ggctccaact ttcaaaccct acacgctgtg gactggcgcc tccccacag caaatgtcat 30480  
 tctaacaac accaccctc ccaacggcac ctttttcta tgccctgacac gtgtgggtgg 30540  
 gttagttttg ggttcctttg cctgaaatc atccatcgac cttactagta tgaccaaaaa 30600  
 ggtcaatttt attttgatg gggcaggtcg gcttcagtca gactccact ataaaggag 30660  
 atttggattt agatccaacg acagcgtaat tgaaccaca gccgcaggac tcagtccagc 30720  
 ctggttaatg ccaagcact ttatttatcc acgcaacacc tccggttctt ccctaacatc 30780  
 atttgtatac attaatcaga catatgtgca tgtggacatc aaggtaaaca cactctctac 30840  
 aaacggatat agcctagaat ttaactttca aaacatgagc ttctccgcc ccttctccac 30900  
 ctctacggg accttctget acgtgcccc gagtgccatg agaaccctgg ccgtcagccg 30960  
 gcctccccct tcccaggcca cccggtacac caccgctcc atgtttctgt atgtgttctc 31020

- continued

---

ctcccgcgc ttgtgcagca ccacctcccg ctgctcgagc tgaggatccg tgatggacac 31080  
aaagccagga agacacatcc tcagctccgt gggggcgtcc aacaactgtt tatgtaaagg 31140  
aaaataaaga ctcagagaaa atccaagttc atatgatttt tcttttattg attgggggaa 31200  
ttgattcagg tgggggtgtc ataatacaca aatcacatc agcaggtaca cacctgagac 31260  
atcagacagg ggtaaggaca ggcctcagc ttctggaaca gacatcagaa atatttaatc 31320  
tgctggtagc taacactcct tcccacacc atacactcct ggagggccct ctgectctcc 31380  
tcctcccgct ccgctccct ctgccgggac caccactccc cctccgtgaa ctgctgcttc 31440  
ctccccgcgc gctgcgcccc gatggcctcc gccgccagct tcagccagtg ccgcaagcgc 31500  
tgggcgcagc gccgagccac cggctcgctc agctcgtggc agcgcggca caccagcact 31560  
atgtaattgg catagtcccc gtcacagtag atgacctccc cccagtggaa catgcgcaac 31620  
agcttcagat cacagtcata catgatcttt atgtacatca ggtgggccc tcgaaacatc 31680  
aactgcccc cgtacatcac gcgactcac ctgggcaggc tcaccgctc cctgaaccac 31740  
cagaagatgc gattgtactc gcagccccgg atgatctcgc gcatcaggga gcgcatcacc 31800  
acctgcccc cgccgactc cagactggac cttttcagac agtggcaatg aaagttccac 31860  
agcgtcgcgc ccgcacagcg tctccgggct gaaacatc tgctccagct ccaaccccc 31920  
acacaggctg tactgcagga aaatccattc ttgatgggaa aggatgtagc gccaggggac 31980  
cacaatctcc aaacagggaa caaacatac cgcggcccgg ctggtgcgca cggccccac 32040  
cggatgcaac gtgctcacgg agcagatacg ggtgggacag cggcccacgt ctcatagcaa 32100  
gtcaagtccg gaagtggcac ggggttcgcc accactgcta ctgctgccgc tggccacca 32160  
gtccatcgg ctctccatc ctctcctgt tccatcggt gaggtgctgc ctctcctcc 32220  
tcctgcgct gctccatcat gctcgtctgc ggtcatcagg agtcaaaaaa ttcattggcc 32280  
accgcacgca gagagaacat ggagcgcagg ggcccaggc cccggcccgt gcgctcgtc 32340  
aactccccca gcaggtactc atagagatgc tctccaaat ccaccgcaa ccaggcatgc 32400  
agaaactctt ccgttcgagg accgcccacg gtaaagacat agccctccc caccttcacc 32460  
gctgccagct gcacgcgctc atgtcgtgg gagtacacc ggaccgggc ctggatgtac 32520  
tccagcact gatcgtcag acacctcaca gagatgccag cctgagccag cttctcatag 32580  
agaggtggct gaatcttgag cttgaagcag cgagcggcta ggcactccc gcccccctgg 32640  
aacagggcgg ccgggtcagc catggacttc ctctacatcc ggggtcctgg ccacctcaca 32700  
aactatctgg ccaatcgct gaccacgggt caccaggtaa ggatgatgtc cgttggtgcg 32760  
aatgagaatg ctcagaggtg actcggtagc gttatcaatc acgtcccaa aggtccaaag 32820  
gtcccagtta gaagtcagg gcttcagacc gcagacacgc ccatagcaac cagtgggaaa 32880  
agccagcaag agatccgtgg gcacatgcac cgaagctccc gcaggaatct ccaaccactc 32940  
cgagcgtag accgtgtaag ctacacacc cgctcccga gtgggagcag aagcattctc 33000  
gctcagccga aagaactca ggggtggcctg catatcctct tttactcact tgtagcagc 33060  
tccacacaga ccaggttgt gttggcggga ataggcagca ggggtacgtc cccagtgagg 33120  
gacacctgga tggggggcag aggattgatg ccaggaagca gcaggtactg ggaaacagag 33180  
accagatccc tcctctgaaa aatctcgtc agtcggaca acacagcaa cccagtgggc 33240  
acgtagacta gcacattaa aaggatcacg ctggcgtgt ctgacgtcag caccagatgt 33300  
cgggacgtgc gcagatgaat gcggttctga tgaattaccg gaggcctctc acccgagcc 33360

-continued

---

```

aacagcagac cgggctgctg atgcgggtccc gcagacatat atgagttcaa tgtgtgtcctt 33420
ttttctaaac gtctagttag tgtgctcgtc ctgctcctgc caatcaaaat ccgggcacca 33480
gggctggtgg ttggacctga tgaagaagcg aggagaggcg gcctcctgag tgtgaagagt 33540
gtcccgatcc tgccacgcga ggtaggcgaa gtacagatag agcacggcga gaacagtcag 33600
caccgcggcc agcagcagtc ggtcgtgggc catgagaggg ggctgatggg aagatggccg 33660
gtgactcctc tcgccccgtt ttcggtttct cctcgtctcg ctctcagtgt ctctctctgt 33720
gtcagcgccg agacgagtgt gagcgaacac cgcgagcggg ccggtgatat acccacagcg 33780
gatgtggcca cgctgcggt cggttaatca gtaccccatc gtccgatcgg aattcccccg 33840
cctccgcggt aacgattaac ccgccagaa gtcccgggaa ttcccgcag ccggctccgc 33900
cgcgacctgc gactttgacc ccgccctcg gactttgacc gttcccacgc cacgtcattt 33960
tcccacgcga cgtcacgttc ccacgctacg tcacaccctt ctccaccaat caccgcccgc 34020
cgcccccaac cctctccgcc aatcaccacg ccacaaaagg ggcaataaaa gtgtgcggtg 34080
tattattgat gatg 34094

```

```

<210> SEQ ID NO 2
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Porcine Adenovirus Type 3

```

```

<400> SEQUENCE: 2

```

```

gcggatcctt aattaacatc atcaataata taccgcacac tttt 44

```

```

<210> SEQ ID NO 3
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Porcine Adenovirus Type 3

```

```

<400> SEQUENCE: 3

```

```

cacctgcaga tacaccaca cacgtcatct cg 32

```

```

<210> SEQ ID NO 4
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Porcine Adenovirus Type 3

```

```

<400> SEQUENCE: 4

```

```

cacctgcagc ctctgagtg tgaagagtg cc 32

```

```

<210> SEQ ID NO 5
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Porcine Adenovirus Type 3

```

```

<400> SEQUENCE: 5

```

```

gactgacgcc ggcatgcaat 20

```

```

<210> SEQ ID NO 6
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Porcine Adenovirus Type 3

```

```

<400> SEQUENCE: 6

```

```

cggatcctga cgctacgagc ggttgta 27

```

```

<210> SEQ ID NO 7
<211> LENGTH: 27

```

-continued

<212> TYPE: DNA  
 <213> ORGANISM: Porcine Adenovirus Type 3

<400> SEQUENCE: 7

cggatccata cgtacagatg aagtagc

27

<210> SEQ ID NO 8  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Porcine Adenovirus Type 3

<400> SEQUENCE: 8

tctgactgaa gccgacctgc

20

What is claimed is:

1. A replication-defective recombinant PAV-3 vector, wherein said PAV-3 vector is capable of duplex formation under conditions of high stringency with the genome of PAV-3 as depicted in SEQ ID NO:1, or its complement, said vector comprising ITR sequences, packaging sequences, and at least one heterologous nucleotide sequence, and wherein the PAV-3 vector lacks E1 function.

2. The replication-defective recombinant PAV-3 vector according to claim 1, wherein the vector is deleted in the E1 region.

3. The replication-defective recombinant PAV-3 vector according to claim 2, wherein the vector is additionally deleted in a region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right the genome.

4. The replication-defective recombinant PAV-3 vector according to claim 3, wherein the vector is additionally deleted in more than one region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the end of the genome.

5. The replication-defective recombinant PAV-3 vector according to claim 1, wherein the heterologous nucleotide sequence encodes a polypeptide selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

6. A method for producing a recombinant PAV-3 that comprises introducing the PAV-3 vector of claim 1 into a helper cell line comprising E1 function and recovering virus from the infected cells.

7. A host cell comprising the vector of claim 1.

8. A method for producing a recombinant polypeptide, the method comprising:

(a) providing a population of host cells according to claim 7, and

(b) growing said population of cells under conditions whereby the polypeptide is expressed.

9. A composition comprising the replication-defective recombinant PAV-3 vector of claim 1.

10. The composition according to claim 9 further comprising a pharmaceutically acceptable vehicle.

11. A composition capable of inducing an immune response in a mammalian subject, said composition comprising a replication-defective recombinant PAV-3 vector according to claim 1, wherein the vector comprises a heter-

ologous nucleotide sequence that encodes an immunogenic polypeptide; and a pharmaceutically acceptable vehicle.

12. The composition according to claim 11, wherein said immunogenic polypeptide is a pathogen antigen.

13. A recombinant PAV-3 vector comprising a PAV-3 genome capable of duplex formation under conditions of high stringency to the PAV-3 genome as depicted in SEQ ID NO:1, or a complement thereof and at least one heterologous nucleotide sequence, wherein the heterologous nucleotide sequence is inserted in a region selected from the group consisting of E1 region, [the E3 region,] and the E4 region [and the region between E4 and the right end] of the genome.

14. The recombinant PAV-3 vector of claim 13, comprising two or more heterologous nucleotide sequences.

15. The recombinant PAV-3 vector of claim 14, wherein the two or more heterologous nucleotide sequences are inserted at different insertion sites.

16. The recombinant PAV-3 vector of claim 13, wherein the heterologous nucleotide sequence encodes a polypeptide selected from the group consisting of coagulation factors, growth hormones, cytokines, lymphokines, tumor-suppressing polypeptides, cell receptors, ligands for cell receptors, protease inhibitors, antibodies, toxins, immunotoxins, dystrophins, cystic fibrosis transmembrane conductance regulator (CFTR) and immunogenic polypeptides.

17. A host cell comprising the vector of claim 13.

18. A method for producing a recombinant polypeptide, the method comprising:

(a) providing a population of host cells according to claim 17, and

(b) growing said population of cells under conditions whereby the polypeptide is expressed.

19. A composition comprising the vector of claim 13.

20. The recombinant PAV-3 vector according to claim 13 wherein the heterologous nucleotide sequence is inserted in the E1 region.

[21. The recombinant PAV-3 vector according to claim 13 wherein the heterologous nucleotide sequence is inserted in the E3 region.]

22. The recombinant PAV-3 vector according to claim 13 wherein the heterologous nucleotide sequence encodes an immunogenic polypeptide.

23. The recombinant PAV-3 vector according to claim 22, wherein said immunogenic polypeptide is a pathogen antigen.

24. The recombinant PAV-3 vector of claim 13, wherein said vector is replication competent.

25. A method for obtaining a recombinant PAV-3 comprising a heterologous nucleotide sequence inserted into a PAV-3

61

insertion site *located in a region selected from the group consisting of the E1 region, and the E4 region of the PAV-3 genome*, the method comprising the steps of:

- (a) providing a PAV-3 genome capable of duplex formation under conditions of high stringency to the PAV-3 genome as depicted in SEQ ID NO: 1;
- (b) providing a heterologous nucleotide sequence;
- (c) linking the heterologous nucleotide sequence to guide sequences, the guide sequences being capable of duplex formation under conditions of high stringency to said PAV-3 genome sequences flanking the PAV-3 insertion site, or the complement of said sequences, such that guide sequences are present at both ends of the heterologous sequence;
- (d) introducing the construct from step (c) into a cell together with the PAV-3 genome;
- (e) allowing homologous recombination to occur between the two sequences from step (d) to generate a recombinant PAV-3 genome;
- (f) purifying the recombinant PAV-3 genome;
- (g) inserting the recombinant PAV-3 genome into a mammalian cell;
- (h) culturing the mammalian cell under conditions wherein the recombinant PAV-3 genome is replicated and packaged; and
- (i) optionally collecting the recombinant PAV-3 from the cell or the culture medium.

**[26.** The method according to claim 25 wherein the insertion site is located in a region of the PAV-3 genome selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.]

**27.** The method according to [claim 26] claim 25 wherein the PAV-3 genome is deleted in a region selected from the group consisting of the E1 region, the E3 region, the E4 region and the region between E4 and the right end of the genome.

**28.** A composition comprising a recombinant PAV-3 obtained according to the method of claim 25.

**29.** The method according to claim 25 wherein said insertion site is E1.

**[30.** The method according to claim 25 wherein said insertion site is E3.]

**31.** A method for eliciting an immune response in a mammalian host comprising administering a composition comprising a recombinant PAV-3 vector that [expresses an immunogenic polypeptide] *comprises a heterologous nucleic acid that encodes an immunogenic polypeptide inserted at an insertion site selected from the group consisting of the E1 region, and the E4 region of the PAV-3 genome*, wherein said PAV-3 vector is capable of duplex formation under conditions of high stringency to the PAV-3 genome as depicted in SEQ ID NO:1, or a complement thereof; and a pharmaceutically acceptable vehicle.

**32.** The method of claim 31 wherein said PAV-3 vector lacks E1 function.

**33.** The method of claim 32 wherein said PAV-3 vector is additionally deleted in a region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right end of the genome.

**34.** The method according to claim 31 wherein said immunogenic polypeptide is a pathogen antigen.

**[35.** A method for obtaining a full-length genomic clone of a PAV-3 genome, the method comprising:

- (a) providing two or more cloned segments of the PAV-3 genome, wherein said segments are capable of duplex formation under conditions of high stringency to the PAV-3 genome as depicted in SEQ ID NO:1, or a

62

complement thereof, and wherein the cloned segments of the PAV-3 genome, taken together, represent the entire PAV-3 genome;

- (b) introducing the two or more cloned segments of the PAV-3 genome into a cell;
- (c) allowing homologous recombination to occur within the cell between the two or more cloned segments of the PAV-3 genome to generate a full-length PAV-3 genome; and
- (d) optionally purifying the full-length PAV-3 genome from the cell.]

**[36.** The method of claim 35 wherein said cell is procaryotic cell.]

**37.** The method of claim 36 wherein bacterial cell is *E. coli*.

**38.** A method for obtaining a recombinant PAV-3 comprising a heterologous nucleotide sequence inserted into a PAV-3 insertion site *located in a region selected from the group consisting of the E1 region and the E4 region of the PAV-3 genome*, comprising the steps of

- a) introducing a recombinant plasmid into a host cell in combination with a PAV-3 genome, wherein said plasmid comprises a heterologous nucleotide sequence flanked by nucleotide sequences that are capable of duplex formation under conditions of high stringency to PAV-3 nucleotide sequences flanking the PAV-3 insertion site, or the complement of said sequences, and wherein the PAV-3 genome is capable of duplex formation under conditions of high stringency to the PAV-3 genome as depicted in SEQ ID NO:1, or a complement thereof,
- b) allowing homologous recombination to occur between the plasmid and the PAV-3 genome thereby generating a recombinant PAV-3 comprising said heterologous nucleotide sequences;
- c) isolating said recombinant PAV-3;
- d) introducing said isolated PAV-3 into a mammalian cell permissive for growth of said PAV-3;
- e) culturing said mammalian cell under conditions suitable for PAV-3 replication and packaging; and
- f) optionally, collecting said recombinant PAV-3 produced from step e).

**39.** The method of claim 38 wherein said PAV-3 vector lacks E1 function.

**40.** The method of claim 39 wherein said PAV-3 vector is additionally deleted in a region selected from the group consisting of E2, E3, E4, L1, L2, L3, L4, L5, L6 and the region between E4 and the right end of the genome.

**41.** The replication-defective recombinant PAV-3 vector according to claim 1 wherein the heterologous nucleotide sequence encodes an immunogenic polypeptide.

**42.** The replication-defective PAV-3 vector according to claim 41, wherein said immunogenic polypeptide is a pathogen antigen.

**43.** A vaccine for protecting a mammalian host against infection comprising a recombinant PAV-3 vector comprising a PAV-3 genome capable of duplex formation under conditions of high stringency to the PAV-3 genome as depicted in SEQ ID NO:1, or a complement thereof, and at least one heterologous nucleotide sequence encoding an immunogenic polypeptide *inserted into the PAV-3 insertion site located in a region selected from the group consisting of the E1 region, and the E4 region of the PAV-3 genome wherein the insertion renders the PAV-3 replication defective*, and a pharmaceutically acceptable excipient.

**44.** The vaccine of claim 43 wherein said immunogenic polypeptide is a pathogen antigen.